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Abstract   
Pesticides must go through a rigorous risk assessment process to demonstrate 
that they are safe for use. One exposure scenario is that of the re-entry worker, 
who may enter a field soon after pesticide application and come in to contact 
with contaminated foliage. Following estimation of the potential dermal 
exposure, prediction of a systemic dose relies on applying a factor for dermal 
absorption. Currently, this value is obtained by carrying out in vitro diffusion 
cell testing of the concentrate and one or more representative spray dilutions. 
However, a worker is exposed to pesticide in a different form to those tested, 
a dried residue. The current work has developed an in vitro protocol to 
measure the absorption of pesticides from dried residues. This method is 
based on applying pesticides to an inert platform, creating dried deposits of 
pesticide, which are then transferred to a skin membrane and absorption 
measured in vitro using Franz diffusion cells.  
This method has been used to compare the dermal absorption of four 
compounds, from spray dilutions and their residues. In each case absorption 
was significantly less from the residue than the spray dilution. Further 
investigation of two of these compounds, found that absorption was affected 
by formulation and loading dose.  Additionally, the effect of decontaminating 
the skin at different time points post-exposure found an effect on the total 
amount absorbed and that this effect may be more pronounced for the dried 
residue than the spray dilution. This work has provided valuable insight into 
an area of exposure science which is poorly documented. This novel method 
has the potential to be used to carry out more realistic risk assessments than 
those which may currently overestimate exposure of re-entry workers and 
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1 BACKGROUND 
1.1 Pesticides  
Humans are arguably the most successful organism on the planet, success which 
we owe to our ability to manipulate our surrounding environment to suit our 
needs. As the human population has grown, the need to increase our supply of 
food has necessitated changes in the way we grow and harvest crops. The 
introduction of monoculture, the growth of one single crop type in a given area, 
represents a large increase in crop output. However, vast changes to the 
environment like this can disrupt the natural equilibrium and nature will react 
accordingly.  
In a ‘natural’ ecosystem each organism fills its own niche within the environment, 
and grows in population size to fill that niche. The limiting factor for growth 
would usually be space, light, supply of nutrients and water, or predation. Each 
ecosystem will reach an equilibrium where populations of each organism remain 
relatively constant. As with any equilibrium, if an external force is applied it will 
change accordingly.  
When a wild area is transformed into a monoculture, many organisms will lose 
their habitat. Any organism present in this area that is not the desired output 
crop; animals that had nested or plants and fungi that had grown in this area, are 
removed. If subsequently left untouched, plants, fungi and animals that 
originally grew there would eventually recolonize the area, unless the introduced 
crop happens to be better adapted to that area, which is rarely the case. However, 
in the short term, the planting of a large quantity of a single crop has changed 
this environment. Due to this change, animals that can feed on the introduced 
crop or other organisms that can use it to their advantage could see a rapid 
Chapter 1: Background 
James Clarke - November 2017   2 
increase in population. This effect is exacerbated in some instances where the 
natural predators of these organisms are forced out of the area. These few 
organisms that are able to flourish in this new environment are now referred to 
as ‘pests’. A system will return to equilibrium in the absence of an external 
driving force. So, in order to maintain a ‘pest-free’ environment and increase the 
yield of the desired crop, humans have long been applying this external driving 
force in the form of pesticides.  
1.1.1 History & Uses 
A pesticide is a chemical that is deliberately applied to an environment to elicit 
an effect, most often death, upon a pest. The most common motivation for the 
use of pesticides is to increase crop yields and the shelf-life of foods. They are 
also used for aesthetic reasons, for example to maintain the grass of a golf course 
or remove weeds on a driveway. Pesticides may also be used to control 
populations of disease-causing organisms such as mosquitos or head lice. The 
latter use is particularly interesting in that the pesticides can be directly applied 
to the skin of a human in order to elicit their effects. 
 As early as 4000 years ago, humans were reported to use sulphur dusting as 
means of controlling insects2. Throughout history examples of other pesticides 
can be found, a medical document from ancient Egypt, ‘The Ebers’ papyrus’ 
details many remedies that were used to control and kill pests3. 
 Arsenic-based compounds were used as insecticides as early as A.D 900 and into 
the 20th century. Paris Green or Emerald green (Figure 1) was commonly used as 
an insecticide through the 19th century. It was also commonly used as a dye at 
this time, proving popular with artists including Monet and van Gogh, and was 
commonly used in the manufacture of green textiles and wallpapers with little 
knowledge of its toxicity. There are anecdotal reports of deaths caused from its 
use in culinary applications such as on cake decorations4.  
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Figure 1 - Copper (II) acetoarsenite (Paris Green) chemical structure 
 In the 1880s, Paris Green was largely replaced by lead arsenate, which was often 
made at home by combining lead salts and sodium arsenate5. With the 
introduction of sprayers at the turn of the century, demand increased for 
commercially formulated pesticides that sprayed well. Most of the compounds 
used around this time such as mercury and arsenic compounds are no longer 
used due to their unacceptable toxicity. One pesticide that has stood the test of 
time is ‘Bordeaux mixture’, containing copper sulphate and slaked lime which is 
still used today (Figure 2). 
 
 
Figure 2 - Copper (II) sulphate (Bordeaux Mixture) chemical structure 
In 1939, Paul Müller discovered the pesticidal properties of 
dichlorodiphenyltrichloroethane (DDT) for which he was awarded a Nobel Prize 
in 1948 (Figure 3). DDT, a broad spectrum insecticide was used during World 
War II to curb the spread of malaria and was used widely, some may say over-
used, in agriculture for many years.  
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Figure 3 - dichlorodiphenyltrichloroethane (DDT) chemical structure 
In the post-war period, several other compounds including parathion, atrazine, 
paraquat and 2,4-D emerged. These compounds were often applied liberally to 
large areas in attempts to control many different types of pest. Although 
relatively effective, this pattern of use was unsustainable, resulting in some 
organisms developing resistance and, due to the ‘broad spectrum’ of many of 
these compounds, their off-target effects were far reaching. Many non-pest 
organisms were inadvertently affected and ecosystems damaged, a topic which 
was bought to the fore in 1962 by Rachel Carson’s “The Silent Spring”6 which is 
generally acknowledged as signalling the beginning of modern pesticide 
regulation2.  
Due to increased regulation in recent times, there has been a move toward 
developing compounds that are more specific to their target and persist in the 
environment for less time. This means that the potential for off-target toxicity is 
much lower. Also, advances in spraying and formulation technology mean that 
it is possible to gain the same efficacy by applying significantly less product.  
Toxicity caused by exposure to pesticides varies by compound and species. 
Adverse effects in humans can be seen acutely upon exposure to high doses, such 
as nausea and vomiting. Chronic exposure can cause long term adverse effects 
such as neurotoxicity or liver damage. These toxicities are often caused by the 
compound affecting the same pathways that makes them so effective as 
pesticides. In the case of an insecticide for example, dose is key: a dose that would 
kill an insect may not cause any tangible acute toxicity in a human. However, it 
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is difficult to study the effects of long term low level exposure to these 
compounds and exposure must be reduced wherever possible.   
1.1.2 Risk Assessment 
Each pesticide product must go through a rigorous risk assessment process to be 
deemed safe for its intended use. There are many models and assessment 
guidelines available, and each country or governing body has different 
approaches for exposure assessment. For the purpose of this thesis, current 
practise for the European Union (EU) will be discussed only. Exposure 
assessment in the EU is overseen by the European Food Safety Authority (EFSA) 
and in 2014 a new guidance document on pesticide exposure assessment was 
released7. Guidance on dermal absorption was released in 20128 based on a 
scientific opinion document released the year before9. This guidance was 
updated in 201710 in consideration of a large dataset held by Industry and the 
German regulatory authority, BfR (Bundesinstitut fϋr Risikobewertung). Much 
of the information in this section is based on these documents.  
1.1.2.1 Modes of Exposure 
Exposure to pesticides can occur in many different scenarios and to several 
different groups of individuals. Oral exposure is the route which is most within 
the public consciousness; many fruits and vegetables may contain small amounts 
of pesticide, which could potentially be consumed by the public. Dietary risk 
assessment is discussed in detail in further EFSA documents11, 12.  
Once a pesticide has been licensed for sale, there are many groups of individuals 
who may inadvertently become exposed to the product. First, workers in the 
manufacturing plants where the compound is produced and formulated may be 
at risk of exposure as part of their daily work. Depending on the type of pesticide 
and its intended use there is a vast array of possible exposure scenarios for the 
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end-use product including use by farmers, pest control professionals and the 
public. In this document, the use of pesticides to be sprayed onto crops in a 
commercial environment will be discussed. Most products are supplied in the 
form of a concentrate which must first be diluted with water before application. 
This task would be carried out by an ‘operator’, who loads the concentrate into 
the spray tank and mixes it to a suitable spray dilution, usually with water as the 
diluent. This spray tank could be in the form of a handheld sprayer or knapsack, 
or a large tractor mounted tank. During this process the operator is typically 
exposed to the concentrate, although exposure to the spray dilution could also 
occur with less sophisticated equipment. However, during the application 
process which ensues, exposure is primarily to the diluted spray solution. 
Equally, post-application there is a risk of exposure when emptying and cleaning 
the spray reservoir. 
Inhalation exposure can occur during the mixing and loading process, if the 
active ingredient is volatile in nature or a fine powder. However, the most likely 
time for inhalation exposure is during the spraying process. Upon spraying, very 
fine droplets can become airborne and subsequently inhaled.  It is also possible 
for bystanders and residents to be exposed via inhalation if significant spray drift 
occurs. Due to the high surface area of the lungs and its relatively minimal barrier 
function, these exposures could potentially cause significant toxicity. In recent 
times, inhalation exposure has been reduced due to the introduction of closed 
cabs, which reduce exposure of the operator, and more efficient spray equipment 
which reduces spray drift.  
Although the oral and inhalation routes of exposure are both important 
pathways, they are not considered further here. Only dermal exposure, which is 
the principal route for most non-dietary exposure scenarios, is discussed in this 
thesis. 
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1.1.3 Dermal Exposure Assessment 
Dermal exposure can occur from spillage of a product directly onto the skin or 
by dermal contact with a surface that has been contaminated. During the mixing 
and loading process it is possible for a worker to be dermally exposed to either 
the concentrate or its spray dilution, i.e., when diluted in water for spraying, this 
would usually occur via splash or spill. As described above for inhalation, 
operators, bystanders or residents could also be dermally exposed via spray drift. 
Again, this has become less common in recent times and precautions can be taken 
such as appropriate engineering controls, the use of drift reduction technology, 
increasing droplet size or lowering the boom height to reduce spray drift.  
This thesis will focus specifically on dermal exposure of re-entry workers. Post-
application, it is necessary for these workers to enter the treated area to carry out 
tasks such as crop inspection or harvest. It is also possible that bystanders could 
be exposed; for example, hikers passing through a field who may be unaware 
that it is has been sprayed recently. This type of exposure is different to those 
described above. Upon contact with foliage, a worker is not exposed to either the 
concentrate or the spray dilution, but rather to a ‘dried residue’ of the spray 
dilution. ‘Dried residue’ here is defined as a form of the spray dilution where all 
the volatile components of the formulation have evaporated away. At the least, 
this means that the water from the dilution has evaporated but, for some 
formulations, other components may have also evaporated. It is therefore 
apparent that exposure to this dried residue may be distinctly different to 
exposure to the spray dilution and it is likely that pesticides would be absorbed 
through the skin differently from this residue. It is also possible that oral 
exposure can occur after contact with contaminated surfaces via ‘hand-to-mouth 
activity’13 but this pathway is secondary to dermal exposure and is not 
considered further here.  
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For each exposure scenario, a specific risk assessment needs to be carried out. 
This is based on a tiered system, whereby a first-tier assessment would use 
conservative default values and if the exposure is deemed to be too high, then 
higher tier assessments can be carried out that take specifics of the active 
ingredient (AI) and formulation into account. An exposure is deemed to be too 
high if it exceeds the Acceptable Operator Exposure Level (AOEL). An AOEL is 
assigned to each compound as a result of toxicological testing during its 
development, these values can vary greatly depending on the potency of the 
compound and its ability to cause adverse effects. The AOEL includes an 
uncertainty factor, typically at least 100, to allow for inter- and intra-species 
differences8. 
Each scenario has an associated methodology for calculating potential exposure. 
For example, in a dietary assessment, the total dose that a person is expected to 
consume is estimated by taking into account the level of pesticide residue in the 
product and the amount of that commodity consumed. A similar process exists 
for estimating dermal exposure, the external dose is first estimated and then an 
absorption factor is applied.  
1.1.3.1 Worker Exposure Assessment 
Estimation of the exposure of a re-entry worker is not an exact science, as the 
dose is not applied directly to the worker but is transferred from a contaminated 
surface. It is therefore necessary to estimate how much pesticide is on the 
contaminated surface and then to estimate how much of that will be 
subsequently transferred to the skin of the worker upon contact.  
Assessment of re-entry worker exposure is based on the following equation for 
estimating Potential Dermal Exposure (PDE): 
PDE (µg active substance/day) = DFR (µg/cm2) x TC (cm2/h) x T (h/day) 
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Where dislodgeable foliar residue (DFR) is the amount of substance upon a 
surface such as a leaf or fruit, that is available to be dislodged. DFR depends on 
application rate and efficiency as well as the concentration of the substance 
applied and the leaf area index. For a first-tier assessment, it is assumed that no 
dissipation occurs over time. If multiple applications are to take place, then 
accumulation of pesticide must be considered, in this case the DFR after the final 
application is used. This is estimated by taking in to account dissipation half-life 
for which the EFSA default value is 30 days in the absence of specific data. 
 In the absence of a measured value for DFR, a default of 3 µg/cm2 per kg of AI 
applied per hectare (ha), is used. For example, if the application rate was 0.1 
kg/ha, then the default value would be 0.3 µg/cm2. This value is considered to be 
an over estimate and a worst-case scenario, if this value does not allow for an 
acceptable risk assessment then field studies to measure more realistic DFR 
values can be carried out. 
The transfer coefficient (TC) is a measure of the intensity of contact with the 
contaminated surface. This value is dependent upon the type of crop and the task 
being performed14, 15.  EUROPOEM II16 values for TC are used for many different 
crop/task combinations; however, unfortunately the sources of these values are 
not publicly available. Generally, it is assumed that the worker will be wearing 
‘workwear’ thereby having the torso, arms and legs covered and it is assumed 
that 10% absorption through this workwear will occur. Several studies have 
measured absorption of chemicals through clothing for potential dermal 
exposure17, 18 and although this value is realistic for liquid forms of pesticide, this 
may not be the case for dried residues, that may not soak into materials and 
therefore could be less likely to penetrate them. Most of the contact with foliage 
will be via the hands, and so an obvious way to decrease exposure would be to 
wear gloves. However, it is not generally assumed that workers will be wearing 
gloves, as compliance is perceived to be low by regulators. This is due to many 
factors including a lack of understanding of potential dangers, and wearing 
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gloves while working in countries with higher ambient temperature can be 
uncomfortable. Furthermore, contrary to popular belief, gloves do not provide a 
complete barrier to exposure of liquid forms of pesticide, with breakthrough 
times ranging from 15 minutes to 24 hours2, 4, 19, 20. It is, however, possible to add 
a recommendation to wear gloves in a higher tier assessment if deemed 
necessary.  
Time (T) is the amount of time in hours spent carrying out the task, default values 
for this are 2 hours for crop inspection and 8 hours for harvest.  
The PDE is the total potential exposure of the worker; this value is given in µg 
per day and represents the external dose i.e., the amount of substance deposited 
on to the surface of the skin. To convert this into an estimate of the internal dose, 
here defined as that which is systemically absorbed, a percentage absorption 
factor must be applied. Default values can be used; the 2017 EFSA guidance on 
dermal absorption10 updated these values to take formulation type in to account. 
For the concentrated products, this guidance recommends default absorption 
values of 25% and 10% respectively for organic-solvent based, and water-
based/dispersed or solid products, respectively. For in-use dilutions, a default of 
70% is recommended for organic-solvent based products and 50% for water-
based/dispersed or solid. Generally, these default values are considered to be 
conservative and it is common for in vitro dermal absorption studies to be carried 
out to generate more realistic absorption values. These studies measure generally 
absorption from the concentrate and two relevant spray dilutions. The 
application that gives the highest percentage absorption value is then used. 
Conduct of these studies is explained in more detail in section 1.5.   
1.1.3.2 Limitations of the Current Approach 
With respect to re-entry worker exposure, the use of these values may not be 
realistic. Previous work21 has demonstrated that dermal absorption of dried 
residues may be different to that of a spray dilution and therefore the use of these 
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values for risk assessment may be inaccurate (discussed in section 1.6). McCarley 
et al22 compared saturated aqueous solutions against solid active ingredient and 
found no significant difference in absorption into silicone membranes. However, 
a further study tested a similar hypothesis on human skin and found that the flux 
of the compound investigated was significantly lower from the powder than 
when in solution23. Although studies on neat active ingredient powders can give 
an insight into how a dried residue may behave, it would not always be the case 
that the residue remaining on a surface is completely dry. This would depend on 
the volatility of other components of the formulation.  
In the case of a worker carrying out harvest, the exposure time is assumed to be 
8 hours. The percentage absorption values are obtained from in vitro diffusion 
cell studies with an 8-hour exposure time i.e., a dose is applied at time 0 which is 
left in contact with the skin for an exposure period of 8 hours before a 
decontamination step is performed.  
However, this is not representative of the exposure scenario. Although it may be 
the case that a worker is in the field for 8 hours in one day, the worker would not 
be exposed to the entire dose at the start of the day. In an example where an 
estimated exposure of the worker is 80 µg/cm2/day, this worker would, in fact, 
be exposed to 10 µg/cm2 each hour or 0.16 µg/cm2 each minute and so on. This 
exposure varies in several ways to the scenario that is investigated in vitro. 
Assuming full decontamination occurs at the end of the working day, pesticide 
transferred from the first piece of foliage that the worker touches in a day (at time 
= 0) may have an exposure time of 8 hours. However, from then on, as time 
progresses, the exposure time is reduced. Taking this into account, and assuming 
a constant rate of exposure throughout the 8-hour working period; the average 
exposure time is in fact 4 hours. It is also unlikely that a worker would be in the 
field for 8 hours straight; it would be reasonable to assume that they may take a 
break to visit the toilet or to eat lunch, in which case it is also likely that they 
would wash their hands during this break. Another factor is that, after initial 
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exposure of an area of skin, contact with a second piece of contaminated foliage 
may not result in the same amount being transferred to the skin, or some of the 
original exposure could even be transferred back on to the foliage or fall to the 
ground. Equally, if the residue is in a form that is not well adhered to the skin 
e.g., solid crystals, just movement of the individual could cause the residue to be 
dislodged from the skin. It is unrealistic therefore, to assume that exposure 
throughout the working day is cumulative.  
This project aims to investigate and address some of these inaccuracies, and 
develop a method where the dermal absorption of dried residues can be 
measured in vitro and compared against current practise, with the eventual aim 
of using this method to generate more realistic absorption values for re-entry 
worker assessment. 
1.2 Structure and Function of the Skin  
The skin is the body’s largest organ, accounting for up to 10% of body mass24-26. 
It has a large surface area that is exposed to the external environment, averaging 
for an adult24 around 1.7m2. The primary function of the skin is to act as a barrier 
to both loss of internal water and uptake of xenobiotics from the environment. It 
also provides protection from mechanical stress and helps to regulate body 
temperature.  
The structure of the skin can be considered as two distinct regions27 (Figure 4) the 
dermis and the epidermis.  
1.2.1 The Dermis 
The dermis is 2-5mm thick24. It consists of mainly collagen and elastin fibres in 
an aqueous gel. It houses blood and lymph vessels which provide nutrients to 
and remove waste products from both the dermis and the avascular epidermis 
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above. Blood vessels extend as far as the dermo-epidermal junction where 
traversing molecules can then be absorbed systemically. The dermis also contains 
skin appendages which are discussed below. 
 
 
Figure 4 - Cross-sectional diagram of the skin 
27 
1.2.2 The Epidermis 
The epidermis is the outermost section of the skin and its depth varies from 0.06 
to 0.8 mm depending on body site24. It is avascular and relies on the underlying 
dermis to sustain it. Figure 5 shows the different layers of the epidermis, the 
innermost of which is the stratum basale or basal layer. The most abundant cell 
type in this layer are the keratinocytes. These cells are the only epidermal 
keratinocytes capable of undergoing mitosis; upon replication, daughter cells 
move towards the surface, differentiating to form the outer layers of the 
epidermis. The basal layer also contains several other cell types. Langerhans cells 
are dendritic antigen-presenting cells that may be important in allergic contact 
dermatitis28. Merkel cells are thoughts to be involved in touch sensation. 
Melanocytes are pigment forming cells, they produce eumelanin (brown) and 
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phaeomelanin (red) which contribute to the skin’s colour and protects from UV 
damage.  
The layer that lies above the basal layer is the stratum spinosum, which gains its 
name from the desmosomes that link the cells, appearing like ‘spines’. As the 
cells migrate outwards, they become more keratinised, flattened and begin to lose 
some organelles, forming the stratum granulosum. Cells within this layer begin to 
synthesise granules of keratohyalin which are thought to be involved in cell 
keratinisation and ‘membrane coating granules’ which release lipids into the 
intercellular space by exocytosis29, 30; the significance of these lipids is discussed 
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1.2.3 The Stratum Corneum  
The stratum corneum (SC) is the outermost layer of the epidermis. It is terminally 
differentiated and consists of non-viable, flattened, keratin-packed cells with no 
nuclei. It is generally only around 10-15 cells thick, giving it a depth under normal 
conditions of around 10 µm24.  Nonetheless, the SC is responsible for most of the 
skin’s barrier function. When it is removed, or damaged by disease, trans 
epidermal water loss increases by an order of magnitude31-33 and xenobiotics may 
pass into the body with greater ease34. The SC is often described in terms of a 
‘bricks and mortar’ model. The bricks represent the keratin packed cells 
described above. The mortar represents the lipids surrounding the cells; which 
are instrumental to the barrier function of the skin35. These lipids have a unique 
composition, consisting of large amounts of ceramides and free fatty acids26, 27, 30. 
Other components include cholesterol, cholesterol sulphate, glucosylceramides 
and sterol/wax esters. The organisation of these lipids is important; a highly 
ordered system of bilayers is formed36, 37 which is responsible for the efficiency of 
the barrier. Disruptions to the SC lipids by disease38 or by solvent extraction33, 39 
have been shown to cause compromised barrier function. Routes of permeation 
through the SC are discussed in section 1.4. As cells move towards the outer 
layers of the SC, desmosomes holding the cells together begin to break down 
causing their loss from the skin’s surface, known as desquamation. The entire SC 
is turned over in around 2-3 weeks40.  
1.2.4 Skin Appendages 
Human skin has four types of appendage, hair follicles, sebaceous glands, eccrine 
sweat glands and apocrine sweat glands. Hair follicles can be found on all areas 
of the skin at differing densities other than the palms, soles and lips. Sebaceous 
glands are most abundant on the forehead and secrete sebum which serves to 
regulate surface pH and keep the skin moist2. Eccrine sweat glands secrete sweat 
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and help regulate body temperature, and are found across most of the skin 
surface. Apocrine sweat glands are larger, localised around the arm pit and 
genital regions27, and respond to emotional stimuli. They secrete a mixture of 
proteins and lipids that upon breakdown by bacteria is responsible for the odour 
associated with sweat41.   
1.3 Physiological Factors Affecting Dermal Absorption 
The effect of ageing of the skin on dermal absorption is not well studied. In 
general, with ageing, the skin becomes more dry42 and the depth of the SC 
increases, which would suggest an increase in barrier function. One study found 
absorption to be significantly lower in aged skin and that this effect may be more 
pronounced for hydrophilic molecules43. It is thought that changes in hydration, 
blood flow and lipid composition could be responsible for changes in barrier 
function44. Some of the changes may not be a direct result of ‘ageing’ but due to 
a lifetime of UV exposure45. Skin damage caused by UV light has been shown to 
adversely affect barrier function46, this could be a relevant factor for re-entry 
workers who will often spend most of their day outside in the sun. 
Dermal absorption varies with anatomical site47-49. The SC is thickest at areas that 
are frequently exposed to mechanical stress such as the palms of the hands and 
soles of the feet. Permeability is greatest through scrotal skin which has a thin SC 
and high density of hair follicles48. This regional variation is of potential relevance 
to re-entry workers because most exposure is via the palms of the hands, where 
the skin is less permeable than the torso for example. Conversely, the forehead is 
an area of high permeability that may also be exposed during re-entry activities.  
Blood flow to the skin is controlled by the sympathetic nervous system in 
response to changes in core temperature50. Increased blood flow serves to 
increase heat loss and consequently decrease core temperature. Re-entry workers 
may spend long periods of time outdoors carrying out manual tasks in warm 
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ambient temperatures; as the optimal time for harvest is usually in the summer. 
Cutaneous blood flow has been shown to increase with increasing temperature51, 
52 and in response to excercise53. This increased blood flow could influence 
permeation54. The activities of the re-entry worker may also increase levels of 
perspiration. An extreme case could mean that the worker has sweat on the 
surface of the skin, which could affect the amount of pesticide that is transferred 
to the skin. This could also be significant when exposure is to a dried residue as 
the sweat may also provide a vehicle in which a dried residue can dissolve, 
possibly resulting in enhanced absorption. In a less extreme case, the SC could be 
more hydrated than it would be under normal conditions. Increased hydration 
of the skin can cause permeation to increase by an order of magnitude55. 
Similarly, occlusion of the skin has been shown to affect absorption56. This excess 
hydration can disrupt SC lipid structure and organisation by introducing ‘pools’ 
of water in the intercellular space55-57.  
Since it is the outer layer of the skin that provides much of the barrier function, 
seemingly superficial damage to the skin can represent serious damage to the SC 
and this can result in a compromised barrier function34, 58. Damage to the skin 
may be relevant to a re-entry worker as abrasion of the skin could occur as part 
of their daily work (e.g., scratches by branches or the skin pierced by thorns), 
although protective gloves are typically worn where this is expected. 
Occupationally related skin diseases are common2, 59, 60 especially when the skin 
is exposed to a humid environment for extended periods of time. Many of these 
diseases such as atopic dermatitis can compromise the skin barrier and dermal 
absorption can be increased58, 61. 
The skin has some metabolic activity, including cytochrome P450 and non-
specific esterase enzymes which reside in the viable epidermis. These enzymes 
can metabolise molecules and consequently reduce their absorption2 such as 
some insecticides62. However, this metabolism is not always protective in nature. 
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One of the best studied incidence of skin metabolism is that of polycyclic 
aromatic hydrocarbons which are not themselves especially toxic, but can be 
activated in the skin, these metabolites can then bind to DNA and can cause 
cancer40. Skin used for dermal absorption studies in vitro is generally not 
metabolically active. This can potentially cause some disparity from the in vivo 
scenario, but this would usually result in an overestimate of absorption due to 
lack of metabolism9.  
1.4 Skin Permeation  
The ability of molecules to be absorbed into and across the skin is of significance, 
both in relation to occupational exposure as described above, and in relation to 
the delivery of drugs through the skin for medical purposes. Although 
absorption into the skin tissue can cause local toxicity, and is important when 
considering locally acting creams and cosmetics, this document will focus mainly 
on permeation of molecules through the skin into systemic circulation as this is 
generally the greatest source of toxicity.  
For a molecule to be systemically absorbed, it must permeate to the dermis where 
it can then pass into the vasculature. Dermal penetration is expressed in terms of 
flux (J); the mass of compound traversing a membrane per unit area per unit time.  
Despite being a heterogeneous membrane with several different permeation 
pathways, it is possible to describe permeation through the skin in terms of 
simple kinetic equations. These equations are useful to aid understanding of how 
the diffusion process works and can also be used to predict the behaviour of a 
molecule applied to the skin.  
The maximum flux 𝐽𝑚𝑎𝑥 of a substance across the skin at steady-state can be 
estimated using Fick’s first law of diffusion (Equation 1) 
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𝐽𝑚𝑎𝑥 =  𝑘𝑝 ∙ 𝐶𝑠𝑎𝑡                                   Equation 1        
 
Where 𝑘𝑝 is the permeability coefficient (cm/h) of the compound across the skin 
from a simple aqueous vehicle and 𝐶𝑠𝑎𝑡 is the chemical’s solubility in water. 
According to Fick’s first law, the concentration gradient across the membrane is 
directly proportional to the flux. If we assume sink conditions, i.e., the dissolution 
of the compound in the plasma or receptor solution is not a limiting factor, then 
the concentration on the receptor side of the membrane is effectively zero. 
Therefore, the concentration gradient can simply be replaced by the applied 
concentration. 𝑘𝑝 is dependent on the molecule’s diffusivity (D), partition 
coefficient (𝑘𝑠𝑐/𝑣 ) and the path length (h) (Equation 2) 
 
𝑘𝑝 =   
𝐷 ∙ 𝑘𝑠𝑐/𝑣
ℎ
                             Equation 2                                                                                             
 
The first step in absorption is partitioning of the molecule into the SC. The 
partition coefficient is dependent upon a molecule’s relative affinity for its 
vehicle and the SC. For example, a lipophilic molecule presented to the skin in a 
lipid-based vehicle would be less likely to partition into the SC than if presented 
in an aqueous vehicle. Similarly, a hydrophilic molecule would show a higher 
affinity for an aqueous vehicle than the lipoidal SC. In the case of an aqueous 
vehicle the partition coefficient can be approximated using the octanol/water 
partition coefficient (P). 
Using this and the molecular weight (MW) of the compound, an algorithm 
developed by Potts and Guy63, using a database of experimentally determined 
fluxes, can be used to estimate 𝑘𝑝 (𝑐𝑚/ℎ) (Equation 3). 
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𝑙𝑜𝑔 𝑘𝑃 =  −2.7 + 0.71 ∙ 𝑙𝑜𝑔 𝑃 − 0.0061 ∙ 𝑀𝑊            Equation 3                  
where P is the chemical’s octanol-water partition coefficient and MW its 
molecular weight. This equation predicts that the permeability of a molecule will 
increase with decreasing MW, as is commonly the case for passive diffusion, due 
to decreased resistance being associated with decreased molecular size. Also, it 
indicates that permeability increases with increasing lipophilicity. This is true for 
moderately lipophilic compound for which the SC is the main barrier to 
absorption. However, for more lipophilic compounds the viable epidermis could 
present more of a barrier, and partitioning into the viable epidermis from the SC 
may become rate limiting. 𝑘𝑝
𝑐𝑜𝑟𝑟  described in Equation 4 is a corrected 
permeability coefficient to take this into account64 : 
 
𝑘𝑝
















 ∙ 𝐶𝑠𝑎𝑡           Equation 5     
 
The equations above describe absorption of molecules from an infinite dose of a 
saturated aqueous solution. In the case of drugs being delivered to the skin from 
a transdermal patch, this model is reasonable and it may be possible to achieve 
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maximum flux. However, it is rarely the case that a molecule is presented to the 
skin in such a way. Formulations of pesticides and medicines often contain other 
solvents, and ingredients such as emulsifiers. Therefore, partitioning is more 
complex and difficult to predict. An increase in a compound’s solubility in its 
vehicle will generally result in a decrease in its partition coefficient and therefore, 
a decrease in flux. Paradoxically, the flux of a compound is directly proportional 
to its concentration in the vehicle. In the case of exposure to pesticide spray 
dilutions, the compound of interest would often be significantly below its 
saturation concentration in the vehicle and therefore maximum flux would never 
be achieved. 
On the other hand, in a case where the molecule is applied to the skin as a 
suspension, the solution may be saturated at the time of application, but 
solubilisation of undissolved material into the vehicle could then become the 
rate-limiting step in absorption. The impact that a vehicle can have upon 
absorption is recognised by EFSA7 in that if the constituents of a formulation are 
changed by at least 25% w/v, then new dermal absorption values must be 
obtained for risk assessment. This guidance has been updated in the 2017 
document10 where a more complex system taking into account the concentration 
of the excipients is being implemented. 
Finally, exposure to chemicals such as pesticides is generally in the form of a 
finite dose. Therefore, the driving force for absorption is greatest at the time of 
application and tails off as the dose depletes over time. Cumulative penetration 
(Figure 6) from a finite dose would increase rapidly after the initial lag time and 
then level out. However, from an infinite dose the cumulative permeation would 
theoretically increase indefinitely.  
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Figure 6 - A model graph of cumulative penetration against time for (a) infinite dose 
(dashed lined) (b) finite dose (solid line) 
There is a grey area between a true ‘infinite dose’ and a ‘finite dose’ where the 
absorption of a compound is ‘flux-limited’. This type of exposure is seen 
regularly in the literature and its significance is often overlooked. Several recent 
critical reviews have outlined the importance of identifying a flux-limited 
scenario and how this can affect percentage absorption results65, 66.  Kissel65 
describes a dimensionless absorption value that could be useful in determining 
if a set of exposure conditions represents a flux-limited dose. In a flux-limited 
scenario, fractional absorption is inversely related to loading67 i.e., the higher the 
loading, the smaller the fraction absorbed. This is particularly important for risk 
assessment because it is common to use percentage absorption factors. If the 
experiment where the percentage absorption value was obtained has relevant 
exposure conditions i.e., application of a similar skin loading from a relevant 
formulation, then this is an acceptable approach. However, the use of the same 
percentage absorption value to describe other exposures to the compound may 
not be appropriate. Additionally, from finite doses, binding to components in the 
skin, and reservoir accumulation in the SC, can have a more significant impact 
on the fraction absorbed.  
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Potential routes across the SC are transcellular, intercellular or appendageal 
(Figure 7). Although there are theoretically three different pathways across the 
SC, absorption of an applied chemical will most likely be via a combination of 
these three pathways. The physicochemical properties of the molecule in 
question will affect which pathways are most dominant.  
 
 
Figure 7 - The bricks and mortar model and pathways across the stratum corneum 
68
 
As described above, the keratinocytes of the SC are surrounded by lipid. 
Therefore compounds that are able to dissolve in both aqueous and lipid phases 
(log P ~ 1-3) generally permeate more effectively69. The theoretical path length of 
a molecule diffusing the SC has been calculated as around 50 times the SC 
depth60, suggesting that the molecules take a tortuous route around the 
corneocytes. It is generally thought that passage through this lipid phase 
represents the major pathway for most compounds through the SC30, 70 apart from 
those that are very hydrophilic. It may be possible for more hydrophilic 
molecules to partition into the keratin packed cells. However, this route is not 
continuous, the molecule would still be required to partition in to the intercellular 
lipids between each cell to traverse the SC.  
The appendageal route is not generally thought to be important at steady-state 
in humans due to their relatively low density, only representing from 0.1 – 0.2 % 
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of the total surface area71. However, it may be more important in transient 
exposure scenarios, in the early stages of absorption72 and for hydrophilic 
molecules73-75. Several studies76, 77 have demonstrated the importance of the 
follicular route in the absorption of the hydrophilic compound caffeine. When 
hair follicles were artificially blocked, caffeine detection in plasma was delayed, 
suggesting that the follicular route provides a faster route through the skin. 
Another study using Stimulated Raman Scattering (SRS) found that the 
penetration of polyethylene glycol (PG) via a hair follicle was rapid compared to 
penetration via the SC lipids78.  
Once a molecule has traversed the SC it must then partition into the viable 
epidermis which is much more hydrated. Compounds that are particularly 
lipophilic may partition into the SC easily but partitioning into the more aqueous 
lower epidermis becomes the rate-limiting step79. As a compound cannot be 
absorbed systemically until it has traversed to the dermis these very lipophilic 
compounds are often poorly systemically absorbed. This can create a ‘reservoir’ 
whereby the lipophilic compound accumulates in the SC from which it is then 
slowly released into the viable tissue and circulation80. Depending on the rate of 
removal of this compound from the reservoir, it could also potentially be lost via 
desquamation. Although, due to the relatively slow rate of epidermal turnover, 
this is only likely to be significant for compounds with very slow absorption81.  
1.5 Measuring Dermal Absorption 
Ideally, in order to gain the most realistic results, dermal absorption for each 
product would be measured in humans in vivo using relevant exposure 
conditions. Although this may frequently be possible for pharmaceuticals, it is 
often deemed unethical to deliberately expose humans to pesticides, due to 
toxicity concerns and the fact that, unlike pharmaceuticals, most pesticides are 
not designed for dosing humans.  
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In the absence of in vivo human studies, in vivo animal testing may be considered. 
Measurement of dermal absorption in vivo is most often carried out in rats; this 
is due to their use being relatively inexpensive, ease of handling, and the 
existence of a well-defined protocol82-84. It is also possible to use hairless mice and 
guinea pigs for in vivo investigation85. However, as mentioned above, the 
permeability of skin varies between species and therefore the use of human skin 
ex-vivo may give a better estimation. One method that attempts to address this is 
the ‘triple pack’ approach9, 86. This method carries out in vivo and in vitro rat as 
well as in vitro human studies. The two in vitro results are compared in order to 
assess the difference in absorption between the species. This difference is then 
used to extrapolate the in vivo rat results and estimate in vivo human absorption.  
Methods for measuring dermal absorption in vitro are widely used. As the SC is 
the main barrier to absorption, skin maintains its barrier function ex-vivo. Several 
studies have shown that trans-epidermal water loss (a good measure for barrier 
function) is similar in vivo and in vitro87, 88 and that in vitro permeation is generally 
a close estimate of in vivo permeation89. 
1.5.1 In vitro diffusion cell testing 
To design a protocol, many decisions need to be made such as the type of skin to 
be used, the type of diffusion cell, which receptor solution, and many more.  In 
an attempt to standardise the conduct of in vitro diffusion testing between labs, 
specific guidance is given in OECD 42890, with more specific guidance for dermal 
absorption studies for pesticide risk assessment by EFSA8, 10.  When the 
absorption of model compounds has been compared between labs, they have 
been shown to give similar results91. Also, it has been shown that in vitro 
absorption measurements give a good approximation of in vivo absorption86, 92, 93. 
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1.5.1.1 Sources of Skin 
It is preferable to use human skin for risk assessment. Human skin can be 
obtained from cosmetic surgery, skin banks or cadavers. However, the use of 
human skin can be expensive and logistically difficult. It is often unknown 
exactly how the skin has been treated before it is received. For example, if the 
skin is from surgery it is common that scrubbing with alcohol will have occurred 
prior to excision. The pieces of skin are also often small and irregularly shaped, 
which can make handling and preparation difficult.   
For these reasons, it is sometimes preferable to use the skin of other species. Many 
animal skins have been tested including rat, hairless mouse, guinea pig, snake 
and dog2, 24. However, absorption of chemicals varies between species2, 9 due to 
variations in follicular density, SC structure and lipid composition. Rat skin is 
commonly used both in vivo and in vitro but has been shown to be more 
permeable91 than human skin. Pig skin is thought to be a good model for human 
skin as it has a similar lipid composition94 and follicle density95 and studies have 
demonstrated similar absorption to human skin96, 97.  
The advantages of using pig skin are that the investigator controls what happens 
to the skin post-mortem, meaning it is less likely to be damaged. Also, the fact 
that the skin received from sacrificing one pig has an area of around 1m2 means 
that handling is much easier, as it can then be cut in to sections of the desired 
size. Additionally, multiple replicates can be taken using the same donor, 
therefore eliminating inter-individual variability. This can be useful in scientific 
investigations where the difference between two outcomes is small and may be 
masked by inter-individual variability. However, if the aim of the study is to gain 
an absolute value of absorption, more than one donor should be used. EFSA 
guidance8 recommends the use of skin from at least 4 donors. This is to provide 
a more representative sample of the population.  
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1.5.1.2 Preparation of Skin 
Skin used in dermal absorption studies is usually not full thickness. The use of 
full thickness skin often results in lower levels of the test compound in the 
receptor solution98 and increased lag times. This is because a molecule must 
traverse the hypo-dermis before reaching the receptor solution, which would not 
be necessary to be absorbed systemically in vivo.  
Probably the most commonly used is split-thickness or dermatomed skin. A 
dermatome is an instrument that can cut the skin to a nominal depth that would 
usually include the epidermis and part of the dermis.  
Another common method for preparing the skin is by heat separation99, the 
process of submerging the skin in water at 60oC. This causes the epidermis to 
separate from the dermis without significantly impairing the barrier function. 
The upper layers can then be used for diffusion studies. SC can also be isolated 
by trypsin digest, but is very fragile due to being extremely thin and will result 
in the SC being unrealistically hydrated27.  
After the skin has been prepared, it is common to freeze it for later use, it is 
generally accepted that barrier function is not affected by this process100. If the 
skin is to be used for regulatory studies then tests are performed to determine the 
integrity of the barrier. When using human skin, as described above, small pieces 
of skin that come from a surgical environment can easily be damaged. Methods 
to measure barrier integrity include trans-epidermal water loss34, 101, 
capacitance102 or diffusion of tritiated water90. 
 
1.5.1.3 Diffusion Cells 
Once the membrane has been selected and prepared, in vitro dermal absorption 
studies can be carried out using diffusion cells. The most common type of cell 
was designed by Franz in 1975, who found a good agreement between in vitro 
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and in vivo absorption of 12 compounds92. Figure 8 shows a static Franz diffusion 
cell, an apparatus usually made of glass, and within which a piece of skin can be 
secured. On the upper side of the skin is the donor chamber, where the product 
to be tested is applied, on the underside is the receptor solution which mimics 
plasma. The receptor solution is stirred with a magnetic bar and is normally 
maintained at 37oC, with the aim of achieving a skin surface temperature of 32oC, 
the average temperature of the skin surface in vivo at rest. 
 
 
Figure 8 - A Franz diffusion cell. 
103
 
Another common cell type is the ‘flow through’ diffusion cell. The receptor 
solution beneath is constantly replaced, with the aim of mimicking blood flow. 
However, generally no differences in the ability of the two cell types to predict 
the in vivo scenario have been found91, 104, 105 and therefore static Franz cells are 
usually preferred due to the experimental setup being significantly less 
complicated.  
1.5.1.4 Receptor Solution 
Any molecule that passes through the skin must then dissolve into the receptor 
solution. The receptor is sampled at various time points to provide an estimate 
of the amount that would be systemically absorbed. The most common receptor 
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solution is phosphate buffered saline (PBS) at pH 7.4. It is essential that ‘sink 
conditions’ are maintained i.e., the dissolution of the compound in to the receptor 
solution is not rate limiting (solubility in the receptor solution should be at least 
10x higher than the highest observed concentration90). For compounds with low 
aqueous solubility this can be achieved by altering the receptor solution to 
increase its solubilisation capacity. The most common methods for achieving this 
are to include up to 6% Volpo, a non-ionic surfactant, or 5% bovine serum 
albumin106. Some studies have used a receptor solution of 50:50 ethanol:water to 
increase solubility of the test compound; however, the use of organic solvents is 
not recommended as this can alter the barrier properties of the skin107.  
1.5.1.5 Exposure Type 
It is important to replicate the exposure that is being investigated as closely as 
possible. The use of a relevant dose and a commercially relevant formulation are 
both important. Although the physicochemical properties of the compound of 
interest will have a large effect upon absorption, this can be modulated by the 
vehicle in which it is presented to the skin. It is important that the application is 
from a vehicle with relevant components. It has been shown that pesticides 
presented to the skin in commercial formulations may be absorbed more 
efficiently than in an aqueous donor108 or acetone vehicle 109. This is because these 
formulations often contain solvents which may enhance penetration through the 
skin. This can occur when the solvent passes into the skin and carries the solute 
with it110, 111   or when the solvent actively damages the barrier function of the 
skin107, 112, 113 
It is also very common for commercial pesticide formulations to contain one or 
more surfactants. Surfactants are often added to lower the surface tension of the 
solution which can improve spreading and wetting, and decrease the amount of 
substance that needs to be applied. Surfactants can also increase mixing between 
hydrophilic and lipophilic substances; this property is useful to enhance 
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penetration of hydrophilic substances into the wax of a leaf, for example. Due to 
these very properties, surfactants can enhance penetration of substances across 
the skin114-117. 
1.5.1.6 Wash Procedure 
At the end of the prescribed exposure time, the skin is decontaminated. 
Depending upon the aims of the study, sampling may continue after this time 
point. In risk assessment, the wash procedure typically uses an aqueous soap 
solution to replicate a worker washing their hands at the end of a working day. 
However, when wash efficiencies have been measured, some studies have found 
that washing immediately after exposure did not remove all pesticide118, 119 and 
that the lipophilicity and solubility of the compound can affect wash off 
efficiency2. This could be due to the short window of time that is available for the 
wash solution to solubilise the compound120, 121. 
1.5.1.7 Tape Stripping 
Tape stripping is a method used both in vivo and in vitro for measuring the 
distribution of a molecule within the SC122. This procedure is generally carried 
out upon termination of the experiment and consists of applying adhesive tapes 
to the surface of the skin and removing them, thereby removing a layer of SC 
cells. It is also possible to weigh the tapes before and after the tape stripping 
process in order to estimate the amount of SC that has been removed. These tapes 
are then extracted and quantified for the molecule of interest. Using a 
combination of the estimated mass of SC and the concentrations of the molecule 
within, a depth profile can be plotted. Although it is not clear if all of the SC 
removed with each tape is from the same depth, as furrows in the skin can cause 
variation123. Regardless, tape stripping is a powerful method that is simple and 
inexpensive.  
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In the case of studies for drug delivery, it is common to assume that any drug 
recovered in the tapes is absorbed. However, in studies carried out for regulatory 
approval of pesticides in the EU it is common practice to assume that any 
substance found in the first two tape strips is not absorbed8 but will instead be 
lost via desquamation. If particularly lipophilic (log P > 3) then it may be 
reasonable to assume that the molecule would stay within the SC long enough to 
be lost via desquamation. However, for moderately lipophilic or hydrophilic 
compounds this assumption may not be true81 and in fact the SC can act as a 
reservoir from which the compound continues to be absorbed after the skin has 
been decontaminated69. One study by Zendzian et al showed 17 out of 19 
compounds continued to be absorbed after skin decontamination124, a reservoir 
remaining in the SC was postulated to be the cause. 
1.6 Absorption of Pesticides from Dried Residues 
As described above, exposure is not always to a solution, but can sometimes be 
to a solid or residue. To measure dermal absorption, EFSA guidance on dermal 
absorption8 recommends that ‘solid material should be moistened with a 
minimal volume of vehicle to make a paste’ or occlusive conditions used. This is 
because there is currently no defined methodology for application of solids in 
dermal risk assessment. Upon application of a finite dose of solid powder, it is 
unclear how much of the skin surface is covered, so moistening the solid would 
likely increase the area of contact. Moistening or using occlusive conditions could 
also mimic sweat on the surface of the skin. However, skin mounted in diffusion 
cells in vitro may already represent an over-hydrated system, which would 
represent a worst-case scenario.   
Previous work21 carried out in Bath designed an in vitro method to measure 
absorption of pesticides from dried residues. The active ingredient (AI) was 
mixed with acetonitrile to form a solution or suspension. This was applied by 
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spin coating to a steel disc and allowed to dry to form a residue. The disc was 
then placed on the skin surface and left in contact for an 8-hour exposure period 
(Figure 9).  
 
 
Figure 9 - Experimental set-up used by Belsey et al
21
, steel discs spin coated with 
pesticide applied to skin mounted in a Franz diffusion cell. 
This work showed that pesticides were absorbed differently when applied as a 
residue than when the same compound was applied as a solution or suspension. 
Four of the six compounds investigated were absorbed significantly less when 
applied as a residue, one compound showed no significant difference, and one 
compound was absorbed significantly more when applied as a residue.  
However, the methods used had several limitations that call in to question 
whether the results are entirely representative of the exposure scenario.  
Formulation effects were not taken into account. Pesticide products come in 
many different formulations, often containing other solvents and surfactants. If 
these other excipients are non-volatile, then they form part of the residue to 
which a worker is exposed and may therefore have an effect on the dermal 
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absorption of the AI. It would be more realistic to measure AI absorption from 
dried residues derived from commercially relevant formulations.  
The two dose levels used were 1000 µg/cm2 and 100 µg/cm2, the lower of these is 
at the upper limit of a realistic exposure. It is possible that absorption is flux-
limited for some compounds at this dose level. As described in section 1.4, 
fractional absorption can be dose-dependent and therefore lower doses more 
relevant to a typical exposure should be investigated.  
Spin coating was used to apply the pesticide in an attempt to achieve a uniform 
covering across the disc. However, this resulted in up to ±15% uncertainty in the 
amount of AI applied. If it is not possible to confidently state the amount 
originally applied, this reduces confidence in the results.  
The diameter of the disc was 12 mm (area of 1.13 cm2) while the area of skin 2cm2, 
meaning only about 60% of the skin surface was covered by the disc. Although 
this was taken in to account in the analysis by expressing absorption per square 
centimetre, it is possible that lateral diffusion occurred. Also, it was not clear how 
much of the disc was in direct contact with the skin, due to the presence of hairs, 
furrows and crevasses. There is uncertainty, therefore about the surface area of 
skin that was exposed.  
Finally, leaving the disc in contact with the skin for the duration of exposure, 
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1.7 Aims 
The aim here, therefore, was to develop and validate a more realistic in vitro 
method for quantifying the dermal absorption of pesticides from dried residues 
that satisfied the following criteria:  
 Exposure under non-occlusive conditions. 
 Quantification of the amount of residue applied to the skin. 
 Use of commercially relevant formulations. 
 Applying doses relevant to re-entry workers.  
 
It was necessary, therefore, to a) create a dried pesticide residue, and b) transfer 
this residue to the surface of the skin in vitro in a quantifiable manner. 
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2 METHODOLOGY 
2.1 Method Development 
Development of the methodology described in this chapter is not presented in 
chronological order, but rather split into three main decisions. The nature of 
method development means that none of these decisions could be made 
independently.  
2.1.1 Surface 
Belsey et al tested many types of artificial surface for uniformity of residue 
coverage after spin coating: glass coverslips, acetate transparency film, steel 
atomic force microscopy (AFM) discs and a selection of 
polyethyleneterephthalate (PET), which were uncoated, aluminiumised, or 
siliconised. Steel AFM discs were chosen due to their ‘ease of handling, regular 
shape, and superior residue coverage’21.   
2.1.1.1 Wheat Leaves 
An initial aim of the present project was to investigate the possibility of using 
a leaf surface (as opposed to a steel disc) in the method i.e., one more 
representative of a re-entry worker exposure scenario.  
However, the properties of leaf surfaces vary greatly between species, age of 
the plant and time of year125. Also, exposure may occur from other parts of the 
plant such as fruit, which will have very different surfaces. Therefore, the 
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choice of a ‘representative’ plant surface is not straightforward. First of all, to 
test the viability of using a leaf surface, wheat was chosen as a model; wheat 
is a very common crop, with 16.1 million tonnes being produced in the UK 
alone in 2015126. Wheat can also be grown fairly quickly and easily in a 
greenhouse.  
 
Figure 10 - 0 hours) Atrazine in methanol applied to a wheat leaf. 24 hours) 
Atrazine crystals remaining on the leaf after evaporation of the solvent. Scale bar 
= 2mm 
Using seeds provided by Syngenta, wheat was grown in a greenhouse at the 
University of Bath and leaves were used after 10 weeks. 
Four 1 µL droplets of atrazine (20 mg/ml in methanol) were pipetted onto a 
wheat leaf, still attached to the living plant, and were allowed to dry for 24 
hours. Application methods are explained further in section 2.1.2. Figure 10 
shows an image of the droplets immediately after application and 24 hours 
later when the solvent has evaporated away, leaving a ‘residue’.  
A potential issue when using leaves is that many pesticides are designed to 
translocate to different parts of the plant to elicit their effects. Therefore, it is 
0 hours 
24 hours 
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probable that after 24 hours, less than 100% of the applied AI would be 
available on the surface of the leaf. To test for translocation of atrazine, leaf 
sections were extracted in methanol 24 and 72 hours post-application. The 
mean recoveries from an 80 µg application were 81.2 ± 2.5 µg and 80.9 ± 1.3 µg 
for 24 and 72 hours respectively (n=5). This demonstrates that the atrazine has 
not moved away from that part of the leaf, however it does not give 
information about whether the atrazine has permeated into the leaf wax or 
into the plant cells themselves. With a log P of 2.7 it is likely that some of the 
atrazine has partitioned into the lipids of the leaf wax. To investigate this, a 
scalpel was used to scrape the residue remaining on the surface of the leaf after 
24 hours into a vial. Although every effort was taken to only remove residue 
on the surface, to make sure all residue was removed, it is possible that some 
leaf wax was also removed. When quantified only 61.5 ± 9.6 µg of the 80 µg 
applied were available, final recovery was 98 ± 5.8 % after extracting the 
remaining amount in the leaves (n = 10), this suggests that around 25% of the 
atrazine has passed into the leaf. Also, the amount recovered was much more 
variable, with highest and lowest recoveries of 71.3 µg and 48.2 µg 
respectively, although this could be an artefact of the removal process. This 
uncertainty about the exact amount of pesticide remaining on the surface of 
the leaf means that it would be difficult to accurately quantify the amount 
applied to the skin following transfer. In addition, experiments where a leaf 
was rubbed against a piece of filter paper to measure the transfer of atrazine 
left green marks on the filter paper. This suggests that not only the atrazine 
was being transferred, but part of the leaf also. 
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2.1.1.2 Inert Disc Coated in Wheat Wax 
To simulate the surface of a leaf, the aim was to use wax extracted from wheat, 
(supplied by the University of York) to create an inert surface onto which 
pesticide droplets would settle and dry in a similar manner to that on a leaf 
surface. This surface should have a smooth, even layer of wax similar to that 
found on the corresponding leaves.  
Various solvents were tested for their ability to solubilise the wax and it was 
found that concentrations up to 3% w/v could be achieved in toluene. 50 µL 
of this solution was then spin coated onto various platforms (glass cover slip, 
aluminium disc, siliconised polyethylene terephthalate (PET)).  
 
Figure 11 - Wheat wax on a 12mm glass disc 
However, spin coating left an uneven surface, often producing a circle of wax 
around the outside of the disc but with none in the middle. It was concluded 
that this may be due to the high boiling point of toluene which therefore was 
not evaporating away quickly enough during the spin coating process. After 
trying various ratios of methanol, ethanol and toluene, it was found that a 3:1 
mixture of methanol to toluene, warmed to 600C before application, gave the 
smoothest surface upon spin coating.  
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This solution was also pipetted directly onto the disc and allowed to evaporate 
without spin coating Figure 11. Under inspection with a light microscope, no 
visual differences in coating consistency were observed between these two 
methods.  
To compare residue consistency between the wax surface and a leaf, droplets 
of pesticide were applied to the treated disc and to a wheat leaf. Upon visual 
comparison it was evident that the wax disc was not a good model for the leaf. 
Liquid on the leaf beaded and formed a droplet (Figure 10) but droplets on the 
wax-treated disc ‘sank’ into the surface and did not form distinct droplets. It 
was not possible, therefore, to produce a dried residue of pesticide on the 
surface of the wax disc, presumably because the complex structure of wax on 
the plant125 is not mimicked well by the model.  
2.1.2 Application 
While Belsey et al used a spin coating technique to apply pesticide to discs, 
this approach is not representative of how a residue would be formed in the 
field. It is also not easily reproducible; specialist equipment is required and 
spin speeds and times have to be optimized for each compound (and 
presumably each formulation) to achieve acceptable results.  
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Figure 12 - A spray bottle mounted above a glass disc ready for application of a 
pesticide solution. 
The most common method of pesticide application is in the form of a spray. 
This may involve a hand-held sprayer/knapsack or a tractor mounted spray 
boom. These methods are obviously inappropriate for an in vitro laboratory 
setting and other more appropriate methods for applying pesticide to the 
platform were therefore investigated.  
A small throat spray bottle marketed as a ‘metered dose system’ was obtained 
(Cavonia, Thornton and Ross Limited, UK). This bottle was pump action and 
had a screw off lid so that the original solution could be replaced with 
pesticide solution (Figure 12). 
For initial testing, the bottle was filled with water and weighed before and 
after each spray. This gave promising results; after each spray the bottle 
weighed 95 ± 5 mg less, showing that around 100µL of water was being 
sprayed consistently. 
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The bottle was then filled with a solution of atrazine and mounted above a 
disc. The spray mechanism was operated once and the disc then assayed for 
atrazine by High Performance Liquid Chromatography (HPLC). The amount 
of atrazine applied had a range of ±70%. Various heights and angles were 
tested but none produced acceptably reproducible results. This may have been 
because, while the spray released the same amount of liquid each time, the 
plume dimensions were not constant. As a result, because the disc only 
represented a small portion of the spray area, small changes in droplet density 
or size had a large effect.  
 
Figure 13 - 0.25 µL pesticide droplets on 1 cm
2
 PET 
Another approach was to apply the pesticide to the platform as separate 
droplets. A micropipette, which could dispense volumes down to 0.1 µL, was 
used.  Droplets of 0.25 µL were applied to the platform, representing a coarse 
spray (Figure 13). When 16 x 0.25 µL droplets of atrazine at a concentration of 
20 mg/ml were applied, a mean deposition of 81 ± 3.2 µg was found with a 
range of less than 10% (n=10). This showed that the application method was 
acceptably reproducible, however, using this technique, the maximum 
number of droplets that fit within 1cm2 was found to be 20. Therefore, to 
achieve a loading of 80 µg/cm2 would require the concentration of the solution 
to be 16 mg/ml, which is simply not realistic for a spray dilution. When 80 µL 
Chapter 2: Methodology 
James Clarke - November 2017   42 
of a 1 mg/ml atrazine solution was applied as a single droplet, the recovery 
upon extraction of platforms was 80.2 ± 1.2 µg with a range of less than 5%.  
2.1.3 Transfer 
As described above, the Belsey method involved a pesticide-coated disc being 
pressed against the skin for the duration of the diffusion experiment. This is 
not representative of the scenario in the field, where only intermittent contact 
between skin and foliage would occur and the residue would be transferred 
to the skin, for example by brushing against the contaminated surface. A 
method to transfer residue to the skin, based around this scenario, was 
therefore developed. 
Three platform materials were tested for transfer efficiency; steel, glass and 
aluminiumised PET. Twenty 0.25 µL droplets of a 16 mg/ml atrazine solution 
were applied to the disc using the droplet application method described above 
and a glass vial was attached to the back of each disc in order to allow easy 
manipulation. The disc was then placed on to a piece of filter paper (which 
acted here as a substitute for the skin to test the methodology) and then rotated 
three times clockwise and three times anticlockwise, to transfer the residue 
(Figure 14). Atrazine was subsequently extracted and quantified from the 
filter paper and the disc, and the results are summarised in Table 1 below.  
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Figure 14 - A disc attached to the bottom of a glass vial to measure transfer of 
pesticide to filter paper 
The percentage transfer to the filter paper was least from the aluminiumised 
PET and greatest from the glass disc. The AFM disc had the most reproducible 
transfer (standard deviation of 5.89% and highest and lowest values of 85.5% 
and 69.25% respectively). Importantly, these results also indicated that it is 
possible to estimate the amount transferred, from the difference between the 
quantity originally on the disc and that remaining post-transfer.  
 
Table 1 - Percentage of dose applied transferred to filter paper n=10 
To investigate how well the residue was spread on the skin, a dye (Nile Red) 
was dissolved in a blank emulsifiable concentrate formulation (supplied by 
Syngenta) and diluted 100x in water to create a relevant spray dilution. With 
this model AI it was possible to visualise the distribution of the residue using 
this transfer technique. Nile Red was considered a suitable model compound 
 Atrazine (% of dose applied):  
Platform Filter Paper Disc Total 
Glass 90.4±18.1 14.5±5.3 105.0±15.7 
AFM 75.8±5.9 21.5±4.5 97.3±4.1 
Aluminiumised PET 63.5±11.9 37.4±10.3 100.9±4.4 
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as its physicochemical properties are similar to some of the pesticides 
considered later in the thesis. 40 µl of the solution was applied to a steel disc 
in a single droplet and allowed to dry. The rotation transfer procedure 
described above was performed on pig skin (n=5) and images taken of the 
resulting distribution of Nile Red.  
 
 
Upon inspection, it was evident that the residue was predominantly being 
applied to the periphery of the skin, leaving a blank area in the middle (Figure 
15(a)). This is because the residue has dried on the disc in a “coffee ring” 
shape. Also, if rotated around the centre axis, residue at the edge of the disc 
will move a considerably longer distance than that at the centre. This greater 
amount of movement at the periphery may results in more transfer. To 
address this, as the diameter of the disc and vial (12mm) was slightly smaller 
than the confines of the diffusion cell lid (16mm) it was possible to also move 
the disc laterally upon the skin surface. This alternative transfer method was 
adopted, whereby, in addition to being rotated, the disc was also moved in a 
‘plus (+)’ movement upon the skin and later in the thesis, in a circular motion 
also. The exact movements are not necessarily important but the idea was to 
Figure 15 - Nile Red residue transferred to pig skin using (a) rotation method (b) 
rotation method with further lateral movements. 
a) b) 
4mm 4mm 
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vary the movement of the disc to achieve an even spread of residue across the 
skin. Figure 15(b) shows the skin after application of Nile Red using this 
improved transfer method. The AI coverage is much more even and is spread 
across almost the whole area.  
The optimised method also showed better reproducibility in the amount 
transferred and it was again possible to estimate the amount applied by 
measuring the quantity remaining on the disc (Table 2).  
 In this case, 20 µL of an emulsified concentrate formulation of trinexapac-
ethyl (TXP, Syngenta) (10% w/w), diluted 100 times in water (to 1 mg/ml) was 
pipetted onto steel AFM discs and allowed to dry to form a residue. The 
transfer protocol was then carried out as described above. Immediately after 
application, three tape strips were taken in order to investigate the disposition 
of the residue on the skin. Pesticide was extracted from the tapes and the rest 
of the skin and quantified by HPLC.  
 
Table 2 - Rotating disc & plus formation results on pig skin, all values in µg. n=5 
The mean amount applied to the skin was the total amount of TXP recovered 
from the three tapes and the remaining skin: 17.7 ± 1.0 µg. This shows very 
good reproducibility with a narrow standard deviation. It is interesting that 
even after three tape strips have been taken 11% of the applied dose still 
remained within the skin. This suggests that some residue is deposited in 
crevasses and/or appendages of the skin.  
Disc Remainder Tape 1 Tape 2 Tape 3 Skin Transferred Total 
2.2±0.3 11.9±1.0 2.8±0.5 0.8±0.2 2.2±0.7 17.7±1.0 19.8±0.8 
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2.2 Final Methods 
With the issues associated with using leaves described above, the benefits of 
using an inert surface were deemed to outweigh the fact that it is less realistic. 
An inert surface is easier to handle in the lab, removes the need to source fresh 
leaves, and provides more reproducible residue deposition. Based on results 
from the transfer tests, 12 mm steel AFM discs were chosen for use in the final 
method. If deemed necessary, it should be possible to adapt the method for 
use with leaves, or a more representative platform, if available in the future.  
Although the use of droplets may be the most realistic method, limitations in 
the amount that can be applied and a less reproducible application meant that 
this approach was not pursued. Application of pesticide solution as one 
droplet to the surface of the platform was the method carried forward. It is 
thought that the residue produced will be similar to that from smaller 
droplets. As it is to be transferred to the skin anyway, any effect on the final 
outcome should be minimal. It may also be possible to adapt the method to 
use a track sprayer to coat the discs in the future.  
The final transfer method consists of three rotations clockwise, three rotations 
anticlockwise, and three movements in a ‘+’ formation. For later experiments 
using other compounds, three movements in a circular motion were added to 
improve spreading. 
2.2.1 Protocol 
The final method used was based on the standard approach for measuring 
pesticide dermal absorption when seeking regulatory approval as advised by 
EFSA8  and OECD90 guidance. 
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General aspects of the methodology are described here; specifics and any 
protocol deviations are discussed in the relevant later chapters of the thesis.  
Static Franz diffusion cells were used with a receptor chamber of 7.4 ml and 
an area of exposed skin of 2 cm2. The receptor chamber was constantly mixed 
using a magnetic stirrer. As opposed to using a water jacket system, diffusion 
cells were incubated at 32 ± 10C in a controlled environment cabinet. Relative 
humidity was monitored but not controlled, the highest recorded % RH value 
for any experiment was 45% and the lowest was 39%. This approach reduced 
variations in temperature and humidity at the surface of the skin that would 
otherwise depend upon time of day and year. This was deemed important, as 
dissolution at the skin surface may be rate limiting for residue absorption. 
Pig skin was obtained from a local abattoir, the hair trimmed with scissors, 
dermatomed to a nominal thickness of 750 µm (Zimmer®, Ohio, US) and 
subsequently stored at -20oC within 24 hours of slaughter. Over the course of 
the work, skin from 5 pigs was used; however, for all replicates within each 
individual study, skin from the same pig was used.  
All receptor solutions contained phosphate buffered saline (PBS) pH 7.4, to 
which, for some compounds, Volpo™ was added to increase solubility. 
Solubility of each test compounds in the receptor solution was experimentally 
determined (given in Table 3) and were at least 10 times great than the highest 
observed receptor solution concentration. 
Skin was allowed to thaw for a minimum of 30 minutes. Skin was then 
clamped between the two chambers, receptor solution added, and allowed to 
equilibrate at room temperature for a minimum of 20 minutes before 
application of pesticide. 
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Application of solution to the skin was by positive displacement pipette, the 
dose was spread across the entire skin surface. For each set of cells, a ‘mock 
dose’ was pipetted in to a vial and the quantity of AI was determined.  
2.2.1.1 Residue Application 
For residue application, pesticide solution was applied to 12 mm AFM discs 
and allowed to dry for ~24 hours at room temperature. Extra ‘mock discs’ were 
also made; these discs were extracted and quantified for AI after the drying 
period to check AI loading levels. Discs were attached to a weighted vial (~10 
g) by double sided adhesive tape (Figure 16). Each disc was placed residue 
side down against the skin and rotated three times clockwise, three times 
anticlockwise, three times in a plus formation (Chapter 3) and three times in a 
circular motion (Chapters 4 and 5). The disc was removed from the skin and 
placed in a vial with 4ml of extraction solution to quantify the amount of AI 
remaining. This remaining amount was then subtracted from the original 
amount applied, giving an estimate of how much was transferred to the skin 
for each cell. 
 
Figure 16 - Application of a dried pesticide residue to skin mounted in a Franz 
diffusion cell 
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After application, cells were immediately placed into the controlled 
environment cabinet and the protocol for liquid and residue applications was 
identical from this point on.  
Prior to sampling, the receptor solution was thoroughly mixed by removal 
and replacement of 0.5 mL of solution three times. The sample was then taken 
by removing 0.3 mL for analysis which was immediately replaced with fresh 
receptor solution. Samples were taken at 2,3,4,5,6,7,8 and 24 hours for TXP and 
only 8 and 24 hours for PPZ, CLF and DFZ. This is because levels in the 
receptor were below or close to the LOQ for these three compounds.  
A wash procedure was carried out 8 hours after initial exposure. This 
consisted of applying 100 µL of a 0.1% w/v soap solution onto the surface of 
the skin followed by immediate swabbing with two cotton Q-tips. Swabs were 
extracted in 1 mL (Chapter 3) or 4 mL (Chapters 4 and 5) of the relevant 
extraction solution.  
The experiment was terminated at 24 hours from initial exposure, a final 
receptor solution sample was taken and tape stripping was performed. For 
each cell 15 adhesive tapes (scotch book tape, 3M, Germany) were cut to size 
2 cm by 2 cm.  For experiments in Chapter 3 and experiments investigating 
the effect of AI in Chapter 4, tapes were weighed before and after tape 
stripping on a balance (precision of 0.1 µg). As data obtained from weighing 
tapes was not deemed to add value to the results, tapes were not weighed for 
later experiments that investigated washing, loading and formulation.  
Prior to tape stripping, parts of the skin outside of the exposure area were cut 
away. The skin was pinned down with a 2 cm2   circular template around the 
exposure area. Each tape was pressed against the surface of the skin and 
removed in sequence. Each tape was extracted separately in 1 mL of extraction 
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solution.  Following the tape stripping procedure, the remaining tissue was 
placed in an extraction vial and remaining AI extracted with 4 mL extraction 
solution. The lid from the donor compartment was extracted in 5 mL of 
extraction solution. All extracted samples were quantified by HPLC analysis 
(Table 3). Mean extraction efficiencies were shown to be greater than 95% from 
the disc, tape strips, wash swabs and remaining tissue. 
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Over the course of the work, four compounds Trinexapac-ethyl (TXP), clodinafop-propargyl (CLF), propiconazole (PPZ) and 
difenoconazole (DFZ) were used. A Shimadzu LC-20101A HPLC was used for analysis throughout the study, with a 25 cm C18 column 
HiQ sil C18HS (Particle Size: 5 μm , Pore Size : 100 Å). The injection volume was 50 µL for all samples. All samples were filtered prior to 
injection, Nylon or reconstituted cellulose (Cronus, nylon 0.45 µm, Labhut, UK and Minisart RC4, 0.45 µm, Fisher, UK). 
 
Table 3 - HPLC methods used for quantification of all samples. 












Limit of Quantitation 
(LOQ) (µg/ml) 
Solubility, 6% volpo in 
PBS (mg/ml)‡ 
CLF 70/30 ACN:H2O 25 226 1.0 8.6 70/30 ACN:H2O 0.035 0.5±0.2  
CLF *
 
75/25 ACN:H2O 25 226 1.0 6.7  0.035 [0.5% Volpo - 0.11±0.04] 
DFZ 70/30 ACN:H2O 35 212 1.5 6.9 80/20 ACN:H2O 0.025 1.4±0.3  
PPZ 70/30 ACN:H2O 25 220 1.5 6.1 70/30 ACN:H2O 0.07 2.0±0.2   
TXP 60/40 ACN:0.1%H2PO4 25 280 1.0 8.5 60/40 ACN:H2O 0.03 16.7±1.1 [PBS- 9.2±0.8] 
 
*Method used specifically for CLF analysis of extracted stratum corneum tape strips.  
† Extraction volumes were 1ml for tape strips, 4ml for remaining skin, swabs and discs and 5ml for the donor lid 
‡ Experimentally determined, mean± SD (n=10) 
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3 PAPER 1 - IN VITRO METHOD TO QUANTIFY DERMAL 
ABSORPTION OF PESTICIDE RESIDUES. 
 
Following the design of methodology to measure pesticide absorption from dried 
residues, as described above, the work in this paper aimed to test this approach.  
 
Aims: 
 To test the applicability and repeatability of the method designed to apply 
pesticide residues for in vitro diffusion cell studies 
 To investigate if dermal absorption of trinexapac-ethyl is different when 
applied as a residue compared to when applied as a spray dilution 
 Investigate the possibility of a ‘wash-in’ effect for the residue 
 
 
3.1.1 Contributions  
This Rapid Report was published in ‘Chemical Research in Toxicology’ in 
February 2015, all practical work described was carried out by the first author. 
The manuscript was written by the first author and edited and approved by all 
authors.  
James F. Clarke1, Sarah F. Cordery1, Neil A. Morgan2, and Richard H. Guy1 
1University of Bath, Department of Pharmacy & Pharmacology, Bath, BA2 7AY, U.K. 
2Syngenta UK Ltd, Jealott's Hill International Research Centre, Bracknell, RG42 6EY, U.K. 
Chapter 3: Paper 1 - in vitro method to quantify dermal absorption of pesticide residues. 
James Clarke - November 2017   53 
 
Chapter 3: Paper 1 - in vitro method to quantify dermal absorption of pesticide residues. 
James Clarke - November 2017   54 
 
Chapter 3: Paper 1 - in vitro method to quantify dermal absorption of pesticide residues. 
James Clarke - November 2017   55 
 
Chapter 3: Paper 1 - in vitro method to quantify dermal absorption of pesticide residues. 
James Clarke - November 2017   56 
3.1.2 Further Discussion 
This work showed that the method designed produces reproducible residue 
application. Applications were 21.7±3.2 µg in the 8-hour exposure experiment 
and 20.5±2.0 µg in the 24-hour experiment. The highest measured transfer was 
26.4 µg and the lowest was 17.8 µg.  
The results showed that TXP is absorbed significantly less from the residue than 
the spray dilution, when decontamination occurred at 8 hours. However, when 
the skin was not decontaminated until 24 hours, total absorption was not 
significantly different between the two application types. Between the two 
exposure times total TXP absorption from the liquid did not change, however, 
absorption from the residue was significantly greater after 24-hour exposure. 
This may be because absorption from the residue is limited by dissolution at the 
skin surface and therefore in the extra 16-hour exposure, TXP is still partitioning 
in to the skin, whereas absorption from the liquid is essentially complete by 8-
hours.  
Up to the 8-hour time point, the protocol for the two experiments was identical. 
However, for the residue experiments, when the amount of TXP in the receptor 
solution is plotted against time (Figure 17), penetration to the receptor is 
significantly higher between 6 and 8 hours for the 24-hour exposure experiment 
than for the 8-hour experiment and this appears to contribute significantly to the 
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This apparent difference may be a consequence of the low concentration of these 
samples. Samples below LOQ (0.03 µg/ml for TXP) were reported as zero.  One 
replicate in the 8-hour exposure experiment had an 8-hour receptor concentration 
of just above this level at 0.046 µg/ml (0.34 µg total in receptor), with the other 4 
replicates containing ‘0 μg’ however, with a receptor volume of 7.4ml they could 
potentially each contain up to 0.22 µg of TXP before reaching the LOQ. The 
receptor samples taken at 8 hours from the 24-hour exposure experiments were 
only just above the LOQ. Therefore, it is likely that the mean concentration of 
TXP in the receptor at 8 hours was higher than the results suggest for the 8-hour 
exposure experiment.   
To test that the results of this experiment were valid and to draw more firm 
conclusions about the effect of exposure time, this experiment was repeated as 
well as adding four further shorter exposure times. These results are described 
in Chapter 4. 
The absorption of three additional compounds following 8-hour exposure was 
also investigated. Although the work in Paper 1 demonstrated the potential of 
the methodology, for it to be fully validated a wider range of pesticides must be 
tested. Also, to draw more firm conclusions about absorption from residues in 
2 4  h r  e x p o s u r e








































2 4 6 8 24
b )
 8  h r  e x p o s u r e










































2 4 6 8 24
L iq u id
R e s id u e
a)
Figure 17 – Cumulative absorption of TXP across the skin in vitro (mean ± SD) 
following liquid spray dilution and residue applications as a function of time for a) 
8-hour exposure (n= 5) b) 24-hour exposure (n= 4-5) 
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general it is necessary to test compounds with varying physicochemical 
properties. TXP is relatively hydrophilic and therefore the stratum corneum is 
the primary barrier to its systemic absorption. Compounds that are more 
lipophilic and therefore dissolve more easily into the SC, could behave differently 
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4 PAPER 2 - DERMAL UPTAKE AND ABSORPTION OF PESTICIDE 
RESIDUES 
 
Following validation of the methodology in Paper 1, the following study aimed 
to extend these findings by investigating absorption from three additional active 
ingredients in the same formulation. Absorption of one compound, TXP, was also 
measured following various exposure times, to investigate how a shorter 




 To investigate the absorption of AIs with different physicochemical 
properties. 
 To investigate the effect of different exposure times on dermal absorption 
of both spray dilution and dried residue. 
 
 
4.2 Contributions  
This manuscript was submitted to ‘Environmental Science and Technology’ in 
August 2017, all practical work described was carried out by the first author. The 
manuscript was written by the first author and edited and approved by all 
authors.  
James F. Clarke1, Sarah F. Cordery1, Neil A. Morgan2, and Richard H. Guy1 
1University of Bath, Department of Pharmacy & Pharmacology, Bath, BA2 7AY, U.K. 
2Syngenta UK Ltd, Jealott's Hill International Research Centre, Bracknell, RG42 6EY, U.K. 
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4.3 Abstract 
Current guidance for dermal exposure assessment of plant protection products 
typically uses in vitro skin penetration data for the active ingredient when applied 
as both the concentrated product and relevant spray dilutions thereof.  However, 
typical “re-entry” scenarios involve potential skin exposure to a ‘dried residue’ 
of the spray dilution, from which the absorption of a pesticide may be quite 
different. The research reported in this paper has shown: [1] A method to transfer 
dried pesticide residues from an inert platform to the skin surface has been 
successfully developed that is reproducible for four active ingredients, of diverse 
physicochemical properties, after their application in a commercially relevant 
formulation.  [2] The skin uptake and absorption of all four pesticides examined 
was significantly less from a dried residue than from a spray dilution; the 
difference, in general, was on the order of a factor of 2.  [3] Decontamination 
experiments with one of the active ingredients tested (trinexapac-ethyl) showed 
that, post-exposure to a spray dilution, skin surface cleaning must be performed 
within 1 hour to significantly reduce potential systemic exposure (as assessed 
relative to continual contact for 24 hours); in contrast, after contact with a dried 
residue, the sooner decontamination was performed, the greater the decrease in 




Chapter 4: Paper 2 - Dermal uptake and absorption of pesticide residues 
James Clarke - November 2017   61 
4.4 Introduction 
When pesticides are used in practice, the application is usually in the form of a 
‘spray dilution’ in which the concentrated formulation has been mixed with 
water. After application, the diluted formulation eventually leaves a ‘dried 
residue’ on surfaces, such as leaves or fruit. For each pesticide product, a series 
of risk assessments must be carried out before use. These calculations encompass 
various scenarios and consider the product’s effect on the ecosystem and on a 
number of specific organisms, including humans. For example, an operator could 
potentially be exposed during mixing and loading of the product into a spray 
tank or, during application, there is a further possibility of exposure, not only to 
the operator, but also to bystanders and nearby residents; in addition, post-
application, anyone entering the treated area may be at risk of exposure to the 
recently applied product.  
A re-entry worker, an individual who enters a field to carry out a task such as 
crop inspection or harvest, may enter a treated area soon after pesticide 
application and risk exposure, therefore, to the dried residue remaining on 
leaves, fruit, etc. Exposure occurs most typically via dermal (the most important7) 
and inhalation routes, with secondary exposure also possible via hand-to-mouth 
transfer.  The potential dermal exposure (PDE) can be estimated for the purpose 
of a risk assessment and depends upon: (a) how much pesticide is present on the 
contaminated surface, the so-called dislodgeable foliar residue (DFR), which is 
dictated by factors such as application rate, concentration of the active ingredient 
(AI), and the pesticide formulation; (b) how much of the DFR is subsequently 
transferred to the skin, as characterised by a transfer coefficient (TC), which is 
dictated by intensity of contact a worker has with the contaminated surface; and 
(c) the duration of the work.  Once the PDE has been determined, the quantity of 
pesticide which will be absorbed through the skin and eventually become 
systemically available can be estimated.  
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The skin’s primary function is to act as a barrier both to the loss of endogenous 
water and to the absorption of exogenous xenobiotics. The outermost layer, the 
non-viable stratum corneum (SC), is typically the rate-limiting barrier to 
absorption, meaning that ex-vivo skin has a competent SC88 and can be used in 
vitro as a surrogate for the in vivo situation89.  Consequently, at present, to 
determine the skin absorption of a pesticide, in vitro diffusion cell experiments 
on the concentrated product, and on representative spray dilutions, are 
performed. The highest fraction of the ‘dose’ absorbed from the three is then used 
for risk assessment, and this value is multiplied by the PDE to yield an estimate 
of systemic exposure.  
However, as articulated above, in an actual re-entry scenario, a worker does not 
come into contact with the concentrate or a spray dilution of the pesticide; rather, 
skin contact occurs with the dried residue of the spray dilution.  In previous 
experiments, a significant difference was observed in the dermal absorption of 
various pesticides from liquid and residue forms21; in some cases, the chemical 
was absorbed more from the residue but, in others, the uptake was less. The in 
vitro method used to measure skin uptake from the residue involved pesticide 
application to an artificial material, the coated surface of which was subsequently 
pressed against the skin for 8 hours (signifying a typical working day). An 
obvious limitation of this approach is that the skin is occluded by the disc 
throughout the exposure, and the resulting increased hydration has been shown 
to amplify dermal absorption56, 57, 127. This effect may be exacerbated for a dried 
residue, as surface moisture resulting from occlusion effectively becomes the 
‘vehicle’ in this exposure. Another shortcoming of the protocol used was that the 
active ingredient was deposited on the artificial surface from a simple solvent 
rather than from a commercially relevant formulation. Furthermore, the lowest 
dose used was at the upper end of a realistic worker exposure. As many studies 
have shown percentage absorption often decreases with increasing skin 
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loading65-67, 128, the use of doses higher than that to which a worker may be 
exposed may provide unrealistic absorption values.  
To overcome these limitations, a method described recently129 was used to 
measure the dermal absorption of pesticide residues in a realistic, non-occlusive 
manner. In the research described in the present paper, this refined approach was 
used to compare the dermal absorption of four pesticides from liquid and residue 
‘vehicles’ following application from the same commercially relevant 
emulsifiable concentrate formulation.  Furthermore, for one of the chemicals, the 
effect of decontamination after different exposure periods was investigated to 
better simulate, for example, hand-washing events prior to rest or lunch breaks 
in a worker’s typical 8-hour day. Clearly, hand-washing can potentially remove 
a significant fraction of a dried residue and therefore reduce the overall systemic 
exposure2. Although it has been found that hand-washing does not completely 
decontaminate the skin119,118, perhaps because mobilisation of material trapped in 
skin crevices and/or appendages is difficult and less than 100% efficient,  the 
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4.5 Methods 
4.5.1 Materials 
Four active ingredients (AI), spanning a range of physicochemical properties, 
were considered: trinexapac-ethyl (TXP), clodinafop-propargyl (CLF), 
difenoconazole (DFZ) and propiconazole (PPZ) (Table 4).  Each was formulated 
in an identical commercially relevant, naphtha-based 10% w/v emulsifiable 
concentrate (EC) supplied by Syngenta (Jealotts Hill, U.K.).  Spray dilutions of 
each AI were prepared by diluting the concentrate 100-fold in water, producing 
thereby a final AI concentration of 1 mg/mL. 
 
Table 4 - Pesticides selected for investigation and their relevant physicochemical 
properties. 
4.5.2 Dermal absorption procedures 
In vitro skin uptake and absorption experiments were performed using static 
Franz diffusion cells with a receptor volume of 7.4 mL and area of 2 cm2. Dorsal 
porcine skin from a single donor was dermatomed to a nominal thickness of 750 
µm, frozen within 24 hours of slaughter and thawed before use. Porcine skin was 
chosen as it is considered to be the closest surrogate to human skin96, 97, 130. 
However, the structure of and penetration across pig skin does differ from that 
















Trinexapac-ethyl (TXP) 252 36.3 -0.29 10.2 0.366 
Clodinafop-propargyl 
(CLF) 
350 59.5 3.9 0.004 0.032 
Difenoconazole (DFZ) 406 82.5 4.36 0.015 0.117 
Propiconazole (PPZ) 342 -23 3.72 0.15 1.02 
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Using skin from the same donor for each set of experiments reduced variability 
in the results and facilitated comparison between different AIs and exposure 
periods. The method used followed OECD90 and EFSA8, 9 guidance documents 
for in vitro diffusion cell studies required in the regulatory approval process. The 
only significant deviation was that, instead of a water jacket system to control 
skin temperature, diffusion cells were incubated at 32 ± 10C, and at a relative 
humidity of 40 ± 5% in a controlled environment cabinet. This approach reduced 
variations in temperature and humidity at the surface of the skin that otherwise 
depend upon time of day and year. The tighter control of the environmental 
conditions at the surface of the skin was considered important for this study 
because of the potentially rate-limiting nature of the dissolution kinetics of the 
AI residue.  
As a control, skin uptake and absorption of the liquid spray dilution of each AI 
was also assessed.  A volume of 25-30 µL* was applied for a period of 8 hours (a 
typical working day), when the skin surface was cleaned.   
The wash procedure involved application to the skin of 100 µL of a 0.1% w/v soap 
solution and cleaning with two cotton swabs, from which the AI was 
subsequently extracted and quantified.  The receptor solution (which consisted 
of 6% Volpo™ (Sigma Aldrich Co., Gillingham, UK) in phosphate-buffered 
saline) was sampled at each hour from 2 to 8 hours for TXP and then at 24 hours. 
For the other three AIs, receptor solution samples were taken at 8 and 24 hours 




* The exact volume used was informed by the average amount of AI residue 
transferred to the skin from the stainless-steel disc to which 40 µg had been applied 
(see following text) in preliminary experiments.  The actual volumes in the control 
experiments were 25 µL for TXP and PPZ, and 30 µL for DFZ and CLF. 
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After the final receptor phase sampling at 24 hours, the skin was removed from 
the diffusion cell and the outer, stratum corneum was removed by adhesive tape-
stripping (Scotch Book Tape, 3M, Germany) as previously described21.  
According to the EFSA guidelines8, AI in the first two tape strips is considered to 
be non-absorbed material lost via desquamation, while that in the subsequently 
removed 13 tape strips is assumed to be absorbed, as is the pesticide recovered 
from the remaining skin tissue post-stripping.   
The methods used to ensure efficient extraction of the AIs from the stratum 
corneum tape-strips and from the remaining skin post-stripping are described in 
the supplementary information, as are the HPLC analytical protocols for each AI. 
‘Total absorption’ of the AI was therefore determined as the sum of the 
cumulative amount of pesticide in (a) stratum corneum tape-strips 3-15, (b) the 
skin remaining post-stripping, and (c) the receptor solution at 24 hours. AI in the 
first two stratum corneum tape-strips was also extracted and quantified but not 
included in the total absorption reported. 
To measure AI absorption from a ‘dried’ residue, exactly 40 μL of the liquid spray 
dilution was applied to a stainless-steel disc of 12 mm diameter (SPM specimen 
discs, TAAB Laboratories Equipment Ltd., Aldermaston, U.K.) and allowed to 
dry for 24 hours. This residue was then applied to the skin with a standardised 
transfer procedure129. In addition to the circular rotations and lateral movements 
described previously, the disc was also moved three times in a circular motion in 
order to ensure adequate spreading. AI remaining on the disc post-transfer was 
then extracted and quantified allowing an estimate of the AI residue transferred 
to the skin to be determined by difference. After application of the residue to the 
skin, the in vitro diffusion cell experimental protocol was identical to that for the 
liquid application explained above.  
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For TXP, additional skin uptake and absorption experiments were performed to 
assess the impact of skin washing after different exposure periods. Identical 
procedures to those already described were used with four modifications: (i) the 
skin surface was cleaned after separate exposure durations of 0.5, 1, 2, 4, 8 and 24 
hr; (ii) the receptor solution was phosphate-buffered saline alone, (iii) the skin 
used was from a different (but single) pig; and (iv) the receptor solution was also 
sampled after 1 hour.  
It is important to note that the aim of this study was not to obtain absorption 
factors for regulatory assessment, but rather to further validate the methodology 
for residue application and to assess differences in absorption from liquid and 
residue applications. 
4.5.3 Results & Discussion 
The 24-hour skin uptake and absorption of the four AIs considered (in terms of 
the % of the applied ‘dose’) is summarised in Figure 18.  Given the close overlap 
between the actual amounts of the AIs applied, the expression of the data as % of 
the applied quantity allows a valid comparison between the chemicals, and 
between uptake and absorption from liquid and residue phases, to be made.  For 
all four AIs, the total % of the applied amount was significantly higher (p < 0.05) 
from the liquid than from the residue.  Across the different AIs, for both liquid 
and residue applications, there was about a 2 to 3 fold range in the absolute skin 
uptake and absorption values. 
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Figure 18 - Stacked bar chart showing the skin uptake and absorption at 24 hours 
after liquid (hatched bars) and residue (plain bars) application of the pesticides 
considered (mean ± SD; n = 3-11). 
 
More detailed skin uptake and absorption data for TXP are shown in Table 5. 
From the liquid spray dilution application, TXP penetration through the skin to 
the receptor phase was detectable from the first measurement at 2 hours and 
increased progressively over the duration of the experiment (Figure 19 (a)).  The 
derived rate of penetration, however, indicated a clear maximum at around 4 
hours (Figure 19 (b)).  Given that only ~10% of the applied TXP was absorbed 
over the entire 24 hours of measurement, the peak in the absorption rate cannot 
be attributed to depletion of the ‘dose’ applied.  Rather, it is more likely that the 
downturn in the rate of penetration is the result of the liquid spray dilution 
drying out and leaving a solid residue after a certain time from which absorption 
is much slower; that is, the pesticide now needs to re-dissolve in the limited 
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Table 5- Skin uptake and absorption results for TXP (mean ± SD; n = 3 for the liquid 
application, n = 7 for the residue). 
Application (washed at 8 hours) Liquid Residue 
   
TXP applied (µg) 25 22.45 ± 4.25 
TXP recovered in swabs (µg)  11.12 ± 1.63 11.06 ± 2.38 
   
TXP disposition   
SC tape-strips 1-2 (µg) 1.20 ± 0.28 0.53 ± 0.24* 
SC tape-strips 3-15 (µg) 0.33 ± 0.09 0.17 ± 0.12 
SC tape-strips 1-15 (µg) 1.53 ± 0.37 0.70 ± 0.33* 
   
Remaining skin (µg) 0.73 ± 0.14 0.38 ± 0.16* 
   
Receptor phase at 2 hr (µg) 0.32 ± 0.13 < LOQ 
Receptor phase at 4 hr (µg) 0.76 ± 0.22 < LOQ 
Receptor phase at 6 hr (µg) 0.96 ± 0.20 < LOQ 
Receptor phase at 8 hr (µg) 1.12 ± 0.23 < LOQ 
Receptor phase at 24 hr (µg) 1.50 ± 0.18 0.27 ± 0.15* 
   
Total TXP uptake/absorption (µg)# 2.56 ± 0.18 0.82 ± 0.34* 
   
% uptake/absorption of TXP applied 10.25 ± 0.40 3.72 ± 1.39* 
*
Significantly smaller (p < 0.01) than the liquid application value (Student’s unpaired t-test). 
< LOQ = below the limit of quantitation of TXP. 
#
Sum of (SC tape-strips 3-15) + (Remaining skin) + (Receptor phase at 24 hr). 
The results from the residue application support this interpretation.  In this case, 
TXP was only detected in the receptor at 24 hours, indicative of a much longer 
lag-time (and reflecting the slow dissolution step referred to above).  This is 
consistent with a previous study129 involving a similar protocol. This study 
involved an additional set of experiments where the skin was not washed until 
24 hours post-application, here an early peak rate of absorption was again seen 
for the liquid application but, over the 8-24 hour period, the fluxes of TXP from 
the liquid and from the residue were essentially the same (0.08 and 0.09 µg/hr, 
respectively). 
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Figure 19 - (a) Cumulative absorption of TXP across the skin in vitro (mean ± SD) 
following liquid spray dilution (n = 3) and residue (n = 7) applications as a function of 
time.  (b) Rate of absorption of TXP across the skin in vitro following application of a 
liquid spray dilution as a function of time (mean ± SD; n = 3). 
In terms of the overall skin disposition of TXP, the total absorption (expressed 
either as an absolute quantity or as a % of the ‘dose’ applied) was 2.8 times larger 
from the liquid spray dilution, than from the residue; this difference was 
significant at p < 0.01.  Differences in amounts recovered from the stratum 
corneum tape-strips and the rest of the skin were somewhat smaller (closer to 2-
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Table 6 - Skin uptake and absorption results for PPZ (mean ± SD; n = 6 for both liquid 
and residue applications). 
Application (washed at 8 hours) Liquid Residue 
   
PPZ applied (µg) 25 24.44 ± 1.28 
PPZ recovered in swabs (µg)  12.59 ± 3.30 19.95 ± 1.53
§ 
   
PPZ disposition   
SC tape-strips 1-2 (µg) 2.83 ± 1.22 1.87 ± 0.40 
SC tape-strips 3-15 (µg) 1.86 ± 0.25 1.33 ± 0.16
* 
SC tape-strips 1-15 (µg) 4.69 ± 1.31 3.20 ± 0.47
†
 
   
Remaining skin (µg) 2.58 ± 0.65 0.75 ± 0.26
*
 
   
Receptor phase at 8 hr (µg) < LOQ < LOQ 
Receptor phase at 24 hr (µg) 0.75 ± 0.27 < LOQ 
   
Total PPZ uptake/absorption (µg)
#
 5.19 ± 0.99 2.08 ± 0.37
*
 
   
% uptake/absorption of PPZ applied 20.77 ± 3.96 8.50 ± 1.36
*
 
§Significantly greater (p < 0.01) than the liquid application value (Student’s unpaired t-test). 
*Significantly smaller (p < 0.01) than the liquid application value (Student’s unpaired t-test). 
†Significantly smaller (p < 0.05) than the liquid application value (Student’s unpaired t-test). 
< LOQ = below the limit of quantitation of PPZ. 
#Sum of (SC tape-strips 3-15) + (Remaining skin) + (Receptor phase at 24 hr). 
 
As indicated in Table 6, PPZ was the most efficiently taken up of the four 
pesticides from both liquid and residue applications with liquid being absorbed 
2.4 times more (20.8% and 8.5%, respectively, in terms of % ‘dose’ applied, a 
significant difference at p < 0.01).  Penetration of the chemical to the receptor 
phase, however, was measurable for the liquid spray dilution application only at 
24 hours; no samples reached LOQ at 8 hours.  For the residue, PPZ in the 
receptor did not reach the LOQ at either 8 or 24 hours.  The relatively high 
solubility of PPZ in the receptor solution (2 mg/mL) suggests that the 
compound’s high lipophilicity is the likely reason behind this observation. 
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Uptake of PPZ into the skin – both in terms of the amounts in stratum corneum 
tape-strips 3-15 and in the remaining skin – was significantly higher (p < 0.01) for 
the liquid application.  This was slightly surprising as the melting point of this 
chemical is -23°C, indicating that it is a liquid at ambient temperature and that, 
when left as a residue, therefore, a lesser resistance to dissolution might have 
been expected. 
 
Table 7 - Skin uptake and absorption results for DFZ (mean ± SD; n = 6 for the liquid 
application, n = 11 for the residue). 
Application (washed at 8 hours) Liquid Residue 
   
DFZ applied (µg) 30 29.01 ± 3.44 
DFZ recovered in swabs (µg)  24.31 ± 1.88 22.45 ± 3.32
 
   
DFZ disposition   
SC tape-strips 1-2 (µg) 1.55 ± 0.59 1.16 ± 0.33 
SC tape-strips 3-15 (µg) 0.57 ± 0.21 0.34 ± 0.15
† 
SC tape-strips 1-15 (µg) 2.12 ± 0.64 1.49 ± 0.45
†
 
   
Remaining skin (µg) 1.93 ± 0.39 1.05 ± 0.28
*
 
   
Receptor phase at 24 hr (µg) < LOQ < LOQ 
   
Total DFZ uptake/absorption (µg)
#
 2.50 ± 0.52 1.38 ± 0.35
*
 
   




Significantly smaller (p < 0.05) than the liquid application value (Student’s unpaired t-test). 
*
Significantly smaller (p < 0.01) than the liquid application value (Student’s unpaired t-test). 
< LOQ = below the limit of quantitation of DFZ. 
#
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Table 8 - Skin uptake and absorption results for CLF (mean ± SD; n = 6 for both liquid 
and residue applications). 
Application (washed at 8 hours) Liquid Residue 
   
CLF applied (µg) 30 29.97 ± 2.64 
CLF recovered in swabs (µg)  21.09 ± 2.56 23.74 ± 4.81
 
   
CLF disposition   
SC tape-strips 1-2 (µg) 2.24 ± 0.47 1.25 ± 0.52
* 
SC tape-strips 3-15 (µg) 0.79 ± 0.12 0.25 ± 0.14
* 
SC tape-strips 1-15 (µg) 3.03 ± 0.42 1.50 ± 0.65
*
 
   
Remaining skin (µg) 1.64 ± 0.19 0.54 ± 0.41
*
 
   
Receptor phase at 24 hr (µg) < LOQ < LOQ 
   
Total CLF uptake/absorption (µg)
#
 2.43 ± 0.30 0.79 ± 0.47
*
 
   




Significantly smaller (p < 0.01) than the liquid application value (Student’s unpaired t-test). 
< LOQ = below the limit of quantitation of CLF. 
#
Sum of (SC tape-strips 3-15) + (Remaining skin) + (Receptor phase at 24 hr). 
 
The results for DFZ and CLF are presented in Table 7 and Table 8, respectively, 
and are relatively similar.  For both chemicals, skin uptake was significantly 
higher (p < 0.01) from the liquid application than from the residue by factors of 
approximately 1.8 (DFZ) and 3.1 (CLF).  Permeation of the two pesticides, from 
both applications, was never detectable in the diffusion cell receptor phase, even 
after 24 hours.  As for PPZ, this was not due to the limited solubilities of DFZ and 
CLF in the receptor phase where both compounds had more than adequate 
values (1.4 and 0.5 mg/mL, respectively).  
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TXP absorption from liquid and residue applications, when the skin was cleaned 
after different exposure periods is summarised in Figure 20. Tabulated results are 
in the Appendix.  
 
Figure 20 - Stacked bar chart showing skin uptake and absorption of TXP after 24 
hours when the skin surface had been decontaminated after exposure periods of 0.5, 
1, 2 ,4, 8 and 24 hours (mean ± SD; n = 3-7) 
A 2-way analysis of variance (ANOVA) of these results shows that the time of 
decontamination had a significant impact on the % of the applied amount of TXP 
absorbed (p < 0.001), as did the application type  (liquid versus residue)                      
(p < 0.0001). The interaction between the two variables, however, was not 
significant (p = 0.3). 
The total uptake and absorption of TXP from the spray dilution was significantly 
reduced when the skin surface was cleaned within 1 hour of exposure.  However, 
if decontamination was delayed to 2 hours post-exposure or longer, then the % 
of the applied ‘dose’ taken up and/or permeated was unchanged (at about 20%).  
This finding is consistent with the results in Figure 19(a) which shows that the 
majority of TXP permeation across the skin had occurred within 4 hours.  In 
contrast, the uptake and absorption of TXP permeation from the residue 
increased progressively with the exposure period; in fact, when the exposure 
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period was 24 hours, the uptake and absorption of TXP from the residue was not 
significantly different to that from the spray dilution. 
Taken together, the results from this research permit three broad conclusions to 
be drawn.  First, with the optimised method employed, residue transfer to the 
skin can be achieved reliably and reproducibly, with good efficiency, so that valid 
comparisons are possible between AIs of different physicochemical properties 
delivered from the same vehicle.  Second, it is evident that the uptake and 
absorption of pesticide from a dried residue is generally less than when the same 
chemical is presented to the skin as a spray dilution; this general behaviour, 
which had been reported previously for one compound only129, seems to hold for 
pesticides differing quite widely in their physicochemical properties.  Despite a 
large range in the predicted maximum fluxes of the four chemicals across the skin 
(Table 4), the difference in the absolute quantities taken up and penetrated 
between the most and the least absorbed only ranged from 1.8 to 3.1-fold between 
spray dilution and residue applications.  Third, the decontamination experiments 
with TXP reveal that, following exposure to the spray dilution, it is important to 
clean the skin within 1 hour to significantly reduce potential systemic exposure; 
indeed, removing material from the surface at 30 minutes post-exposure can 
reduce dermal uptake by 4-fold. With respect to exposure to a dried residue, the 
data indicate that the sooner decontamination is performed, the greater the 
reduction in exposure is achieved.  For example, cleaning the skin after 30 
minutes of contact with the residue reduces potential systemic exposure by a 
factor of 12 to that resulting from continual contact for 24 hours.  Even if the 
residue-contaminated skin is only washed at the end of an 8-hour working day, 
the potential systemic exposure (relative to that at 24 hours) is halved. As this 
study was performed in vitro using pig skin, conclusions about the in vivo human 
scenario should be drawn with caution, however, this work provides further 
validation of the methodology for residue application and some insight in to how 
these residues may be absorbed in a re-entry scenario. Further work should focus 
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on validating the conclusions drawn in vitro using human skin from several 
donors and in vivo in humans using a model compounds such as ibuprofen. 
4.5.4 Further Discussion 
The results from this study found that AI had a significant effect on total 
absorption, from both liquid and residue application. This is not a new 
observation of course, however, the differences observed between the 
compounds were not as large as perhaps may have been expected, taking in to 
account their varying physicochemical properties.  
The predicted maximum flux values of the four compounds were more than 30-
fold different from the highest, 1.02 µg/cm2/h for PPZ, to the lowest, 0.032 
µg/cm2/h for CLF. However, the difference in observed total absorption between 
the highest and lowest was only around 2.5-fold when applied as a spray dilution 
and 3.3-fold as a residue. These values did however predict the correct rank order 
of absorption efficiency for these compounds.  
Potential reasons for this difference may be that these predicted values are based 
on absorption from an infinite dose of a saturated aqueous donor, which was not 
the case for the present study. By considering the specific examples of TXP and 
CLF flux, it is possible to follow how these factors may affect total absorption.  
Firstly, the concentration of AI used was 1 mg/ml; for TXP this value is 10-fold 
lower than its maximum aqueous solubility, whereas for CLF this value is far 
higher than its maximum aqueous solubility (0.004 mg/ml). It is not known to 
what extent the presence of the solubility enhancing excipients would increase 
the solubility of either AI in the spray dilution, but it is clear that TXP was present 
at a concentration significantly below saturation in the vehicle, which would 
negatively impact its partitioning in to the SC. Conversely, CLF was present at a 
concentration significantly above its maximum aqueous solubility. 
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Secondly, only 30 µL of this solution was applied to the skin, representing a finite 
dose scenario i.e., dose depletion could become a factor. This would likely have 
a more significant impact on TXP, as it is absorbed faster than CLF. 
Finally, from such a small volume, as time progresses, volatile components of the 
vehicle would evaporate away or pass in to the skin, changing its thermodynamic 
activity. This could result in a temporary increase in flux due to concentration of 
the AI in the vehicle, however, as seen in Figure 27 in Chapter 6, most of the water 
has evaporated away just 1 hour post-application. This would then leave a 
deposition on the skin surface that is not dissimilar to the dried residue being 
investigated. Consequently, dissolution from this ‘residue’ is now necessary 
before the AI can be absorbed further. The more lipophilic compound, CLF, at 
this point would likely partition in to the SC more effectively than TXP which is 
more hydrophilic.  
Thus, overall, it is not unexpected that observed fluxes were significantly lower 
than the predicted values. The examples above also show how the 
physicochemical properties of the compounds can modulate these effects, 
explaining why only a 2.5-fold, rather than 30-fold, difference was observed 
between the compounds. 
Further to the results shown in Paper 2, Figure 21 (a to f) shows cumulative TXP 
in the receptor for each exposure time investigated. The largest difference 
between TXP absorption from liquid and residue was seen when 
decontamination occurred at 0.5 hours post-exposure (Figure 21 (a)). In this case, 
TXP was absorbed 4-fold more when applied as a spray dilution compared to 
when applied as a residue. The longer the exposure time, in general, absorption 
from the two application types tended towards each other, up to 24-hour 
exposure where there was no significant difference between the two (Figure 21 
(f)).  
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If it is assumed that these results are representative of the in vivo human scenario 
(discussed further in Chapter 6), these graphs highlight how decontamination of 
the skin as early as possible is important if exposed to TXP in any form. If exposed 
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Figure 21 – Cumulative amount of TXP in Receptor (µg) from exposure times of (a) 0.5-hr (b) 1-hr 
(c) 2-hr (d) 4-hr (e) 8-hr (f) 24-hr. Open = Liquid application Solid = Residue 
Chapter 4: Paper 2 - Dermal uptake and absorption of pesticide residues 
James Clarke - November 2017   79 
to a spray dilution of TXP it would be crucial to decontaminate the area within 
the first hour to reduce systemic exposure. A similar observation can be made for 
exposure to TXP residue, washing early can reduce exposure by an order of 
magnitude. Additionally, these results show that even if a worker is not able to 
wash until after the working day has finished, 8 hours after first contact with TXP 
residue, this decontamination can still significantly reduce systemic exposure.  
This observation could also influence risk assessment. The current approach for 
re-entry workers assumes a fixed exposure time of 8 hours for the entire daily 
potential dermal exposure calculated. However, in reality, the worker would not 
be exposed to all of the daily dose at once, but to small amounts throughout the 
day. It may therefore be possible to take this exposure pattern into account to 
procure more realistic systemic exposure estimates.  
The results from paper 2 have further validated the methodology for application 
of pesticide residues in vitro. Residue transfer was consistent throughout the 
study. Although the transfer procedure had been changed slightly, transfer of 
TXP was similar to that described in Paper 1 at 22.5 ± 4.3µg. PPZ, CLF and DFZ 
transfers were 24.4 ± 1.3 µg, 30.0 ± 2.6 µg and 29.0 ± 3.4 µg, respectively. The fact 
that all four compounds had similar transfer efficiencies despite varying 
physicochemical properties suggests that the formulation may play a more 
important role in transfer than the AI. So far, all experiments have been with 
compounds in the same emulsifiable concentrate formulation. Pesticide products 
come in many different formulations and in order to fully validate the 
methodology, it should be tested on more than one formulation type. Different 
formulations are likely to have a significant effect on the nature of the dried 
residue even when the same AI is used. Additionally, all experiments to date 
have been performed at one dose level, 30 µg (15 µg/cm2), in order to validate the 
methodology and investigate how different ‘doses’ could affect the absorption of 
dried residues, absorption should be measured from different loading doses.  
Chapter 5: Paper 3 - Effects of formulation and loading on dermal absorption of pesticide residues 
James Clarke - November 2017   80 
5 PAPER 3 - EFFECTS OF FORMULATION AND LOADING ON 
DERMAL ABSORPTION OF PESTICIDE RESIDUES 
 
The experiments carried out in Paper 2 have served to further validate the 
methodology by demonstrating its reproducibility using various active 
ingredients. However, all experiments thus far have been from a single EC 
formulation and at a single dose level. The research presented in this section 
aimed to investigate two compounds, CLF and TXP, from three commercial 
formulations and various loading doses, with a view to further validate the 
methodology and probe how these varied experimental conditions may affect 
absorption.  
Aims: 
 Investigate the effect of formulation on dermal absorption of TXP and CLF 
from both spray dilution and residue applications.  
 Investigate dermal absorption of TXP and CLF from various loading 
doses, and determine if absorption from spray dilution and residue 
applications is affected.  
 
5.1 Contributions  
This manuscript was submitted to ‘Chemical Research in Toxicology’ in 
September 2017, all practical work described was carried out by the first author. 
The manuscript was written by the first author, and edited and approved by all 
authors.  
James F. Clarke1, Sarah F. Cordery1, Neil A. Morgan2, and Richard H. Guy1 
1University of Bath, Department of Pharmacy & Pharmacology, Bath, BA2 7AY, U.K. 
2Syngenta UK Ltd, Jealott's Hill International Research Centre, Bracknell, RG42 6EY, U.K. 
Chapter 5: Paper 3 - Effects of formulation and loading on dermal absorption of pesticide residues 
James Clarke - November 2017   81 
5.2 Abstract 
Dermal risk assessment for re-entry workers, who enter a field after pesticide 
application to perform a task such as crop inspection or harvest involves 
exposure to a dried residue of the spray dilution.  In this research, a robust and 
reproducible in vitro methodology, designed by this group, is used to measure 
absorption of these residues in vitro and compared against the conventional 
approach whereby dermal uptake and absorption is determined by testing liquid 
forms of the pesticide.  Experiments have been conducted on liquid spray 
dilutions and their dried residues of two physicochemically distinct pesticides, 
trinexapac-ethyl (TXP) and clodinafop propargyl (CLF), formulated in two 
emulsifiable concentrate formulations and one wettable powder.  As a control, 
deposition from a simple solvent was also examined.  Furthermore, from one of 
the formulations, the effect of ‘loading’ (dose per unit area) on skin uptake and 
absorption of the two pesticides was quantified for both the liquid spray dilution 
and the dried residue.  Overall, the results presented indicate that dermal 
exposure of re-entry workers to dried pesticide residues is determined by the 
chemical’s properties, the formulation used, and the amount contacting the skin. 
It appears that dermal uptake and penetration of a pesticide from dried residues 
is typically less than that for liquid spray dilutions, and that penetration of the 
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5.3 Introduction 
The amount of pesticides used globally each year is measured in millions of 
tonnes131. These chemicals are usually designed to target specific organisms but 
negative effects can also be elicited in humans when inadvertent exposure occurs. 
Consequently, before being licensed for use, each pesticide product must 
undergo a risk assessment involving different, potential routes of exposure, such 
as oral, inhalation and dermal7. Dermal exposure can occur via accidental spillage 
of a product on the skin during, for example, mixing and loading procedures8. 
Skin contact with contaminated surfaces is another common exposure scenario, 
particularly for re-entry workers, to whom pesticide transfer from treated plants 
and fruits is a potential hazard during the course of their daily work. 
The European Food Safety Authority (EFSA) exposure assessment7,8 for re-entry 
workers estimates the Potential Dermal Exposure (PDE), in µg of active 
substance per day, using the following relationship: 
PDE = DFR x TC x T 
DFR is the Dislodgeable Foliar Residue (in µg of active substance per cm2 of leaf 
surface) and corresponds to the amount of pesticide that can potentially be 
dislodged and transferred to the skin. The DFR depends on several factors 
including application rate and crop type. In an initial risk assessment, the DFR is 
typically unknown, and a conservative, default value of 3 µg/cm2 per kg AI 
applied per hectare is used in the EU.  
TC is the Transfer Coefficient (with units of cm2/h), which measures the extent of 
contact with the foliage and is specific to the crop type and task being performed. 
There are a number of sources of TC values, such as the EUROPOEM II 
database16. Generally, risk assessments assume that the arms, body and legs of a 
field worker are covered while the hands are not7.  EU TC values for harvesting 
vary from a relatively low 2,500 cm2/h for vegetables up to as high as 10,100 cm2/h 
for grapes.  
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T is the duration of exposure (in hours per day); for instance, 2 h/day is 
considered typical for crop inspection, 8h/day for harvest. Examples of exposures 
calculated using this equation are given below, one representing a worst-case 
high exposure, the other corresponding to a relatively low exposure.  
 
PDEgrape harvest = 3 µg/cm
2
 x 10,100 cm
2
/h x 8 h/day = 242 mg/day (assuming 1 kg AI/ha) 
 
PDEvegetable harvest = 0.03 µg/cm
2
 x 2,500 cm
2
/h x 8 h/day = 0.6 mg/day (assuming 0.01 kg AI/ha) 
 
Dividing the PDEs by 820 cm2, the EFSA default value for the surface area of the 
hands, yields estimated doses of 296 and 0.7 µg/cm2/day, respectively. It should 
be noted that the above calculations represent a very simplistic model, but they 
serve to give a general estimate of exposure levels.  
Once the PDE has been calculated, systemic exposure is then estimated using a 
percentage absorption factor, which is currently determined experimentally by 
measuring the skin penetration of the pesticide from the concentrate product and 
spray dilutions thereof, typically in vitro.  These different formulations are tested 
because it has been found that dermal loading can affect the percentage 
absorption (and, generally as dermal loading increases, the fraction absorbed 
decreases)65-67. However, with respect to skin contact with a contaminated plant 
surface, exposure occurs to a so-called ‘dried residue’ of the pesticide spray 
dilution; ‘dried’, in this case, implies only that the volatile components of the 
formulation (in particular, water) have evaporated away. Still, no matter the final 
composition of the ‘dried’ residue, the uptake of a pesticide from this film may 
well be different to that from a liquid spray dilution.  
In terms of assessing systemic exposure to a pesticide from a dried residue, it is 
important that the residue is formed from an appropriate formulation, the uptake 
from which may differ to that from a simple aqueous solution108, 109. This may be 
due to the presence of non-volatile solvents, for example, which can influence the 
partitioning and/or diffusion of pesticide in the stratum corneum (SC), the 
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outermost, and principal barrier layer of the skin107, 112, 113.  Surfactants are also 
common ingredients in pesticide formulations, and these chemicals may also 
comprise part of a ‘dried’ residue. Consequently, they may facilitate the 
dissolution of a sparingly soluble AI and enable its solubilisation in the skin as 
well (and even, perhaps, facilitate penetration across the SC114-116). EFSA has 
recognised the importance of the potential effect of a formulation on dermal 
uptake8 and requires a new risk assessment to be carried out when a single 
component of a product is changed by more than 25% w/v.  
An improved experimental methodology has been reported for the measurement 
of pesticide dermal absorption from a dried residue in vitro129.  It was shown that 
the skin uptake and absorption of trinexapac-ethyl from the spray dilution of a 
naphtha-based emulsifiable concentrate (EC) formulation was significantly 
higher than that from its dried residue. This initial proof-of-concept, however, 
involved one pesticide, at a single dermal loading, and applied from one 
formulation.  The research described in the present study aims at a broader scope 
so that firmer conclusions may be drawn about the effects of formulation and 
dermal loading on the skin penetration of pesticides from dried residues.   
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5.4 Materials & Methods  
Two pesticides were considered: (a) clodinafop-propargyl (CLF), a herbicide 
with a log(octanol-water partition coefficient)(log P) of 3.9, molecular weight = 
350 Daltons, and aqueous solubility of 4 µg/mL132; and (b) trinexapac-ethyl (TXP), 
a plant growth regulator having log P = -0.29, molecular weight = 252 Daltons, 
and water solubility = 10.2 mg/mL132.  Spray dilutions of three commercially 
relevant formulations (see below) of the two pesticides were prepared.  For TXP, 
a simple aqueous solution (1 mg/mL in distilled water) acted as a control.  For 
CLF, which has a very low water solubility (0.004 mg/mL), an aqueous 
suspension was flocculent and, to create a control residue of this chemical, a 
1mg/mL solution in acetone was used instead.  
Static Franz diffusion cells, having a receptor volume of 7.4 mL and area of 
exposed skin of 2 cm2, were used with porcine skin (dermatomed to a nominal 
thickness of 750 µm).  The receptor solution was phosphate-buffered saline (pH 
7.4) for TXP, and 0.5% w/v Volpo™ (Sigma-Aldrich Co., Gillingham, UK) in PBS 
for CLF.  A positive displacement pipette, was used to apply 30µl of each 
pesticide spray dilution to the skin. Samples of the receptor solution were taken 
hourly from 2 to 8hrs and at 24 hours for TXP; at 8 and 24 hours only for the more 
poorly penetrating CLF.  For both chemicals, the skin was ‘decontaminated’ at 8 
hours: 100µl of a 0.1% w/v soap solution was applied to the skin surface followed 
by immediate swabbing with two cotton buds.  
Application of pesticide residues to the skin followed a previously described and 
validated methodology:129 40µl of the spray dilution was applied to a steel disc 
(SPM specimen discs, TAAB Laboratories Equipment Ltd., Aldermaston, U.K.) 
and allowed to dry for 24 hours to form a residue, which was then transferred to 
the skin with a standardised procedure129. Subsequently, the amount of pesticide 
remaining on the disc was quantified to determine precisely the ‘dose’ applied 
for each replicate. 
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The pesticide formulations examined were: [1] An emulsifiable concentrate 
formulation (EC-A) (Syngenta, Jealott’s Hill, UK) that contained naptha as the 
primary solvent and castor oil, calcium dodecylbenzene sulphonate and 
tristyrylphenol ethoxylated as emulsifiers. The pesticide concentration in EC-A 
was 100mg/mL.  [2] A second emulsifiable concentrate formulation (EC-B) (also 
supplied by Syngenta at a pesticide concentration of 100 mg/mL) with 1-
phenylethan-1-one as the primary solvent, the same emulsifiers as EC-A, and the 
surfactant, oleic acid methyl ester. Both EC formulations were diluted 100-fold in 
water to provide nominal spray dilution concentrations of the active ingredient 
of 1 mg/ml.  [3] A wettable powder (WP) formulation based on the filler, kaolin, 
and also containing a dispersant, lignin sodium sulphate, and a wetting agent, 
butylnaphthalenesulphonic acid salt was also tested. The pesticide concentration 
in the WP was 15% w/w.  To prepare a spray dilution at a concentration of 1 
mg/mL, 667 mg were made into a paste, passed through a sieve (Endecotts, 
London, UK) of aperture 125 µm, and then made up to 100 mL in water. As the 
resulting formulation was a suspension, thorough mixing by vortex was 
performed before each use.  
In addition, both TXP and CLF were investigated as various ‘dose’ levels. 30, 70 
and 120 µL of TXP EC-A spray dilution were applied. The corresponding residue 
discs were loaded with 40, 100 and 180 µL of the same spray dilution to match 
the dose levels. 30, 70, 120 and 160 µL of CLF EC-A spray dilution were applied 
and residue discs were loaded with 40, 100, 180 and 250 µL. 
5.5 Results 
CLF and TXP were applied to the skin from three commercial formulations, as a 
liquid spray dilution and as a residue.  TXP was also applied from an aqueous 
solution and from its relative dried residue; CLF was additionally applied as a 
residue after evaporation of an acetone solution of the compound.  
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The amount of CLF residue transferred to the skin surface depended on the 
formulation used (one-way analysis of variance, p < 0.01). The average amounts 
applied were: 22.6 (± 1.8) µg for EC-A, 26.2 (± 1.3) µg for EC-B, 35.2 (± 1.96) µg for 
WP, and 17.9 (± 3.3) µg for the AI deposited from acetone.  These quantities were 
used when calculating percentages of the applied dose absorbed. No CLF was 
detected in the receptor solution from any application. The total absorption of 
this pesticide was therefore considered as the sum of the amounts of CLF in 
stratum corneum tape-strips 3-15 (assuming CLF in tapes 1 and 2 to be lost via 

































































Figure 22 - Stacked bar chart showing the skin uptake of CLF at 24 hours after liquid 
and residue applications from different formulations (mean ± SD; see Tables 9 and 10 
for number of replicates). 
Formulation type had no significant impact on CLF uptake and absorption for 
the liquid application (Table 9). There was also no difference observed in total 
CLF uptake and absorption from dried residues (Table 10). However, when the 
estimated amount applied for each formulation was taken in to account, % 
uptake/absorption was significantly different between formulations (1-way 
ANOVA, p < 0.01). Formulation also influenced the amount of CLF recovered 
from the stratum corneum on tapes 1 and 2; notably, if these quantities were 
included in the % uptake/absorption, no significant difference was observed 
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between formulations.  This information is potentially important because the 
amount of pesticide recovered from the first two stratum tape-strips was greater 
than that recovered from the remaining tapes and skin combined. Hence, when 
one discards this mass from the % amount taken up and absorbed, the effect is 
substantial and is quite different than that found for TXP, which has been 
demonstrated to be absorbed across the skin much more quickly than CLF (see 
Table 11 and Table 12 below).  
 
Table 9 - Skin uptake and absorption of CLF from liquid spray dilution application of 
three formulations (mean ± SD). 
CLF formulation - liquid EC-A EC-B WP 
Number of replicates (n) 6 6 8 
CLF applied (µg) 30 30 30 
CLF recovered in swabs (µg)  21.70 ± 2.84 21.82 ± 1.89 24.67 ± 2.35 
    
CLF disposition    
SC tape-strips 1-2 (µg) 1.25 ± 0.49 1.28 ± 0.40 1.78 ± 0.53 
SC tape-strips 3-15 (µg) 0.54 ± 0.26 0.60 ± 0.24 0.67 ± 0.23 
SC tape-strips 1-15 (µg) 1.80 ± 0.69 1.88 ± 0.46 2.45 ± 0.62 
    
Remaining skin (µg) 0.67 ± 0.30 0.75 ± 0.33 0.41 ± 0.31 
    
Receptor phase at 24 hr (µg) < LOQ < LOQ < LOQ 
    
Total CLF uptake/absorption (µg)
#
 1.21 ± 0.43 1.35 ± 0.30 1.08±0.34 
    
% uptake/absorption of CLF applied 4.04 ± 1.42 4.50 ± 1.01 3.60 ± 1.13 
< LOQ = below the limit of quantitation of CLF. 
#
Sum of (SC tape-strips 3-15) + (Remaining skin) 
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Table 10 -Skin uptake and absorption of CLF from residue application of three 
formulations and acetone vehicle. (mean ± SD). 
CLF formulation - residue EC-A EC-B WP Acetone 
Number of replicates (n) 6 4 8 5 
CLF applied (µg) * 22.58 ± 1.81 26.16 ± 1.33 35.23 ± 1.96 17.87 ± 3.26 
CLF recovered in swabs (µg) * 18.16 ± 2.46 19.68 ± 1.41 32.00 ± 5.59 9.76 ± 2.66 
     
CLF disposition     
SC tape-strips 1-2 (µg) 
†
 0.48 ± 0.07 0.58 ± 0.17 1.08 ± 0.57 0.47 ± 0.13 
SC tape-strips 3-15 (µg)  0.37 ± 0.14 0.35 ± 0.13 0.42 ± 0.20 0.24 ± 0.03 
SC tape-strips 1-15 (µg) 
†
 0.85 ± 0.17 0.93 ± 0.19 1.50 ± 0.72 0.71 ± 0.11 
     
Remaining skin (µg) 0.13 ± 0.20 0.20 ± 0.07 0.12 ± 0.08 0.20 ± 0.05 
     
Receptor phase at 24 hr (µg) <LOQ <LOQ <LOQ <LOQ 
     
Total CLF uptake/absorption (µg)
#
 0.49 ± 0.09 0.55 ± 0.07 0.54 ± 0.15 0.45 ± 0.07 
     
% uptake/absorption of CLF applied * 2.17 ± 0.31 2.09 ± 0.29 1.54 ± 0.44 2.55 ± 0.54 
*
Significantly different (p < 0.01) between formulation type (1-way ANOVA). 
†
Significantly different (p < 0.05) between formulation type (1-way ANOVA). 
< LOQ = below the limit of quantitation of CLF. 
#
Sum of (SC tape-strips 3-15) + (Remaining skin) 
 
Transfer of TXP residue was not significantly different between the three 
commercial formulations: 27.1 (± 1.5) µg for EC-A, 29.1 (± 3.1) µg for EC-B, 27.3 
(± 5.7) µg for WP. However, the AI transferred from residue formed from an 
aqueous solution was considerably less (11.34 (± 0.96) µg).  A 2-way ANOVA 
revealed that skin uptake and absorption of TXP was significantly different 
between formulations and application type (p < 0.001). There was also an 
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interaction between these two variables (p < 0.01). TXP was absorbed 
significantly less (relative to the liquid spray dilutions) when applied as a residue 
from EC-A and EC-B, but not from WP (Figure 23, Table 11 and Table 12). 
Permeation of TXP from the spray dilutions was significantly different between 
formulations. On the other hand, the amounts of TXP taken up in the SC and the 
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Figure 23 -Stacked bar chart showing the skin uptake and absorption of TXP at 24 
hours after liquid and residue applications from different formulations (mean ± SD; 
see Tables 11 and 12 for number of replicates). 
In Table 12, the statistical analysis presented was performed on the results from 
the three commercial formulations.  The data of TXP absorption from the aqueous 
solution residue was not included because of the much smaller quantity that was 
able to be transferred; clearly, the amounts of pesticide found to have been taken 
up by, or absorbed through, all the skin ‘compartments’ were considerably 
smaller than from the commercial formulations.  The total % ‘dose’ exposure was 
also significantly less.  With respect to the three commercial formulation residues, 
there was notably no significant difference between them for any of the measured 
quantities.  
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Table 11 - Skin uptake and absorption of TXP from liquid spray dilution application 
of three formulations and from an aqueous solution (mean ± SD). 
TXP formulation - liquid EC-A EC-B WP Aq. solution 
Number of replicates 5 4 5 4 
TXP applied (µg) 30 30 30 30 
TXP recovered in swabs (µg) * 18.84 ± 1.77 17.07 ± 1.95 20.27 ± 0.80 13.13 ± 0.76 
     
TXP disposition     
SC tape-strips 1-2 (µg) 1.10 ± 0.33 0.82 ± 0.12 0.97 ± 0.13 1.12 ± 0.47 
SC tape-strips 3-15 (µg) 0.55 ± 0.38 0.56 ± 0.24 0.43 ± 0.20 0.36 ± 0.07 
SC tape-strips 1-15 (µg) 1.65 ± 0.70 1.39 ± 0.28 1.40 ± 0.29 1.48 ± 0.53 
     
Remaining skin (µg) 1.09 ± 0.29 1.18 ± 0.41 0.87 ± 0.25 1.18 ± 0.38 
     
Receptor phase (µg) 
2 hr
†
 1.07 ± 0.35 0.66 ± 0.46 0.50 ± 0.13 0.80 ± 0.39 
3 hr* 1.72 ± 0.52 1.38 ± 0.09 0.76 ± 0.15 1.25 ± 0.64 
4 hr* 2.14 ± 0.68 1.73 ± 0.18 0.98 ± 0.20 1.57 ± 0.81 
5 hr
†
 2.52 ± 0.88 1.91 ± 0.21 1.16 ± 0.25 1.75 ± 0.93 
6 hr
†
 2.78 ± 0.90 2.20 ± 0.23 1.27 ± 0.25 2.00 ± 1.04 
7 hr
†
 2.93 ± 0.92 2.24 ± 0.25 1.27 ± 0.20 2.14 ± 1.07 
8 hr
†
 3.09 ± 1.02 2.51 ± 0.26 1.35 ± 0.25 2.26 ± 1.12 
24 hr* 4.04 ± 1.09 3.63 ± 0.23 1.90 ± 0.42 2.94 ± 1.29 
     
Total TXP uptake/absorption 
#
 (µg) * 5.69 ± 0.90 5.38 ± 0.79 3.20 ± 0.78 4.49 ± 1.16 
     
% uptake/absorption of TXP applied * 18.95 ± 2.99 17.92 ± 2.63 10.65 ± 2.59 14.96 ± 3.85 
*
Significantly different (p < 0.01) between formulation type (1-way ANOVA). 
†
Significantly different (p < 0.05) between formulation type (1-way ANOVA). 
#
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Table 12 - Skin uptake and absorption of TXP from residue application of three 
formulations and from aqueous solution (mean ± SD). 
TXP formulation - residue EC-A EC-B WP AI 
Number of replicates 5 7 9 3 
TXP applied (µg) 27.07 ± 1.46 29.12 ± 3.09 27.28 ± 5.72 11.34 ± 0.96 
TXP recovered in swabs (µg)  18.87 ± 3.54 14.28 ± 2.11 15.74 ± 3.41 3.34 ± 0.95 
     
TXP disposition     
SC tape-strips 1-2 (µg) 0.66 ± 0.24 0.85 ± 0.32 1.16 ± 0.84 0.19 ± 0.10 
SC tape-strips 3-15 (µg) 0.29 ± 0.14 0.41 ± 0.14 0.37 ± 0.20 0.04 ± 0.01 
SC tape-strips 1-15 (µg) 0.95 ± 0.38 1.26 ± 0.42 1.54 ± 0.93 0.23 ± 0.09 
     
Remaining skin (µg) 0.76 ± 0.40 0.75 ± 0.60 0.61 ± 0.29 0.06 ± 0.11 
     
Receptor Phase (µg) 
2 hr 0.72 ± 0.89 0.69 ± 0.40 0.71 ± 0.46 < LOQ 
3 hr 0.99 ± 1.06 1.06 ± 0.39 0.95 ± 0.55 < LOQ 
4 hr 1.23 ± 1.02 1.26 ± 0.43 1.07 ± 0.61 < LOQ 
5 hr 1.35 ± 1.09 1.46 ± 0.46 1.20 ± 0.62 < LOQ 
6 hr 1.49 ± 1.26 1.68 ± 0.56 1.31 ± 0.68 < LOQ 
7 hr 1.56 ± 1.24 1.83 ± 0.55 1.36 ± 0.68 0.06 ± 0.11 
8 hr 1.64 ± 1.26 2.00 ± 0.58 1.42 ± 0.72 0.09 ± 0.15 
24 hr 2.27 ± 1.34 2.76 ± 0.66 1.86 ± 0.88 0.25 ± 0.25 
     
Total TXP uptake/absorption (µg)
#
 3.32 ± 1.33 3.92 ± 0.99 2.84 ± 1.00 0.35 ± 0.26 
     
% uptake/absorption of TXP applied 12.18 ± 4.53 13.40 ± 2.79 10.30 ± 2.70 3.04 ± 2.26 
‘AI’ was not included in statistical analysis 
†
Significantly different (p < 0.05) between formulation type (1-way ANOVA). 
#
Sum of (SC tape-strips 3-15) + (Remaining skin) + (Receptor phase at 24 hr). 
 
In a further set of experiments, the skin uptake and penetration of CLF and TXP 
in EC-A were determined as a function of the applied quantities of the pesticide 
following both liquid spray dilution and residue applications.  From the former, 
for CLF, 30, 70, 120 and 160 µg were deposited on the skin (2 cm2) while the 
corresponding exposures from the residues were 23.9 (± 2.6), 67.2 (± 2.5), 130.5 (± 
7.9) and 169.4 (± 3.0) µg, respectively.  For TXP, three liquid and residue 
exposures were considered, with 30, 70 and 120 µg being applied from the 
former, and 25.8 (± 1.5), 66.9 (± 3.0) and 119.9 (± 7.9) µg from the latter. 
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The total skin uptake and absorption of CLF increased linearly with increasing 
quantity of the chemical applied for both the liquid and residue applications 
(Figure 24 (a); r2 = 0.97 and 0.94, respectively).  In terms of the % ‘dose’ absorbed, 
a 2-way ANOVA revealed that, while more CLF was absorbed from the liquid, 
there was no significant effect of dose loading on either method of application 
(Figure 24 (b)).  There was, however, a significant interaction between the two 
variables (i.e., the nature of the application and the skin ‘loading’).  Interestingly, 
when the quantities of CLF recovered in the first two stratum corneum tape-
strips were included in the total skin uptake and absorption calculation, the 2-
way ANOVA found that the chemical loading did have a significant effect of the 
% ‘dose’ absorbed, especially for the liquid application (Figure 24 (c)).                     
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Figure 24 - CLF uptake and absorption into the skin (mean ± SD; n = 6 - 13) at 24 hours 
following 8-hour liquid and residue applications as a function of chemical loading 
(‘applied dose’) expressed (a) as the absolute quantity (mass), (b) as the % of the applied 
‘dose’, and (c) as in (b) but including the pesticide recovered in the first two stratum 
corneum tape-strips (TS 1&2).  
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The total skin uptake and absorption of TXP also increased linearly with 
increasing quantity of the chemical applied for both the liquid and residue and 
applications (Figure 25 (a); r2 = 0.94 and 0.82, respectively).  In terms of the % 
‘dose’ absorbed, there was no significant effect of dose loading for either method 
of application (Figure 25 (b)). 
 
 
Figure 25- TXP uptake and absorption into the skin (mean ± SD; n = 4) at 24 hours 
following 8-hour liquid and residue applications as a function of chemical loading 
(‘applied dose’) expressed (a) as the absolute quantity (mass), and (b) as the % of the 
applied ‘dose’. 
The cumulative permeation of TXP into the receptor phase over time is shown in 
Figure 26 as a function of applied formulation and ‘dose’. There was significantly 
less permeation from the residue at all loadings.  Notably, TXP penetration from 
the highest residue loading only matched that from the lowest liquid ‘dose’, 
despite a nearly 4-fold difference in the quantities applied. The rates of TXP 
absorption can be inferred from the temporal change in the slopes of the lines in 
Figure 26.  From the spray dilutions, the rates were clearly higher at the earlier 
times (especially up to 4 hours), before slowing to an approximately constant rate 
thereafter.  In contrast, the rate of pesticide penetration from the residues was 
much steadier over the entire exposure period, even after ‘decontamination’ of 
the skin at 8 hours.  The rates of TXP transfer across the skin between 8 and 24 
hours were ‘dose’ dependent for both liquid and residue applications but, at each 
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loading, there was no significant difference between the rates for the two 
different applications (see Table 13). 
 
Figure 26 - Cumulative permeation of TXP (mean ± SD; n = 3 - 9) into the receptor 
phase over time as a function of applied formulation (open symbols = liquid; closed 
symbols = residue) and ‘dose’ (high = triangles; intermediate = squares; low = circles). 




The exact TXP loadings are given in the text 
 
5.6 Discussion 
This study was designed to shed further light on the impact of pesticide 





Low Intermediate High 
Liquid Residue Liquid Residue Liquid Residue 
0 – 4 hr (µg/hr) 0.50 ± 0.06 0.06 ± 0.07 1.48 ± 0.50 0.20 ± 0.20 2.28 ± 0.48 0.34 ± 0.18 
4 – 8 hr (µg/hr) 0.12 ± 0.07 0.05 ± 0.04 0.39 ± 0.13 0.15 ± 0.07 0.35 ± 0.27 0.31 ± 0.13 
8 - 24 hr (µg/hr) 0.06 ± 0.01 0.04 ± 0.01 0.08 ± 0.06 0.08 ± 0.02 0.16 ± 0.02 0.17 ± 0.05 
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following dermal exposure of re-entry workers to dried residues on crops, plants, 
fruit, etc. The investigation was designed to include parallel measurements using 
liquid spray dilutions containing the same pesticides, at similar loadings in the 
same formulations. This comparison is valuable as risk assessments for re-entry 
workers are typically based on this exposure scenario (i.e., to the liquid spray 
dilution) rather than on the more realistic contact with a dried residue.  
Consistent with previous reports129, for the two pesticides considered (CLF and 
TXP, which differed appreciably in their physicochemical properties), skin 
uptake and absorption was significantly lower from the dried residue for all 
formulations and loading doses studied. The only exceptions were for CLF when 
applied at high dermal loading and for TXP applied in a wettable powder (WP) 
formulation, where no difference between spray dilution and residue was 
observed. A key component of the WP used is kaolin powder, a material used in 
traditional medicine and in numerous skin-care products (e.g., face masks, 
cosmetics, and in skin barrier formulations). Here, it seems possible that 
adsorption of the pesticide to the surface of the kaolin particles may become the 
common, principal factor controlling ‘release’ of the chemical to the skin, 
regardless of its application as a spray dilution or as a dried residue.  
Otherwise, the kinetics of TXP penetration across the skin reveal some insight 
into the physics associated with dermal exposure. From the liquid spray dilution, 
the initial rate of penetration (over, say, the first 4 hours) is more rapid, 
presumably reflecting a ‘metamorphosis’ of the formulation as the aqueous 
phase evaporates, driving the thermodynamic activity of the pesticide higher 
(and increasing flux). However, once the solvent has gone, TXP penetration slows 
down as the chemical would now have to undergo a dissolution step before it is 
able to commence diffusing across the skin. From the residue, on the other hand, 
TXP is being released under fairly constant conditions as the residue is already 
dry when the application begins. While there may be some outward movement 
of water from the receptor solution towards the skin surface (and this may help 
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with dissolving the pesticide), transepidermal water loss is probably insufficient 
to completely redissolve the TXP in the residue.  
Support for this analysis of the physical events taking place is found in the fact 
that, over the 8-24 hour period of the diffusion cell experiment, the penetration 
rates of TXP from the liquid spray dilution and from the residue are essentially 
the same, suggesting their control by the same mechanism; a potential candidate 
may simply be the slow emptying of the pesticide from the stratum corneum into 
the receptor solution. 
With respect to the specific impact of the formulations, it is first worth noting that 
the reproducibility of transfer of the residues was very good, no matter the 
vehicle or the loading used. The transfer of CLF was affected by the formulation 
type, whereas TXP was not, an unsurprising observation given the differences in 
the physical chemical properties of the two pesticides. Transfer of both pesticides 
was more efficient from the commercial formulations than from simple solutions 
of the chemical (water for TXP, acetone for CLF), reflecting, it may be surmised, 
the role of excipients (e.g., surfactants) in facilitating solubilisation of the active 
ingredients.  
An additional, noteworthy formulation-related observation concerned the 
emulsifiable concentrates (EC). The components of these products differ by more 
than 25% w/v, meaning that EFSA guidance would not allow bridging between 
the dermal absorption values for these two formulations. However, the results 
obtained in this work reveal no differences in skin uptake and absorption from 
the two formulations for either of the two pesticides considered.  
Finally, as far as the impact of pesticide loading is concerned, it is worth pointing 
out that the lowest liquid application of 30 µL (i.e., 15 µL/cm2 given the area of 
skin used) is approximately the minimum volume needed to just cover the skin 
surface. Larger loadings, or volumes, do not therefore increase the area of contact 
of the formulation with the skin, but do provide a greater reservoir of the 
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penetrant. The increased loadings also deposit more of the solvent from the 
liquid spray dilutions and prolong, as a result (and, as was discussed before) the 
time before the ‘metamorphosis’ of the deposited material is complete. Again, as 
previously explained, this behaviour is much less, if at all, apparent with the 
residues for which solvent has evaporated.  Regardless, no matter the loading, 
the skin uptake and absorption of pesticide over 24 hours never exceeded 30% of 
the applied ‘dose’; that is, an insufficient depletion to account for the slowing 
permeation of the chemicals as the experiment proceeded. 
In conclusion, the results of the research reported here, together with those from 
earlier work, reveal that the potential systemic dose after dermal exposure of re-
entry workers to dried pesticide residues is affected by the nature of the active 
ingredient, the type of formulation from which it is applied, and its ‘loading’ on 
the skin. Overall, though, while the effects are generally subtle, it is clear that (a) 
skin uptake and penetration from dried residues is smaller than that for liquid 
spray dilutions, and (b) formulation components can impact upon the ultimate 
‘delivery’ of the pesticide across the dermal barrier.  
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6 ADDITONAL RESULTS & DISCUSSION 
6.1 Deposition of Nile Red on Skin from Liquid and Residue 
Applications. 
The spray dilutions used within this thesis are 99% v/v water. This water acts to 
solubilise the AI and can play a crucial role in the absorption process. Therefore, 
when water has been allowed to evaporate away before application to the skin, 
as is the case for the residue, the ability of the compound to partition in to the SC 
can be affected. This section aims to look more closely at deposition from both 
spray dilutions and residues.  
To visualise how an AI might be distributed on the skin surface, the flourescent 
dye Nile Red (NR) was used as a model compound. Nile Red’s physicochemical 
properties ( Log P, 3.4 and MW, 318) are comparable to that of CLF which has a 
Log P of 3.9 and MW of 350. NR has been used in skin permeation studies 
previously133, 134. 
10 mg of NR was dissolved in 100 µL of a blank EC-A formulation, and then 
made up to 10 mL in water to form a spray diltuon (1 mg/mL), matching the 
concentration of the pesticide solutions studied in previous chapters of this 
thesis.  
In initial experiments, 30 µL of NR spray dilution was applied to pig skin 
mounted in a diffusion cell positioned beneath a camera (Veho Discovery VMS-
004 Deluxe Microscope, Coventry, UK). Images were taken before application, 
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Although the solution was spread evenly across the surface of the skin, it is clear 
that NR is concentrated on the hairs and around the hair follicles (Figure 27 (b)). 
There is a noticeably bright reflection of light from the skin surface immediately 
post-application of the spray dilution (Figure 27 (a)), that is still visible 20 
minutes later (Figure 27 (b)); however, this has dissipated by 1 hour (Figure 27 
(c)).  Most likely, this is due to the initial presence of water on the skin surface 






Figure 27 – Images taken (a) before application, (b) immediately 
post-application, and then (c)20 and (d) 60 minutes thereafter.  
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Figure 28 - Images of the AFM disc taken (a) before application to the skin and (b) 
immediately post-application. Images of the skin taken (c) immediately post-
application and (d) 60 minutes thereafter.  
40 µL of the 1 mg/mL NR dilution was then loaded onto an AFM disc and 
allowed to dry for 24 hours (Figure 28 (a)). As observed previously, NR was 
deposited around the edge of the disc in a ‘coffee ring’ formation. NR was then 
transferred to the skin using the protocol described in previous chapters of this 
thesis. Figure 28 (b) shows the disc post-application with some NR still remaining 
around the edges of the disc. Figure 28 (c) shows the skin surface immediately 
after application of the residue and, again, NR is predominantly localised around 
the hair follicles. After 60 minutes, no further change in NR disposition has 
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Subsequently, skin to which the NR spray dilution (Figure 29) and residue 
(Figure 30) had been applied was also examined under a light microscope (Motic 
BA210, Motic, Hong Kong) with a 5 Megapixel camera attachment (Moticam, 
Motic, Hong Kong). 
 
 
Figure 29 (a) is an image of the skin surface immediately after application of 30 
µL of the NR spray dilution solution. The dispersion of the oily NR in water is 
clearly localised around the hair follicle.  Panels (b), (c) and (d) of Figure 29 were 
taken 24 hours later and show, respectively, accumulation of NR around the base 
of a hair follicle, the presence of NR ‘trapped’ in the crevasses of the skin surface, 










Figure 29 - Light microscope images of Nile Red Spray dilution on the surface of the 
skin taken (a) immediately post-application and (b, c & d) 24 hours post-application 
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Figure 30 - Light microscope images of Nile Red residue on the surface of the skin 
taken immediately post-application  
Figure 30 shows NR disposition on the skin immediately after application of a 
dried residue. A significant presence of NR in the crevasses of the skin is 
apparent, presumably because the rough topography of the surface dislodges the 
residue from the disc during the application process (panels (a) and (c)). NR 
seems to be distributed relatively evenly across the skin, except where a hair shaft 
appears to protect the skin below from exposure to the residue (see Figure 30 (c), 
for example). At higher magnification, (Figure 30 (b)), the presence of crystals of 
NR can sometimes be seen. As for deposition from the spray dilution, the affinity 
of NR to the hair shaft was also quite obvious when the compound was applied 
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Imaging the behaviour of NR when applied to the skin from liquid and residue 
highlighted some interesting differences between the two application types, it 
also demonstrated that hair follicles and fibres may be an important factor, 
although this effect could be specific to NR. It is probable however, that the effect 
of the hair fibre protecting the skin from transfer of residue would be present for 
other compounds and formulations. While the coverage of NR residue was 
generally quite good, these areas of no deposition could potentially contribute to 
diminished absorption from the residue, due to the contact area being less than 
when applied as a spray dilution. This effect, may have contributed to the lower 
absorption values observed from residue applications thus far. However, it 
should be noted, that these values are still relevant to the exposure scenario, as a 
similar phenomenon would likely occur in vivo for a re-entry worker. 
6.2 Applicability to the in vivo human exposure scenario 
Within this document an attempt has been made to relate results back to the re-
entry worker exposure scenario. However, it should be noted that the results 
presented here do not allow firm conclusions to be drawn about in vivo human 
absorption. Although porcine skin is generally considered to be a good model95-
97, inter-species differences can cause differences in absorption when compared 
to human skin. EFSA do not currently accept studies conducted using pig skin to 
be used for risk assessment purposes. Current EFSA guidance for in vitro 
absorption studies recommends 8 replicates using human skin from at least 4 
donors10. With OECD guidance recommending a minimum of 4 replicates from 
2 donors90. The use of more than one donor is recommended so that the results 
are representative of the population, and is essential if the aim of the study is to 
obtain absolute absorption factors for use in risk assessment. The aim of the 
current study was not to obtain absorption factors, but to validate new 
methodology and compare exposure conditions, therefore skin from only one 
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donor was used within each investigation, to reduce inter-individual variability. 
However, throughout the course of the work, skin from 5 pigs was used, and a 
retrospective analysis of inter-individual difference is outlined below in section 
6.3. 
For firm conclusions to be drawn about residue absorption in re-entry workers, 
the methodology must be further validated. One method to achieve this could be 
investigation in vitro using human skin. Similar studies to those described here 
could be performed using human skin from several donors. Further validation 
could be achieved by investigation in vivo using an animal model. The most 
common animal used rat, this is due to an abundance of data and a well-defined 
protocol. It is becoming more common to use minipig135 as the skin more closely 
models that of human, however, this is not currently accepted by EFSA. Studies 
investigating dermal absorption of pesticides in vivo with human volunteers are 
deemed un-ethical in the EU. However, in vivo studies could be performed using 
a model compound such as ibuprofen, similar to that described by Belsey et al21. 
A basic study protocol may, for example, apply an ibuprofen solution to a 
subject’s forearm on one visit, and an ibuprofen residue on a second visit. Urine 
samples and tape-stripping could then be taken to assess differences in 
absorption between the application types. One limitation could be that the 
volunteer would be required to remain still for the exposure duration, so as not 
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6.3 Retrospective analysis of Inter-Individual Difference 
Over the course of the works carried out in this thesis over 280 diffusion cell 
replicates have been carried out. Experiments that involved application of 30 µL 
of the spray dilution and transfer of residue from a 40 µg disc were performed 
frequently as a control. These experiments were repeated 46 times for TXP and 
32 times for CLF over the course of 3 years. Over these three years 5 different pig 
donors were available as a source of skin. Within each set of experiments the 
donor was kept constant, however, between sets different donors were usually 
used. Below is retrospective analysis of the effect of inter-individual difference 
from these control experiments. The protocols were identical, apart from a few 
minor deviations (e.g., inclusion of Volpo in the receptor solution, which was not 
expected to influence the results for TXP). The only notable differences for TXP 
were application volumes; 20 µL for Pig 1, 25 µL for Pig 2 and 30 µL for the other 
three studies. Residue experiments were generally well matched to the liquid 
application within each study. Results from 4 different pigs are compiled in 
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Figure 31 - Retrospective analysis of inter-individual difference in absorption of TXP 
from EC-A formulation. Results were taken from (1) Paper 1 (n = 5) (2) Paper 2, AI 
comparison (n = 3 – 7) (3) Paper 3 Loading dose (n = 3-4)  (4a) Paper 2 exposure time 
(n = 3-4) and (4b) Paper 3 formulation (n = 5). 
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A 2-way analysis of variance revealed a significant difference between pigs              
(p < 0.0001) and found that TXP was absorbed significantly less when applied as 
a residue than from liquid application across the entire data set (p < 0.0001). There 
was found to be no interaction between the two variables, which shows that 
although absorption varied between donors, the ratio between liquid and residue 
remained relatively constant. Pig 2 had the largest difference between application 
types with TXP from liquid absorbed 2.8 times more. Pig 3 had the smallest 
difference, with TXP from liquid absorbed 1.7 times more on average. Pig 4 was 
used for both the exposure time experiments (Pig 4a) and the formulation 
experiments (Pig 4b), the mean observed % absorption was essentially the same 
each time. This shows that the differences observed between the data sets is due 
to inter-individual difference rather than the differences being a result of 
experiments carried out at different times. The similarity between these two data 
sets, that were produced more than 6 months apart, also serves to demonstrate 
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Figure 32 - Retrospective analysis of inter-individual difference in absorption of CLF 
when applied from EC-A formulation. Results were taken from (2) Paper 2, AI 
comparison (n = 6), (5a) Paper 3 loading (n = 3-5) and (5b) Paper 3 formulation (n = 
6). 
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CLF experiments were carried out for three separate studies, however, the same 
donor was used in the studies investigating loading (Pig 5a) and formulation (Pig 
5b). Results from the two papers were obtained 3 months apart and again the 
results were very similar.  
A 2-way analysis of variance of CLF results again found a significant difference 
between pigs and application type. There was also a significant interaction 
between the two variables (p < 0.001), suggesting that the donor may have had 
an effect upon the difference between liquid and residue. Residue absorption 
from Pig 1 was 3.1 times less than the liquid compared to only 2.2 times for pig 5 
overall and only 1.9 times from results with Pig 5b.  
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7 CONCLUSIONS 
 
The work carried out in this thesis is the first to quantify dermal absorption of 
pesticides from dried residues, under non-occlusive conditions. The 
methodology developed has been proven reproducible over the course of several 
studies; investigating various AIs, formulations, dose levels and exposure times.  
In general, these studies have shown that dermal absorption from a dried residue 
is lower than that from its corresponding spray dilution. However, this was not 
always observed, absorption of TXP from a WP formulation was not significantly 
different between the residue and liquid applications. This exception to the 
general trend suggests that formulation may be an important factor in dermal 
absorption from dried residues. This demonstrates the need to investigate a 
larger sample of AI-formulation combinations before general conclusions can be 
drawn. The findings also highlight the importance of investigating each 
compound of interest in a relevant formulation if results are to be used for risk 
assessment.  
Additionally, absorption of higher doses of CLF were not significantly different 
between the two application types, although residue absorption was still lower 
on average. Fractional absorption from the spray dilution was negatively affected 
by increasing dose, whereas absorption from the residue remained unaffected. 
This may be because from a liquid application, an increase in dose did not result 
in a proportional increase in contact area. Whereas, for the residue, due to lack of 
a vehicle, it did. This theory, by extension, suggests that the lower residue 
application may not be covering the entire surface area of the skin. This therefore, 
could be part of the reason why absorption is less from the residue compared to 
the spray dilution. It should be noted that these dose levels are towards the 
higher end of those obtained from the exposure assessment which, with its many 
built in conservatisms means that these doses are likely higher than a worker 
would ever be exposed to. Indeed, it is unlikely that a worker would ever be 
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exposed to a dose level that is flux limited in this way, excess pesticide may not 
remain on the skin but run off if liquid or fail to adhere if residue.  
Investigation of how the duration of exposure to TXP can affect total absorption 
found that it is important to wash as soon as possible after exposure. When 
applied as a spray dilution, if decontamination of the skin occurred after more 
than 2 hours, total TXP absorption after 24 hours was the same as if the skin had 
not been decontaminated at all. However, when applied as a residue, in general, 
total absorption decreased as a function of how early decontamination occurred. 
These findings highlight the importance of regular washing for a re-entry worker 
to reduce systemic exposure. However, as this study was only carried out with 
one compound, in one formulation, generalised conclusions should be drawn 
with caution. This effect may well be influenced by the physicochemical 
properties of the AI, as well as its formulation. 
7.1 Impact and future work 
The methodology developed has the potential to be used to carry out diffusion 
cell experiments for use in regulatory risk assessment. In the case where a 
product has failed based on a re-entry worker assessment, it may be possible to 
use this methodology to obtain more realistic fractional absorption values from 
the specific dried residue in question. In this case, further refinement of the 
methodology could be possible. For example, if there is a specific foliar surface 
in question, it may be possible to use this surface to create the residue, thereby 
making the results obtained more realistic to the scenario. It could even be 
possible to take leaf samples from an area that has been sprayed and use these to 
proceed with an experiment. Although this approach would give the most 
accurate values, as described above, it also adds new uncertainty factors. It would 
be more difficult to accurately state how much of the pesticide has been applied 
to the skin. There may also be issues with leaf wax transferring to the skin along 
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with the AI, although this is arguably more realistic, assuming that the transfer 
procedure is similar to that which a worker would experience.  
Another factor that should be considered, is the presence of moisture in the 
system. This moisture could arise from many sources including, precipitation, 
sweat or increased humidity. It is likely that highly water soluble molecules 
would be affected more by the addition of moisture. An increase in moisture may 
affect the transfer efficiency of the residue to the skin. Upon being transferred, it 
may also be absorbed differently to one that is ‘drier’ and crystalline in nature. If 
sufficient moisture is present then this may be enough to resolubilise the residue, 
restoring it to something resembling a spray dilution.  
Although the work here has investigated four compounds, this only represents a 
small sample of pesticide AIs currently in use. In order to fully validate the 
methodology and to be able to draw general conclusions about residue 
behaviour, as many products as possible should be investigated. Similarly, 
although three different formulation and the AI alone have been investigated 
there are many more types of formulation that have not been investigated, as well 
as different excipients that exist within these types of formulation.  
The doses used in this study were more realistic than those used previously, 
however, it should be noted that a worker is likely to be exposed to doses lower 
than those used here. With the aid of radiolabelled compounds, it would be 
useful to carry out experiments with lower doses. However, this creates issues 
such as uncertainty of how well spread the dose is, especially from residue 
application. It is unlikely that a dose level of 0.01µg/cm2 for example would cover 
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TXP Liquid  
       
 Replicate Number 1 2 3 4 5 Mean StDev 
Applied (µg) 20 20 20 20 20 20  
Recovered in swabs (µg) 12.89 9.15 12.53 9.16 11.16 10.98 1.78 
Total recovery (%) 76.84 68.4 83.15 72.02 73.27 74.74 5.00 
  
       
        
Disposition 
       
SC tape-strips 1-2 (µg) 0.33 0.64 1.50 1.08 0.78 0.86 0.45 
SC tape-strips 3-15 (µg) 0.18 0.25 0.48 0.4 0.27 0.32 0.12 
SC tape-strips 1-15 (µg) 0.51 0.88 1.98 1.48 1.04 1.18 0.57 
  
       
Remaining skin (µg) 0.80 2.13 0.54 1.34 0.61 1.08 0.66 
  
       
Receptor phase at 2 hr (µg) < LOQ < LOQ < LOQ < LOQ 0.39 0.08 0.17 
Receptor phase at 4 hr (µg) 0.34 0.47 0.40 0.58 0.80 0.52 0.18 
Receptor phase at 6 hr (µg) 0.61 0.65 0.67 0.87 0.85 0.73 0.12 
Receptor phase at 8 hr (µg) 0.76 0.90 0.73 1.05 1.09 0.91 0.16 
Receptor phase at 24 hr (µg) 1.18 1.51 1.58 2.42 1.83 1.71 0.47 
  
       
Total uptake/absorption (µg)
#
 2.15 3.89 2.60 4.16 2.71 3.11 0.87 
  
       
% uptake/absorption of amount 
applied 
10.77 19.45 13.02 20.82 13.57 15.53 4.36 
Table A1 1- Full Results from Paper 1, TXP liquid application 
TXP Residue 
       
Replicate Number 1 2 3 4 5 Mean StDev 
Applied (µg) 22.99 17.82 26.43 19.94 21.20 21.68 3.26 
Recovered in swabs (µg) 15.58 11.58 13.87 8.57 11.37 12.19 2.67 
Total recovery (%) 88.39 66.21 85.6 51.43 68.84 72.09 13.57 
  
       
Disposition 
       
SC tape-strips 1-2 (µg) 0.56 0.58 0.81 0.42 0.43 0.56 0.16 
SC tape-strips 3-15 (µg) 0.08 0.17 0.35 0.19 0.36 0.23 0.12 
SC tape-strips 1-15 (µg) 0.63 0.74 1.17 0.61 0.79 0.79 0.22 
  
       
Remaining skin (µg) 0.43 0.22 0.38 0.20 0.28 0.30 0.10 
  
       
Receptor phase at 2 hr (µg) < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ 
Receptor phase at 4 hr (µg) < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ 
Receptor phase at 6 hr (µg) < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ 
Receptor phase at 8 hr (µg) < LOQ < LOQ 0.34 < LOQ < LOQ 0.07 0.15 
Receptor phase at 24 hr (µg) 1.03 0.7 1.72 0.91 1.39 1.15 0.40 
  
       
Total uptake/absorption (µg)
#
 1.54 1.09 2.45 1.30 2.03 1.68 0.56 
  
       
% uptake/absorption of amount 
applied 
6.69 6.11 9.28 6.52 9.56 7.63 1.65 
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TXP Residue 24 hour wash 
      
  1 2 3 4 Mean Stdev 
Applied (µg) 18.15 23.10 20.52 20.09 20.47 2.03 
Recovered in swabs (µg) 8.97 9.42 9.25 6.85 8.62 1.19 
Total recovery (%) 58.66 71.00 67.83 52.27 62.44 8.56 
  
      
Disposition 
      
SC tape-strips 1-2 (µg) 0.61 1.02 0.85 0.64 0.78 0.19 
SC tape-strips 3-15 (µg) 0.31 0.49 0.38 0.34 0.38 0.08 
SC tape-strips 1-15 (µg) 0.92 1.51 1.22 0.97 1.16 0.27 
  
      
Remaining skin (µg) 0.52 0.89 0.90 0.70 0.75 0.18 
  
      
Receptor phase at 2 hr (µg) < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ 
Receptor phase at 4 hr (µg) < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ 
Receptor phase at 6 hr (µg) < LOQ < LOQ < LOQ 0.23 0.06 0.11 
Receptor phase at 8 hr (µg) 0.34 0.63 0.66 0.41 0.51 0.16 
Receptor phase at 24 hr (µg) 1.33 2.37 2.20 1.93 1.96 0.46 
  
      
Total uptake/absorption (µg)
#
 2.15 3.76 3.47 2.97 3.09 0.70 
  
      
% uptake/absorption of amount 
applied 
11.87 16.27 16.92 14.76 14.95 2.25 







TXP Liquid 24 hour exposure 
       
  1 2 3 4 5 Mean Stdev 
Applied (µg) 20 20 20 20 20 20 
 
Recovered in swabs (µg) 3.70 8.77 6.95 9.03 7.65 7.22 2.14 
Total recovery (%) 33.83 68.27 56.40 64.59 61.05 56.83 13.59 
  
       
Disposition 
       
SC tape-strips 1-2 (µg) 0.47 0.92 0.74 0.67 0.61 0.68 0.16 
SC tape-strips 3-15 (µg) 0.32 0.47 0.29 0.25 0.45 0.36 0.10 
SC tape-strips 1-15 (µg) 0.80 1.39 1.03 0.92 1.06 1.04 0.22 
  
       
Remaining skin (µg) 0.98 0.79 0.90 1.02 0.74 0.89 0.12 
  
       
Receptor phase at 2 hr (µg) < LOQ < LOQ < LOQ 0.34 0.28 0.12 0.17 
Receptor phase at 4 hr (µg) 0.45 0.86 0.54 0.37 0.54 0.55 0.19 
Receptor phase at 6 hr (µg) 0.77 1.27 0.73 0.47 0.82 0.81 0.29 
Receptor phase at 8 hr (µg) 0.74 1.31 0.80 0.51 1.17 0.91 0.33 
Receptor phase at 24 hr (µg) 1.29 2.71 2.39 1.94 2.76 2.22 0.61 
  
       
Total uptake/absorption (µg)
#
 2.59 3.96 3.59 3.22 3.95 3.46 0.58 
  
       
% uptake/absorption of amount 
applied 
12.94 19.80 17.93 16.08 19.77 17.30 2.88 
   Table A1 3- Full Results from Paper 1, TXP liquid application, 24-hour exposure. 
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Replicate Number 1 2 3 4 5 6 7 Mean StDev 
Applied (µg) 23.68 15.28 17.86 27.04 24.33 23.64 25.34 22.45 4.25 
Recovered in swabs (µg) 15.82 8.62 10.20 11.44 10.47 9.15 11.68 11.06 2.38 
Total recovery (%) 83.80 87.02 83.89 65.51 69.13 70.37 70.98 75.81 8.74 
Donor wash (µg) 0.21 0.20 0.44 0.61 0.35 0.29 0.49 0.37 0.15 
  
         
Disposition 
         
SC tape-strips 1-2 (µg) 0.46 0.54 0.27 0.63 0.52 0.99 0.32 0.53 0.24 
SC tape-strips 3-15 (µg) 0.12 0.14 0.11 0.11 0.07 0.41 0.23 0.17 0.12 
SC tape-strips 1-15 (µg) 0.58 0.68 0.37 0.74 0.60 1.40 0.56 0.70 0.33 
  
         
Remaining skin (µg) 0.30 0.31 0.21 0.45 0.23 0.62 0.52 0.38 0.16 
  
         




< LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ 




< LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ 




< LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ 




< LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ 
Receptor phase at 24 hr 
(µg) 
0.29 0.27 0.23 < LOQ 0.33 0.33 0.49 0.27 0.15 
  





0.70 0.72 0.54 0.56 0.64 1.36 1.25 0.82 0.34 
  
         
% uptake/absorption of 
amount applied 
2.97 4.72 3.01 2.07 2.61 5.75 4.92 3.72 1.39 




     
Replicate Number 1 2 3 Mean StDev 
Applied (µg) 25.00 25.00 25.00 25.00 
 
Recovered in swabs (µg) 12.04 9.23 12.07 11.12 1.63 
Total recovery (%) 71.83 58.13 69.66 66.54 7.36 
Donor wash (µg) 2.21 1.72 1.35 1.76 0.43       
Disposition 
     
SC tape-strips 1-2 (µg) 1.03 1.03 1.52 1.20 0.28 
SC tape-strips 3-15 (µg) 0.28 0.28 0.44 0.33 0.09 
SC tape-strips 1-15 (µg) 1.31 1.32 1.96 1.53 0.37       
Remaining skin (µg) 0.68 0.89 0.63 0.73 0.14 
      
Receptor phase at 2 hr (µg) 0.47 0.21 0.29 0.32 0.13 
Receptor phase at 4 hr (µg) 1.02 0.60 0.67 0.76 0.22 
Receptor phase at 6 hr (µg) 1.19 0.83 0.85 0.96 0.20 
Receptor phase at 8 hr (µg) 1.39 0.99 0.99 1.12 0.23 
Receptor phase at 24 hr (µg) 1.71 1.38 1.41 1.50 0.18       
Total uptake/absorption (µg)
#
 2.67 2.55 2.47 2.56 0.10 
      
% uptake/absorption of amount 
applied 
10.69 10.18 9.89 10.25 0.40 
    Table A1 5- Full Results from Paper 2, TXP liquid 
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CLF Liquid  
        
Replicate Number 1 2 3 4 5 6 Mean StDev 
Applied (µg) 30 30 30 30 30 30 30 
 
Recovered in swabs (µg) 19.56 17.29 23.97 20.04 23.29 22.37 21.09 2.56 
Total recovery (%) 84.15 73.90 99.27 84.56 98.61 91.79 88.72 9.76 
Donor wash (µg) 0.81 0.68 0.89 1.10 0.85 0.84 0.86 0.14 
  
        
Disposition 
        
SC tape-strips 1-2 (µg) 2.79 2.06 2.58 1.75 2.57 1.69 2.24 0.47 
SC tape-strips 3-15 (µg) 0.62 0.73 0.71 0.86 0.93 0.88 0.79 0.12 
SC tape-strips 1-15 (µg) 3.41 2.80 3.28 2.60 3.50 2.57 3.03 0.42 
  
        
Remaining skin (µg) 1.47 1.41 1.64 1.63 1.94 1.76 1.64 0.19 
  
        
Receptor phase at 24 hr (µg) < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ 
  





2.08 2.14 2.35 2.49 2.88 2.64 2.43 0.30 
  
        
% uptake/absorption of 
amount applied 
6.95 7.13 7.83 8.28 9.59 8.79 8.09 1.00 




        
Replicate Number 1 2 3 4 5 6 Mean StDev 
Applied (µg) 31.20 31.27 31.58 28.70 31.96 25.12 29.97 2.64 
Recovered in swabs (µg) 29.08 28.49 25.87 20.98 20.99 17.03 23.74 4.81 
Total recovery (%) 102.37 101.07 95.56 83.78 80.80 82.43 91.00 9.81 
Donor wash (µg) 0.81 0.91 0.87 0.27 0.53 0.16 0.59 0.32 
  
        
Disposition 
        
SC tape-strips 1-2 (µg) 1.44 1.48 1.46 0.63 1.89 0.58 1.25 0.52 
SC tape-strips 3-15 (µg) 0.35 0.17 0.30 0.14 0.46 0.11 0.25 0.14 
SC tape-strips 1-15 (µg) 1.79 1.65 1.76 0.77 2.35 0.69 1.50 0.65 
  
        
Remaining skin (µg) 0.47 0.65 1.31 0.19 0.41 0.20 0.54 0.41 
  
        
Receptor phase at 24 hr 
(µg) 
< LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ 
  





0.82 0.82 1.61 0.33 0.87 0.32 0.79 0.47 
  
        
% uptake/absorption of 
amount applied 
2.63 2.61 5.09 1.14 2.72 1.27 2.58 1.42 
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DFZ Liquid  
        
Replicate Number 1 2 3 4 5 6 Mean StDev 
Applied (µg) 30 30 30 30 30 30 30  
Recovered in swabs (µg) 24.85 23.45 23.78 24.80 21.66 27.33 24.31 1.88 
Total recovery (%) 98.06 96.12 98.90 98.70 87.44 102.43 96.94 5.09 
Donor wash (µg) 0.76 0.58 1.04 0.35 0.95 0.62 0.72 0.25 
  
        
Disposition 
        
SC tape-strips 1-2 (µg) 0.73 1.95 2.37 1.66 1.54 1.07 1.55 0.59 
SC tape-strips 3-15 (µg) 0.84 0.44 0.76 0.65 0.43 0.29 0.57 0.21 
SC tape-strips 1-15 (µg) 1.57 2.39 3.12 2.32 1.97 1.36 2.12 0.64 
  
        
Remaining skin (µg) 2.25 2.41 1.73 2.15 1.65 1.42 1.93 0.39 
  
        
Receptor phase at 24 hr 
(µg) 
< LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ 
  





3.09 2.85 2.48 2.80 2.08 1.71 2.50 0.52 
  
        
% uptake/absorption of 
amount applied 
10.29 9.51 8.28 9.32 6.95 5.70 8.34 1.74 
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Table A1 10 - Full Results from Paper 2, DFZ residue application 
DFZ Residue 
             
Replicate Number 1 2 3 4 5 6 7 8 9 10 11 Mean StDev 
Applied (µg) 27.76 29.70 27.38 33.30 36.23 29.72 30.38 26.38 25.96 24.13 28.15 29.01 3.44 
Recovered in swabs (µg) 18.44 21.89 22.59 26.72 29.40 23.69 22.30 18.96 20.45 19.38 23.11 22.45 3.32 
Total recovery (%) 81.13 80.63 92.71 89.59 91.67 91.72 86.27 83.14 88.02 90.81 90.19 87.81 4.39 
Donor wash (µg) 0.60 0.61 0.38 0.61 0.76 0.51 0.76 0.35 0.37 0.34 0.29 0.51 0.17 
  
             
Disposition 
             
SC tape-strips 1-2 (µg) 1.71 0.65 1.31 1.37 1.22 1.31 1.43 1.16 0.97 0.99 0.60 1.16 0.33 
SC tape-strips 3-15 (µg) 0.66 0.25 0.28 0.33 0.56 0.42 0.29 0.20 0.28 0.26 0.15 0.34 0.15 
SC tape-strips 1-15 (µg) 2.36 0.90 1.59 1.71 1.78 1.73 1.72 1.36 1.25 1.26 0.75 1.49 0.45 
  
             
Remaining skin (µg) 1.12 0.55 0.82 0.81 1.28 1.33 1.42 1.27 0.78 0.93 1.23 1.05 0.28 
  
             
Receptor phase at 24 hr (µg) < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ 
  





1.78 0.80 1.10 1.14 1.83 1.75 1.71 1.47 1.06 1.20 1.38 1.38 0.35 
  
             
% uptake/absorption of 
amount applied 
6.41 2.69 4.02 3.43 5.06 5.89 5.64 5.58 4.08 4.96 4.90 4.79 1.13 
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PPZ Liquid  
        
Replicate Number 1 2 3 4 5 6 Mean StDev 
Applied (µg) 25 25 25 25 25 25 25 
 
Recovered in swabs (µg) 16.04 13.80 15.22 13.43 8.89 8.16 12.59 3.30 
Total recovery (%) 105.12 80.84 100.27 84.98 76.25 63.55 85.17 15.44 
Donor wash (µg) 1.56 0.71 1.46 1.24 1.86 1.74 1.43 0.41 
  
        
Disposition 
        
SC tape-strips 1-2 (µg) 5.04 1.62 3.09 2.10 2.96 2.16 2.83 1.22 
SC tape-strips 3-15 (µg) 1.92 1.90 1.77 1.82 2.27 1.49 1.86 0.25 
SC tape-strips 1-15 (µg) 6.96 3.52 4.86 3.92 5.23 3.65 4.69 1.31 
  
        
Remaining skin (µg) 1.72 2.18 3.52 2.65 3.08 2.34 2.58 0.65 
  
        
Receptor phase at 8 hr (µg) < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ 
Receptor phase at 24 hr 
(µg) 
0.54 0.45 1.07 0.82 1.05 0.57 0.75 0.27 
  





4.18 4.53 6.35 5.30 6.40 4.40 5.19 0.99 
  
        
% uptake/absorption of 
amount applied 
16.73 18.13 25.41 21.18 25.58 17.59 20.77 3.96 
    Table A1 11 - Full Results from Paper 2, PPZ liquid application. 
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Replicate Number 1 2 3 4 5 6 Mean StDev 
Applied (µg) 24.10 22.53 26.14 24.93 23.67 25.29 24.44 1.28 
Recovered in swabs (µg) 20.33 17.29 21.79 19.45 20.85 20.00 19.95 1.53 
Total recovery (%) 102.78 97.68 100.45 99.34 102.75 101.64 100.77 2.02 
Donor wash (µg) 0.66 0.59 0.84 0.86 0.66 0.85 0.74 0.12 
  
        
Disposition 
        
SC tape-strips 1-2 (µg) 1.91 2.14 1.69 2.16 1.15 2.16 1.87 0.40 
SC tape-strips 3-15 (µg) 1.28 1.21 1.37 1.25 1.25 1.65 1.33 0.16 
SC tape-strips 1-15 (µg) 3.19 3.34 3.06 3.40 2.40 3.81 3.20 0.47 
  
        
Remaining skin (µg) 0.59 0.79 0.57 1.05 0.42 1.06 0.75 0.27 
  
        
Receptor phase at 24 hr 
(µg) 
< LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ 
  





1.87 1.99 1.94 2.29 1.67 2.71 2.08 0.37 
  
        
% uptake/absorption of 
amount applied 
7.75 8.85 7.43 9.21 7.04 10.69 8.50 1.36 
Table A1 12- Full Results from Paper 2, PPZ residue application.
Appendix – Full Results Tables 




TXP Residue 0.5 hr wash 
     
Replicate Number 1 2 3 Mean StDev 
Applied (µg) 29.48 28.44 28.47 28.79 0.59 
Recovered in swabs (µg) 17.20 18.29 19.51 18.33 1.16 
Total recovery (%) 72.34 79.08 81.89 77.77 4.91 
Donor wash (µg) 0.85 0.93 0.89 0.89 0.04 
  
     
Disposition 
     
SC tape-strips 1-2 (µg) 0.07 0.53 0.10 0.23 0.26 
SC tape-strips 3-15 (µg) < LOQ < LOQ 0.06 0.02 0.03 
SC tape-strips 1-15 (µg) 0.07 0.53 0.16 0.25 0.24 
  
     
Remaining skin (µg) < LOQ 0.32 0.28 0.20 0.17 
  
     
Receptor phase at 2 hr (µg) 0.18 < LOQ < LOQ 0.06 0.10 
Receptor phase at 3 hr (µg) 0.28 < LOQ < LOQ 0.09 0.16 
Receptor phase at 4 hr (µg) 0.26 < LOQ < LOQ 0.09 0.15 
Receptor phase at 5 hr (µg) 0.27 < LOQ < LOQ 0.09 0.16 
Receptor phase at 6 hr (µg) 0.29 < LOQ 0.19 0.16 0.15 
Receptor phase at 7 hr (µg) 0.27 < LOQ 0.20 0.15 0.14 
Receptor phase at 8 hr (µg) 0.30 < LOQ 0.25 0.18 0.16 
Receptor phase at 24 hr (µg) 0.29 < LOQ 0.37 0.22 0.20 
  
     
Total uptake/absorption (µg)
#
 0.29 0.32 0.71 0.44 0.24 
  
     
% uptake/absorption of amount 
applied 
0.97 1.12 2.51 1.53 0.85 




TXP Liquid 0.5 hr wash 
     
Replicate Number 1 2 3 Mean StDev 
Applied (µg) 30 30 30 30 
 
Recovered in swabs (µg) 21.87 19.32 20.60 20.59 1.28 
Total recovery (%) 82.95 74.45 79.50 78.96 4.28 
Donor wash (µg) 0.84 0.42 0.63 0.63 0.21 
  
     
Disposition 
     
SC tape-strips 1-2 (µg) 0.41 0.75 0.80 0.65 0.21 
SC tape-strips 3-15 (µg) 0.07 0.12 0.10 0.10 0.02 
SC tape-strips 1-15 (µg) 0.48 0.87 0.90 0.75 0.23 
  
     
Remaining skin (µg) 0.80 0.47 0.60 0.62 0.17 
  
     
Receptor phase at 2 hr (µg) 0.58 0.67 0.64 0.63 0.04 
Receptor phase at 3 hr (µg) 0.71 0.98 0.76 0.82 0.15 
Receptor phase at 4 hr (µg) 0.74 1.11 0.86 0.90 0.19 
Receptor phase at 5 hr (µg) 0.73 0.92 0.87 0.84 0.10 
Receptor phase at 6 hr (µg) 0.77 0.96 0.92 0.89 0.10 
Receptor phase at 7 hr (µg) 0.73 1.04 0.95 0.91 0.16 
Receptor phase at 8 hr (µg) 0.73 0.93 0.94 0.86 0.12 
Receptor phase at 24 hr (µg) 0.88 1.27 1.13 1.10 0.20 
  
     
Total uptake/absorption (µg)
#
 1.76 1.86 1.83 1.81 0.05 
  
     
% uptake/absorption of amount 
applied 
5.86 6.19 6.08 6.04 0.17 
     Table A1 13- Full Results from Paper 2, TXP 0.5-hr exposure liquid application 
Appendix – Full Results Tables 




TXP Residue 1 hour wash 
     
Replicate Number 1 2 3 Mean StDev 
Applied (µg) 23.79 28.32 28.40 26.84 2.64 
Recovered in swabs (µg) 15.44 18.38 19.21 17.67 1.98 
Total recovery (%) 86.06 83.43 82.64 84.04 1.79 
Donor wash (µg) 1.30 0.82 0.35 0.82 0.48 
  
     
Disposition 
     
SC tape-strips 1-2 (µg) 0.30 0.50 0.32 0.37 0.11 
SC tape-strips 3-15 (µg) 0.02 0.22 0.23 0.16 0.12 
SC tape-strips 1-15 (µg) 0.32 0.72 0.55 0.53 0.20 
  
     
Remaining skin (µg) 0.14 0.08 0.17 0.13 0.05 
  
     
Receptor phase at 2 hr (µg) 0.89 1.27 0.93 1.03 0.21 
Receptor phase at 3 hr (µg) 0.99 1.37 1.00 1.12 0.22 
Receptor phase at 4 hr (µg) 1.06 1.48 1.09 1.21 0.23 
Receptor phase at 5 hr (µg) 1.10 1.50 1.12 1.24 0.22 
Receptor phase at 6 hr (µg) 1.08 1.64 1.16 1.29 0.30 
Receptor phase at 7 hr (µg) 1.04 1.56 1.18 1.26 0.27 
Receptor phase at 8 hr (µg) 1.00 1.57 1.19 1.25 0.29 
Receptor phase at 24 hr (µg) 1.02 1.69 1.18 1.30 0.35 
  
     
Total uptake/absorption (µg)
#
 1.18 1.99 1.58 1.58 0.40 
  
     
% uptake/absorption of 
amount applied 
4.96 7.03 5.57 5.85 1.06 
Table A1 16 - Full Results from Paper 2, TXP 1-hr exposure Residue application 
 
TXP Liquid 1 hour wash 
     
      
Replicate Number 1 2 3 Mean StDev 
Applied (µg) 30 30 30 30 
 
Recovered in swabs (µg) 18.28 24.60 25.77 22.88 4.03 
Total recovery (%) 75.14 98.28 99.56 91.00 13.75 
Donor wash (µg) 1.18 0.78 0.37 0.78 0.41 
  
     
Disposition 
     
SC tape-strips 1-2 (µg) 0.31 0.55 0.41 0.42 0.12 
SC tape-strips 3-15 (µg) 0.05 0.29 0.23 0.19 0.12 
SC tape-strips 1-15 (µg) 0.36 0.84 0.64 0.61 0.24 
  
     
Remaining skin (µg) 1.19 0.56 0.57 0.77 0.36 
  
     
Receptor phase at 2 hr (µg) 1.16 2.06 1.76 1.66 0.46 
Receptor phase at 3 hr (µg) 1.44 2.38 2.12 1.98 0.49 
Receptor phase at 4 hr (µg) 1.53 2.56 2.24 2.11 0.53 
Receptor phase at 5 hr (µg) 1.60 2.70 2.22 2.17 0.55 
Receptor phase at 6 hr (µg) 1.67 2.78 2.44 2.30 0.57 
Receptor phase at 7 hr (µg) 1.67 2.77 2.47 2.30 0.57 
Receptor phase at 8 hr (µg) 1.57 2.76 2.54 2.29 0.63 
Receptor phase at 24 hr (µg) 1.53 2.71 2.52 2.25 0.63 
  
     
Total uptake/absorption (µg)
#
 2.78 3.56 3.32 3.22 0.40 
  
     
% uptake/absorption of amount 
applied 
9.26 11.86 11.06 10.73 1.33 
    Table A1 15 - Full Results from Paper 2, TXP 1-hr exposure Liquid application 
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TXP Liquid 2 hour wash 
         
Replicate Number 1 2 3 4 5 6 7 Mean StDev 
Applied (µg) 30 30 30 30 30 30 30 30.00 
 
Recovered in swabs (µg) 22.33 22.04 18.82 17.84 18.48 17.33 18.23 19.29 2.03 
Total recovery (%) 88.28 85.91 86.39 89.27 96.29 85.68 88.28 88.59 3.66 
Donor wash (µg) 0.47 0.80 0.66 0.35 0.54 0.47 0.43 0.53 0.15 
  
         
Disposition 
         
SC tape-strips 1-2 (µg) 0.72 1.14 0.46 0.62 0.46 0.78 0.20 0.63 0.30 
SC tape-strips 3-15 (µg) 0.22 0.13 0.15 0.44 0.23 0.35 0.04 0.22 0.14 
SC tape-strips 1-15 (µg) 0.94 1.27 0.61 1.06 0.69 1.13 0.24 0.85 0.35 
  
         
Remaining skin (µg) 0.98 0.37 2.17 1.39 1.32 1.60 2.24 1.44 0.65 
  
         
Receptor phase at 2 hr (µg) 1.07 0.67 1.35 2.48 3.50 1.70 3.24 2.00 1.09 
Receptor phase at 3 hr (µg) 1.60 1.02 2.02 3.56 5.00 2.56 4.22 2.85 1.45 
Receptor phase at 4 hr (µg) 1.89 1.37 2.49 4.04 5.71 2.97 4.62 3.30 1.56 
Receptor phase at 5 hr (µg) 2.00 1.39 2.58 4.31 5.95 3.25 4.77 3.46 1.63 
Receptor phase at 6 hr (µg) 1.94 1.47 2.75 4.72 6.30 3.65 5.07 3.70 1.76 
Receptor phase at 7 hr (µg) 2.01 1.51 2.98 4.77 6.69 3.82 5.18 3.85 1.84 
Receptor phase at 8 hr (µg) 1.95 1.39 3.07 4.86 6.69 4.00 5.26 3.89 1.89 
Receptor phase at 24 hr 
(µg) 
1.76 1.29 3.66 6.16 7.86 5.18 5.35 4.47 2.37 
  





2.96 1.79 5.98 7.99 9.41 7.12 7.63 6.13 2.78 
  
         
% uptake/absorption of 
amount applied 
9.88 5.97 19.93 26.63 31.37 23.73 25.42 20.42 9.26 
Table A1 17 - Full Results from Paper 2, TXP 2-hr exposure Liquid application. 
Appendix – Full Results Tables 




TXP Residue 2 hour wash 
         
Replicate Number 1 2 3 4 5 6 7 Mean StDev 
Applied (µg) 31.99 31.09 26.37 26.60 25.50 29.04 27.67 28.32 2.48 
Recovered in swabs (µg) 17.85 19.03 18.54 17.15 16.99 18.46 19.19 18.18 0.87 
Total recovery (%) 75.51 81.66 88.89 82.39 86.05 79.13 84.63 82.61 4.45 
Donor wash (µg) 0.81 0.61 1.00 0.96 0.47 1.17 0.21 0.75 0.34 
  
         
Disposition 
         
SC tape-strips 1-2 (µg) 1.33 0.69 0.50 0.34 0.42 0.27 0.35 0.56 0.37 
SC tape-strips 3-15 (µg) 0.33 0.25 0.12 0.07 0.05 0.20 0.11 0.16 0.10 
SC tape-strips 1-15 (µg) 1.66 0.94 0.62 0.41 0.47 0.47 0.46 0.72 0.45 
  
         
Remaining skin (µg) 0.72 0.84 0.10 < LOQ 0.25 0.19 0.43 0.36 0.32 
  
         
Receptor phase at 2 hr (µg) 0.76 1.92 0.94 0.35 1.02 < LOQ 0.61 0.80 0.61 
Receptor phase at 3 hr (µg) 1.15 2.44 1.18 0.59 1.33 0.25 0.80 1.11 0.70 
Receptor phase at 4 hr (µg) 1.24 2.61 1.31 0.64 1.43 0.30 1.00 1.22 0.73 
Receptor phase at 5 hr (µg) 1.29 2.67 1.44 0.73 1.52 0.38 1.04 1.29 0.73 
Receptor phase at 6 hr (µg) 1.30 2.82 1.47 0.77 1.63 0.41 1.11 1.36 0.77 
Receptor phase at 7 hr (µg) 1.35 2.79 1.49 0.73 1.71 0.32 1.14 1.36 0.79 
Receptor phase at 8 hr (µg) 1.29 2.62 1.56 0.75 1.68 0.51 1.19 1.37 0.69 
Receptor phase at 24 hr (µg) 1.15 2.32 1.66 1.02 1.73 0.39 1.23 1.36 0.62 
  





2.20 3.42 1.88 1.09 2.03 0.78 1.77 1.88 0.85 
  
         
% uptake/absorption of 
amount applied 
6.89 11.01 7.14 4.12 7.95 2.70 6.40 6.60 2.68 
Table A1 18 - Full Results from Paper 2, TXP 2-hr exposure residue application. 
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TXP Liquid 4 hour wash 
         
Replicate Number 1 2 3 4 5 6 7 Mean StDev 
Applied (µg) 30 30 30 30 30 30 30 30.00 
 
Recovered in swabs (µg) 21.86 22.25 20.36 14.50 13.16 16.66 14.32 17.59 3.84 
Total recovery (%) 86.15 86.14 90.86 76.75 75.76 89.07 77.24 83.14 6.36 
Donor wash (µg) 0.55 0.74 0.74 0.48 0.58 0.70 0.86 0.66 0.13 
  
         
Disposition 
         
SC tape-strips 1-2 (µg) 0.91 0.79 0.76 0.60 0.45 0.42 0.66 0.66 0.18 
SC tape-strips 3-15 (µg) 0.23 0.15 0.25 0.44 0.25 0.26 0.43 0.29 0.11 
SC tape-strips 1-15 (µg) 1.14 0.94 1.01 1.04 0.69 0.68 1.10 0.94 0.18 
  
         
Remaining skin (µg) 0.78 0.38 1.13 1.33 1.91 1.26 0.92 1.10 0.48 
  
         
Receptor phase at 2 hr (µg) 0.96 0.85 1.55 2.57 3.24 3.18 2.35 2.10 0.99 
Receptor phase at 3 hr (µg) 1.28 1.31 2.16 3.31 4.09 4.26 3.30 2.82 1.24 
Receptor phase at 4 hr (µg) 1.46 1.60 2.46 3.87 4.62 5.39 3.96 3.34 1.52 
Receptor phase at 5 hr (µg) 1.54 1.67 2.85 4.35 4.99 5.80 4.47 3.67 1.66 
Receptor phase at 6 hr (µg) 1.63 1.85 3.07 4.76 5.43 6.53 4.78 4.01 1.86 
Receptor phase at 7 hr (µg) 1.59 1.87 3.12 5.01 5.79 6.75 5.11 4.18 1.99 
Receptor phase at 8 hr (µg) 1.56 1.83 3.29 4.96 5.69 6.88 5.13 4.19 2.01 
Receptor phase at 24 hr (µg) 1.52 1.53 4.02 5.68 6.38 7.42 5.97 4.65 2.36 
  
         
Total uptake/absorption (µg)
#
 2.53 2.06 5.40 7.45 8.54 8.95 7.32 6.03 2.79 
  
         
% uptake/absorption of amount 
applied 
8.43 6.88 17.99 24.82 28.46 29.82 24.41 20.12 9.32 
  Table A1 19 - Full Results from Paper 2, TXP 4-hr exposure liquid application. 
Appendix – Full Results Tables 




TXP Residue 4 hour wash 
        
Replicate Number 1 2 3 4 5 6 Mean StDev 
Applied (µg) 23.99 32.86 28.68 25.80 27.38 28.90 27.93 3.04 
Recovered in swabs (µg) 18.01 15.91 14.40 12.54 17.49 17.15 15.92 2.10 
Total recovery (%) 90.64 72.20 76.57 82.16 79.45 76.06 79.51 6.40 
Donor wash (µg) 0.79 0.72 0.44 0.30 0.47 0.98 0.62 0.26 
  
        
Disposition 
        
SC tape-strips 1-2 (µg) 0.30 1.35 0.72 0.50 0.25 0.30 0.57 0.42 
SC tape-strips 3-15 (µg) 0.06 0.36 0.16 0.07 0.03 0.08 0.13 0.12 
SC tape-strips 1-15 (µg) 0.36 1.71 0.88 0.57 0.28 0.38 0.70 0.54 
  
        
Remaining skin (µg) 0.28 1.14 0.23 0.24 0.55 0.37 0.47 0.35 
  
        
Receptor phase at 2 hr (µg) 0.59 1.38 1.11 2.98 < LOQ < LOQ 1.01 1.12 
Receptor phase at 3 hr (µg) 0.80 1.83 1.64 3.54 < LOQ < LOQ 1.30 1.35 
Receptor phase at 4 hr (µg) 0.94 2.11 2.13 3.79 0.26 0.27 1.58 1.37 
Receptor phase at 5 hr (µg) 0.96 2.25 2.70 4.12 0.32 0.29 1.77 1.52 
Receptor phase at 6 hr (µg) 1.02 2.55 2.90 4.30 0.39 0.41 1.93 1.58 
Receptor phase at 7 hr (µg) 1.00 2.51 2.96 4.32 0.45 0.50 1.95 1.56 
Receptor phase at 8 hr (µg) 0.98 2.66 3.07 4.55 0.47 0.51 2.04 1.65 
Receptor phase at 24 hr (µg) 0.80 2.25 3.35 5.01 0.38 0.45 2.04 1.87 
  
        
Total uptake/absorption (µg)
#
 1.14 3.75 3.74 5.33 0.95 0.89 2.63 1.89 
  
        
% uptake/absorption of amount 
applied 
4.74 11.42 13.06 20.66 3.48 3.09 9.41 6.94 
Table A1 20 - Full Results from Paper 2, TXP 4-hr exposure residue application. 
Appendix – Full Results Tables 

























TXP Liquid 8 hour wash 
     
Replicate Number 1 2 3 Mean StDev 
Applied (µg) 30 30 30 30 
 
Recovered in swabs (µg) 21.66 14.73 17.86 18.08 3.47 
Total recovery (%) 85.36 79.88 83.22 82.82 2.76 
Donor wash (µg) 0.31 0.56 0.73 0.53 0.21 
  
     
Disposition 
     
SC tape-strips 1-2 (µg) 1.37 0.48 0.29 0.71 0.57 
SC tape-strips 3-15 (µg) 0.35 0.16 0.02 0.18 0.17 
SC tape-strips 1-15 (µg) 1.71 0.65 0.30 0.89 0.74 
  
     
Remaining skin (µg) 0.42 1.84 1.69 1.32 0.78 
  
     
Receptor phase at 2 hr (µg) 0.78 1.60 < LOQ 0.79 0.80 
Receptor phase at 3 hr (µg) 1.09 2.46 < LOQ 1.18 1.23 
Receptor phase at 4 hr (µg) 1.21 3.18 0.31 1.57 1.47 
Receptor phase at 5 hr (µg) 1.42 3.65 0.44 1.84 1.65 
Receptor phase at 6 hr (µg) 1.57 4.17 0.73 2.16 1.80 
Receptor phase at 7 hr (µg) 1.46 4.70 0.88 2.35 2.06 
Receptor phase at 8 hr (µg) 1.44 4.97 1.15 2.52 2.12 
Receptor phase at 24 hr (µg) 1.51 6.18 4.38 4.02 2.36 
  
     
Total uptake/absorption (µg)
#
 2.28 8.19 6.09 5.52 3.00 
  
     
% uptake/absorption of 
amount applied 
7.59 27.29 20.30 18.39 9.99 
 Table A1 21 - Full Results from Paper 2, TXP 8-hr exposure liquid 
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TXP Residue 8 hour wash 
        
Replicate Number 1 2 3 4 5 6 Mean StDev 
Applied (µg) 27.46 28.62 25.62 29.01 26.02 28.60 27.56 1.45 
Recovered in swabs (µg) 12.63 15.60 23.63 18.85 16.37 17.90 17.50 3.69 
Total recovery (%) 76.05 79.02 105.90 88.69 81.32 79.75 85.12 11.02 
Donor wash (µg) 0.87 0.96 < LOQ 0.33 0.12 0.17 0.41 0.41 
  
        
Disposition 
        
SC tape-strips 1-2 (µg) 0.56 0.73 0.99 0.62 0.40 0.45 0.63 0.21 
SC tape-strips 3-15 (µg) 0.15 0.23 0.45 0.31 0.17 0.12 0.24 0.13 
SC tape-strips 1-15 (µg) 0.71 0.96 1.45 0.93 0.57 0.57 0.87 0.33 
  
        
Remaining skin (µg) 0.28 0.40 0.89 0.31 0.54 0.63 0.51 0.23 
  
        
Receptor phase at 2 hr (µg) 1.51 0.59 0.65 2.11 < LOQ < LOQ 0.81 0.84 
Receptor phase at 3 hr (µg) 1.88 0.80 0.88 2.63 < LOQ 0.26 1.07 1.00 
Receptor phase at 4 hr (µg) 2.05 0.98 1.08 2.84 0.28 0.56 1.30 0.97 
Receptor phase at 5 hr (µg) 2.26 1.08 1.18 3.08 0.37 0.62 1.43 1.03 
Receptor phase at 6 hr (µg) 2.39 1.23 1.30 3.51 0.42 0.65 1.58 1.17 
Receptor phase at 7 hr (µg) 2.55 1.24 1.30 3.55 0.48 0.80 1.65 1.17 
Receptor phase at 8 hr (µg) 2.75 1.50 1.39 3.67 0.59 0.80 1.79 1.19 
Receptor phase at 24 hr (µg) 3.39 2.31 2.01 4.39 1.07 1.40 2.43 1.26 
  
        
Total uptake/absorption (µg)
#
 3.82 2.94 3.36 5.02 1.77 2.14 3.18 1.18 
  
        
% uptake/absorption of 
amount applied 
13.89 10.28 13.12 17.30 6.82 7.50 11.48 4.04 
Table A1 22 - Full Results from Paper 2, TXP 8-hr exposure residue
Appendix – Full Results Tables 
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TXP Residue 24 hour wash  
     
Replicate Number 1 2 3 Mean StDev 
Applied (µg) 29.76 31.85 32.43 31.35 1.40 
Recovered in swabs (µg) 12.99 15.64 15.89 14.84 1.61 
Total recovery (%) 72.84 78.13 76.93 75.97 2.77 
Donor wash (µg) 0.39 0.72 0.88 0.66 0.25 
  
     
Disposition 
     
SC tape-strips 1-2 (µg) 0.25 0.17 0.25 0.23 0.05 
SC tape-strips 3-15 (µg) 0.37 0.07 0.23 0.22 0.15 
SC tape-strips 1-15 (µg) 0.62 0.24 0.49 0.45 0.20 
  
     
Remaining skin (µg) 0.50 0.51 0.48 0.50 0.02 
  
     
Receptor phase at 2 hr (µg) 1.41 1.75 1.73 1.63 0.19 
Receptor phase at 3 hr (µg) 1.62 2.00 2.05 1.89 0.24 
Receptor phase at 4 hr (µg) 1.90 2.25 2.29 2.15 0.22 
Receptor phase at 5 hr (µg) 2.04 2.60 2.63 2.42 0.33 
Receptor phase at 6 hr (µg) 2.27 2.98 3.03 2.76 0.42 
Receptor phase at 7 hr (µg) 2.29 3.03 3.15 2.83 0.47 
Receptor phase at 8 hr (µg) 2.49 3.23 3.24 2.99 0.43 
Receptor phase at 24 hr (µg) 4.39 5.99 5.47 5.28 0.81 
  
     
Total uptake/absorption (µg)
#
 5.26 6.57 6.18 6.00 0.67 
  
     
% uptake/absorption of 
amount applied 
17.69 20.62 19.05 19.12 1.46 






TXP Liquid 24 hour wash  
     
Replicate Number 1 2 3 Mean StDev 
Applied (µg) 30 30 30 30 
 
Recovered in swabs (µg) 19.14 17.51 19.79 18.81 1.17 
Total recovery (%) 87.00 83.06 88.06 86.04 2.63 
Donor wash (µg) 0.47 0.38 0.16 0.34 0.16 
  
     
Disposition 
     
SC tape-strips 1-2 (µg) 0.23 0.71 0.24 0.39 0.27 
SC tape-strips 3-15 (µg) 0.21 0.28 0.23 0.24 0.04 
SC tape-strips 1-15 (µg) 0.44 0.99 0.47 0.63 0.31 
  
     
Remaining skin (µg) 0.94 0.59 0.63 0.72 0.19 
  
     
Receptor phase at 2 hr (µg) 1.86 2.01 1.65 1.84 0.18 
Receptor phase at 3 hr (µg) 2.40 2.43 2.09 2.31 0.19 
Receptor phase at 4 hr (µg) 2.69 2.75 2.55 2.67 0.10 
Receptor phase at 5 hr (µg) 2.96 3.04 2.88 2.96 0.08 
Receptor phase at 6 hr (µg) 3.21 3.33 3.17 3.24 0.08 
Receptor phase at 7 hr (µg) 3.33 3.35 3.37 3.35 0.02 
Receptor phase at 8 hr (µg) 3.43 3.62 3.49 3.51 0.10 
Receptor phase at 24 hr (µg) 5.11 5.44 5.36 5.30 0.17 
  
     
Total uptake/absorption (µg)
#
 6.26 6.32 6.22 6.27 0.05 
  
     
% uptake/absorption of amount 
applied 
20.87 21.07 20.74 20.89 0.17 
Table A1 23- Full Results from Paper 2, TXP 24-hr exposure liquid application 
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TXP Residue 40µg disc 
     
Replicate Number 1 2 3 Mean StDev 
Applied (µg) 25.27 24.60 25.21 25.03 0.37 
Recovered in swabs (µg) 17.24 16.91 18.69 17.61 0.95 
Total recovery (%) 85.98 85.18 89.71 86.96 2.42 
Donor wash (µg) 0.13 < LOQ 0.13 0.09 0.08 
Disposition 
     
SC tape-strips 1-2 (µg) 0.43 0.35 0.58 0.45 0.12 
SC tape-strips 3-15 (µg) 0.18 0.16 0.21 0.18 0.03 
SC tape-strips 1-15 (µg) 0.60 0.51 0.79 0.63 0.14 
  
     
Remaining skin (µg) 0.57 0.47 0.50 0.51 0.05 
  
     
Receptor phase at 2 hr (µg) < LOQ < LOQ < LOQ < LOQ < LOQ 
Receptor phase at 3 hr (µg) < LOQ < LOQ < LOQ < LOQ < LOQ 
Receptor phase at 4 hr (µg) 0.30 < LOQ < LOQ 0.10 0.17 
Receptor phase at 5 hr (µg) 0.39 < LOQ < LOQ 0.13 0.23 
Receptor phase at 6 hr (µg) 0.44 < LOQ < LOQ 0.15 0.25 
Receptor phase at 7 hr (µg) 0.50 < LOQ < LOQ 0.17 0.29 
Receptor phase at 8 hr (µg) 0.63 < LOQ 0.21 0.28 0.32 
Receptor phase at 24 hr (µg) 1.13 0.79 0.98 0.96 0.17 
  






1.87 1.35 1.60 1.61 0.26 
  
   
  
% uptake/absorption of 
amount applied 
7.40 5.51 6.33 6.41 0.95 






TXP Liquid 30µl 
      
Replicate Number 1 2 3 4 Mean StDev 
Applied (µg) 30 30 30 30 30 
 
Recovered in swabs (µg) 17.24 19.34 20.05 15.47 18.02 2.08 
Total recovery (%) 79.80 83.40 93.64 74.28 82.78 8.15 
Donor wash (µg) 1.00 0.35 1.08 0.79 0.81 0.33 
Disposition 
      
SC tape-strips 1-2 (µg) 0.87 0.77 1.76 0.81 1.05 0.48 
SC tape-strips 3-15 (µg) 0.68 0.38 0.28 0.25 0.40 0.20 
SC tape-strips 1-15 (µg) 1.55 1.14 2.04 1.05 1.45 0.45 
  
      
Remaining skin (µg) 0.96 0.86 1.57 1.43 1.20 0.35 
  
      
Receptor phase at 2 hr (µg) 1.59 1.40 1.20 1.07 1.31 0.23 
Receptor phase at 3 hr (µg) 1.75 1.84 1.58 1.44 1.65 0.18 
Receptor phase at 4 hr (µg) 2.12 2.25 1.73 1.76 1.97 0.26 
Receptor phase at 5 hr (µg) 2.16 2.22 1.82 2.02 2.06 0.18 
Receptor phase at 6 hr (µg) 2.09 2.39 2.05 2.21 2.19 0.15 
Receptor phase at 7 hr (µg) 2.28 2.43 2.14 2.32 2.29 0.12 
Receptor phase at 8 hr (µg) 2.29 2.51 2.48 2.42 2.43 0.10 
Receptor phase at 24 hr (µg) 3.18 3.33 3.36 3.53 3.35 0.14 
  





4.82 4.57 5.10 5.12 4.90 0.26 
  
      
% uptake/absorption of 
amount applied 
16.08 15.23 17.00 17.08 16.35 0.87 
Table A1 25 - Full Results from Paper 3, TXP 30 µl liquid loading dose 
Appendix – Full Results Tables 





TXP Residue 100µg disc 
      
Replicate Number 1 2 3 4 Mean StDev 
Applied (µg) 68.79 63.51 69.89 65.47 66.91 2.95 
Recovered in swabs (µg) 47.94 49.87 55.68 51.24 51.18 3.29 
Total recovery (%) 86.21 93.97 90.44 91.04 90.42 3.20 
Donor wash (µg) 0.37 2.16 0.24 0.40 0.79 0.91 
Disposition 
      
SC tape-strips 1-2 (µg) 0.75 1.05 1.00 1.25 1.01 0.21 
SC tape-strips 3-15 (µg) 0.20 0.39 0.44 0.59 0.41 0.16 
SC tape-strips 1-15 (µg) 0.95 1.44 1.44 1.84 1.42 0.37 
  
      
Remaining skin (µg) 1.21 1.59 0.83 1.52 1.29 0.35 
  
      
Receptor phase at 2 hr (µg) 0.82 < LOQ < LOQ < LOQ 0.20 0.41 
Receptor phase at 3 hr (µg) 1.11 0.27 0.25 < LOQ 0.41 0.48 
Receptor phase at 4 hr (µg) 1.94 0.57 0.49 0.17 0.79 0.79 
Receptor phase at 5 hr (µg) 2.03 0.65 0.60 0.23 0.88 0.79 
Receptor phase at 6 hr (µg) 2.47 0.83 0.85 0.33 1.12 0.93 
Receptor phase at 7 hr (µg) 2.72 0.96 0.93 0.36 1.24 1.02 
Receptor phase at 8 hr (µg) 2.93 1.06 1.03 0.48 1.38 1.07 
Receptor phase at 24 hr 
(µg) 
4.53 2.42 2.14 1.51 2.65 1.31 
  





5.95 4.40 3.41 3.46 4.30 1.19 
  
      
% uptake/absorption of 
amount applied 
8.64 6.93 4.88 5.28 6.44 1.72 




TXP Liquid 70µl 
      
Replicate Number 1 2 3 4 Mean StDev 
Applied (µg) 70 70 70 70 70 
 
Recovered in swabs (µg) 46.88 34.85 48.08 47.36 44.29 6.31 
Total recovery (%) 85.98 74.54 89.80 82.99 83.33 6.48 
Donor wash (µg) 0.59 1.20 0.41 0.83 0.76 0.34 
Disposition 
      
SC tape-strips 1-2 (µg) 1.11 1.74 1.41 1.00 1.32 0.33 
SC tape-strips 3-15 (µg) 0.65 0.83 0.79 0.47 0.69 0.16 
SC tape-strips 1-15 (µg) 1.77 2.57 2.20 1.47 2.00 0.48 
  
      
Remaining skin (µg) 2.73 2.61 2.07 2.52 2.49 0.29 
  
      
Receptor phase at 2 hr (µg) 3.63 4.98 3.22 2.18 3.50 1.16 
Receptor phase at 3 hr (µg) 4.84 5.75 5.08 2.84 4.63 1.26 
Receptor phase at 4 hr (µg) 6.01 7.98 6.37 3.17 5.88 2.00 
Receptor phase at 5 hr (µg) 5.98 7.71 6.66 4.41 6.19 1.38 
Receptor phase at 6 hr (µg) 6.45 8.23 7.12 3.67 6.37 1.94 
Receptor phase at 7 hr (µg) 6.53 8.11 7.34 4.70 6.67 1.46 
Receptor phase at 8 hr (µg) 7.75 8.78 8.06 5.21 7.45 1.56 
Receptor phase at 24 hr (µg) 8.22 10.94 10.09 5.91 8.79 2.23 
  





11.60 14.39 12.96 8.91 11.96 2.34 
  
      
% uptake/absorption of 
amount applied 
16.57 20.56 18.51 12.72 17.09 3.34 
Table A1 27 - Full Results from Paper 3, TXP 70 µl liquid loading dose 
Appendix – Full Results Tables 
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TXP Residue 180µg disc 
      
Replicate Number 1 2 3 4 Mean StDev 
Applied (µg) 123.65 125.86 121.70 108.31 119.88 7.90 
Recovered in swabs (µg) 104.12 104.12 102.21 89.16 99.90 7.22 
Total recovery (%) 94.00 95.49 94.14 93.99 94.41 0.73 
Donor wash (µg) 0.51 1.12 0.37 0.89 0.72 0.35 
Disposition 
      
SC tape-strips 1-2 (µg) 1.92 1.85 1.45 1.24 1.62 0.32 
SC tape-strips 3-15 (µg) 0.76 0.90 0.60 0.38 0.66 0.22 
SC tape-strips 1-15 (µg) 2.68 2.75 2.05 1.68 2.29 0.51 
  
      
Remaining skin (µg) 0.82 2.75 1.54 3.28 2.10 1.12 
  
      
Receptor phase at 2 hr (µg) 0.77 0.54 0.40 0.20 0.48 0.24 
Receptor phase at 3 hr (µg) 1.12 0.85 0.63 0.27 0.72 0.36 
Receptor phase at 4 hr (µg) 1.96 1.88 1.30 0.36 1.37 0.74 
Receptor phase at 5 hr (µg) 2.23 2.53 1.63 0.48 1.72 0.91 
Receptor phase at 6 hr (µg) 2.57 2.93 1.96 0.64 2.03 1.01 
Receptor phase at 7 hr (µg) 2.80 3.31 2.23 0.88 2.30 1.05 
Receptor phase at 8 hr (µg) 3.13 3.79 2.53 1.03 2.62 1.18 
Receptor phase at 24 hr (µg) 5.33 7.46 5.58 3.07 5.36 1.80 
  





6.90 11.11 7.72 6.73 8.11 2.04 
  
      
% uptake/absorption of 
amount applied 
5.58 8.83 6.34 6.21 6.74 1.43 






TXP Liquid 120µl 
      
Replicate Number 1 2 3 4 Mean StDev 
Applied (µg) 120 120 120 120 120 
 
Recovered in swabs (µg) 59.32 72.81 80.00 74.54 71.67 8.78 
Total recovery (%) 69.36 84.10 86.07 80.13 79.92 7.46 
Donor wash (µg) 2.41 3.32 1.31 2.72 2.44 0.84 
Disposition 
      
SC tape-strips 1-2 (µg) 0.75 1.94 1.83 1.75 1.57 0.55 
SC tape-strips 3-15 (µg) 0.98 1.46 1.01 0.94 1.10 0.25 
SC tape-strips 1-15 (µg) 1.72 3.40 2.84 2.69 2.66 0.70 
  
      
Remaining skin (µg) 6.02 8.59 4.93 4.38 5.98 1.87 
  
      
Receptor phase at 2 hr (µg) 5.47 5.66 7.00 3.93 5.51 1.26 
Receptor phase at 3 hr (µg) 8.30 7.45 9.03 5.61 7.60 1.47 
Receptor phase at 4 hr (µg) 10.76 9.03 10.27 6.49 9.14 1.91 
Receptor phase at 5 hr (µg) 10.99 9.26 10.20 7.36 9.45 1.56 
Receptor phase at 6 hr (µg) 11.41 9.20 11.00 8.52 10.03 1.39 
Receptor phase at 7 hr (µg) 11.49 9.95 11.31 9.08 10.46 1.15 
Receptor phase at 8 hr (µg) 11.40 9.62 11.77 9.40 10.55 1.21 
Receptor phase at 24 hr (µg) 13.76 12.80 14.20 11.83 13.15 1.06 
  
      
Total uptake/absorption (µg)
#
 20.75 22.86 20.14 17.15 20.23 2.36 
  
      
% uptake/absorption of 
amount applied 
17.29 19.05 16.79 14.29 16.86 1.96 
Table A1 29 - Full Results from Paper 3, TXP 120 µl liquid loading dose 
Appendix – Full Results Tables 





CFL Residue 40µg disc 
     
Replicate Number 1 2 3 Mean StDev 
Applied (µg) 24.33 26.57 29.06 26.65 2.36 
Recovered in swabs (µg) 24.29 23.20 19.91 22.47 2.28 
Total recovery (%) 102.42 96.87 84.67 94.65 9.08 
Donor wash (µg) 0.51 0.64 0.72 0.62 0.10 
  
     
Disposition 
     
SC tape-strips 1-2 (µg) 0.49 1.32 2.07 1.29 0.79 
SC tape-strips 3-15 (µg) 0.39 0.78 1.82 1.00 0.74 
SC tape-strips 1-15 (µg) 0.10 0.54 0.24 0.29 0.22 
  
     
Remaining skin (µg) < LOQ 0.16 0.23 0.13 0.12 
  
     
Receptor phase at 24 hr (µg) < LOQ < LOQ < LOQ < LOQ < LOQ 
  
     
Total uptake/absorption (µg)
#
 0.10 0.70 0.47 0.42 0.30 
  
     
% uptake/absorption of 
amount applied 
0.43 2.63 1.62 1.56 1.11 








CFL Liquid 30µl 
       
Replicate Number 1 2 3 4 5 Mean StDev 
Applied (µg) 30 30 30 30 30 30  
Recovered in swabs (µg) 22.38 21.81 22.17 20.05 24.98 22.28 1.77 
Total recovery (%) 86.08 87.97 88.20 81.34 98.38 88.39 6.23 
Donor wash (µg) 0.83 0.75 0.64 0.92 0.31 0.69 0.24 
  
       
Disposition 
       
SC tape-strips 1-2 (µg) 1.94 2.56 1.71 1.89 3.05 2.23 0.56 
SC tape-strips 3-15 (µg) 0.19 0.93 0.54 0.60 0.52 0.56 0.26 
SC tape-strips 1-15 (µg) 2.14 3.49 2.24 2.49 3.53 2.78 0.68 
  
       
Remaining skin (µg) 0.47 0.35 1.41 0.93 0.69 0.77 0.42 
  
       
Receptor phase at 24 hr (µg) < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ 
  
       
Total uptake/absorption (µg)
#
 0.67 1.28 1.95 1.53 1.17 1.32 0.47 
  
       
% uptake/absorption of 
amount applied 
2.22 4.25 6.49 5.11 3.90 4.40 1.57 
Table A1 31 - Full Results from Paper 3, CFL 30 µl liquid loading dose 
Appendix – Full Results Tables 
















CFL Liquid 70µl 
         
Replicate Number 1 2 3 4 5 6 7 Mean StDev 
Applied (µg) 70 70 70 70 70 70 70 70  
Recovered in swabs (µg) 63.72 56.46 54.52 56.12 45.98 51.28 52.72 54.40 5.44 
Total recovery (%) 100.72 91.28 91.46 93.82 75.78 83.28 82.63 88.42 8.34 
Donor wash (µg) 0.98 0.91 2.44 2.61 1.84 < LOQ 1.82 1.51 0.93 
  
         
Disposition 
         
SC tape-strips 1-2 (µg) 4.26 4.38 4.89 4.65 2.02 4.61 2.20 3.86 1.21 
SC tape-strips 3-15 (µg) 1.32 1.57 1.97 1.72 1.58 1.28 0.83 1.46 0.36 
SC tape-strips 1-15 (µg) 5.59 5.94 6.85 6.37 3.60 5.89 3.03 5.32 1.44 
  
         
Remaining skin (µg) 0.21 0.57 0.21 0.57 1.63 1.13 0.28 0.66 0.54 
  
         
Receptor phase at 24 hr (µg) < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ 
  





1.54 2.14 2.17 2.29 3.21 2.40 1.11 2.12 0.67 
  
         
% uptake/absorption of 
amount applied 
2.19 3.06 3.10 3.27 4.58 3.43 1.58 3.03 0.95 
Table A1 33 - Full Results from Paper 3, CFL 70 µl liquid loading dose 
Appendix – Full Results Tables 








CFL Residue 100µg disc 
         
Replicate Number 1 2 3 4 5 6 7 Mean StDev 
Applied (µg) 67.88 64.31 65.21 64.44 69.55 69.44 69.51 67.19 2.46 
Recovered in swabs (µg) 56.31 50.46 48.67 48.93 54.19 56.87 58.07 53.36 3.96 
Total recovery (%) 91.86 90.79 87.58 88.84 89.23 92.18 94.09 90.65 2.25 
Donor wash (µg) 0.32 1.55 1.07 0.52 1.10 1.25 1.38 1.03 0.45 
  
         
Disposition 
         
SC tape-strips 1-2 (µg) 1.39 1.17 2.15 1.97 1.53 2.00 2.29 1.79 0.42 
SC tape-strips 3-15 (µg) 0.48 0.15 0.31 0.33 0.77 0.67 0.44 0.45 0.22 
SC tape-strips 1-15 (µg) 1.88 1.32 2.47 2.29 2.30 2.67 2.72 2.24 0.49 
  
         
Remaining skin (µg) 1.23 1.76 0.58 1.53 1.19 0.83 1.42 1.22 0.41 
  
         
Receptor phase at 24 hr (µg) < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ 
  





1.72 1.91 0.89 1.86 1.96 1.50 1.86 1.67 0.38 
  
         
% uptake/absorption of 
amount applied 
2.53 2.98 1.37 2.88 2.82 2.16 2.68 2.49 0.56 
Table A1 34 - Full Results from Paper 3, CFL 100µg disc residue loading dose 
Appendix – Full Results Tables 








CFL Liquid 120µl 
        
Replicate Number 1 2 3 4 5 6 Mean StDev 
Applied (µg) 120 120 120 120 120 120 120 
 
Recovered in swabs (µg) 99.29 103.72 88.28 93.23 99.02 100.44 97.33 5.58 
Total recovery (%) 89.66 94.71 80.51 85.98 91.85 95.86 89.76 5.76 
Donor wash (µg) < LOQ 1.95 2.45 2.90 2.03 6.54 2.64 2.15 
  
        
Disposition 
        
SC tape-strips 1-2 (µg) 6.06 5.68 2.32 1.88 5.44 3.47 4.14 1.83 
SC tape-strips 3-15 (µg) 0.67 1.77 1.39 1.79 1.40 0.73 1.29 0.49 
SC tape-strips 1-15 (µg) 6.73 7.45 3.71 3.67 6.85 4.19 5.43 1.75 
  
        
Remaining skin (µg) 1.58 0.54 2.18 3.37 2.32 3.85 2.31 1.20 
  
        
Receptor phase at 24 hr (µg) < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ 
  





2.24 2.31 3.57 5.17 3.73 4.58 3.60 1.18 
  
        
% uptake/absorption of 
amount applied 
1.87 1.93 2.98 4.30 3.11 3.82 3.00 0.98 
Table A1 35 - Full Results from Paper 3, CFL 120 µl  liquid loading dose 
Appendix – Full Results Tables 









CFL Residue 180µg disc 
        
Replicate Number 1 2 3 4 5 6 Mean StDev 
Applied (µg) 137.69 141.69 129.26 129.48 121.64 123.23 130.50 7.89 
Recovered in swabs (µg) 105.51 120.76 84.94 99.39 102.88 104.51 103.00 11.52 
Total recovery (%) 87.52 92.66 81.93 87.64 94.35 93.12 89.54 4.72 
Donor wash (µg) 1.63 2.29 4.05 3.19 4.36 1.32 2.81 1.26 
  
        
Disposition 
        
SC tape-strips 1-2 (µg) 3.94 3.63 4.17 2.16 1.87 3.57 3.22 0.97 
SC tape-strips 3-15 (µg) 1.49 0.96 1.80 1.21 0.89 1.64 1.33 0.37 
SC tape-strips 1-15 (µg) 5.43 4.59 5.97 3.38 2.75 4.89 4.50 1.23 
  
        
Remaining skin (µg) 2.65 0.84 1.78 1.27 1.47 0.32 1.39 0.80 
  
        
Receptor phase at 24 hr (µg) < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ 
  
        
Total uptake/absorption (µg)
#
 4.14 1.80 3.58 2.49 2.35 1.64 2.67 0.99 
  
        
% uptake/absorption of 
amount applied 
3.01 1.27 2.77 1.92 1.94 1.33 2.04 0.72 
Table A1 36 - Full Results from Paper 3, CFL 180 µg disc residue loading dose 
Appendix – Full Results Tables 
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CFL Residue 250µg disc 
     
Replicate Number 1 2 3 Mean StDev 
Applied (µg) 165.93 171.48 170.81 169.41 3.03 
Recovered in swabs (µg) 154.93 154.75 150.63 153.43 2.43 
Total recovery (%) 94.88 93.10 92.02 93.33 1.44 
Donor wash (µg) 2.98 2.89 2.14 2.67 0.46 
  
     
Disposition 
     
SC tape-strips 1-2 (µg) 2.18 2.36 3.75 2.76 0.86 
SC tape-strips 3-15 (µg) 1.32 0.95 0.79 1.02 0.27 
SC tape-strips 1-15 (µg) 3.50 3.31 4.54 3.78 0.67 
  
     
Remaining skin (µg) 1.20 2.61 2.76 2.19 0.86 
  
     
Receptor phase at 24 hr (µg) < LOQ < LOQ < LOQ < LOQ < LOQ 
  
     
Total uptake/absorption (µg)
#
 2.52 3.56 3.55 3.21 0.60 
  
     
% uptake/absorption of 
amount applied 
1.52 2.07 2.08 1.89 0.32 












CFL Liquid 160µl 
     
Replicate Number 1 2 3 Mean StDev 
Applied (µg) 160 160 160 160 
 
Recovered in swabs (µg) 136.67 139.58 142.99 139.75 3.16 
Total recovery (%) 91.21 93.71 94.17 93.03 1.60 
Donor wash (µg) 2.22 1.92 < LOQ 1.38 1.20 
  
     
Disposition 
     
SC tape-strips 1-2 (µg) 3.32 4.45 4.36 4.04 0.62 
SC tape-strips 3-15 (µg) 0.64 1.24 0.95 0.94 0.30 
SC tape-strips 1-15 (µg) 3.96 5.69 5.31 4.99 0.91 
  
     
Remaining skin (µg) 3.08 2.74 2.38 2.73 0.35 
  
     
Receptor phase at 24 hr (µg) < LOQ < LOQ < LOQ < LOQ < LOQ 
  
     
Total uptake/absorption (µg)
#
 3.72 3.98 3.33 3.68 0.33 
  
     
% uptake/absorption of 
amount applied 
2.33 2.49 2.08 2.30 0.21 
 Table A1 37 - Full Results from Paper 3, CFL 160 µl liquid loading dose 
Appendix – Full Results Tables 





TXP Residue EC- A 
       
Replicate Number 1 2 3 4 5 Mean StDev 
Applied (µg) 25.19 28.68 25.59 27.99 27.89 27.07 1.57 
Recovered in swabs (µg) 24.35 19.42 16.87 18.86 14.88 18.87 3.54 
Total recovery (%) 109.56 92.23 84.12 84.45 79.66 90.01 11.83 
Donor wash (µg) 0.18 0.34 0.13 0.18 0.24 0.21 0.08 
Disposition 
       
SC tape-strips 1-2 (µg) 1.02 0.64 0.42 0.48 0.75 0.66 0.24 
SC tape-strips 3-15 (µg) 0.47 0.32 0.17 0.13 0.35 0.29 0.14 
SC tape-strips 1-15 (µg) 1.49 0.96 0.59 0.61 1.10 0.95 0.38 
  
       
Remaining skin (µg) 0.92 0.32 0.55 0.66 1.36 0.76 0.40 
  
       
Receptor phase at 2 hr (µg) 0.67 2.17 < LOQ < LOQ 0.77 0.72 0.89 
Receptor phase at 3 hr (µg) 0.90 2.71 < LOQ 0.27 1.05 0.99 1.06 
Receptor phase at 4 hr (µg) 1.11 2.93 0.29 0.59 1.23 1.23 1.02 
Receptor phase at 5 hr (µg) 1.22 3.17 0.38 0.65 1.31 1.35 1.09 
Receptor phase at 6 hr (µg) 1.34 3.62 0.43 0.68 1.40 1.49 1.26 
Receptor phase at 7 hr (µg) 1.34 3.66 0.49 0.84 1.48 1.56 1.24 
Receptor phase at 8 hr (µg) 1.43 3.79 0.61 0.85 1.52 1.64 1.26 
Receptor phase at 24 hr 
(µg) 
2.07 4.53 1.10 1.47 2.18 2.27 1.34 
  





3.46 5.17 1.83 2.26 3.88 3.32 1.33 
  
       
% uptake/absorption of 
amount applied 
13.75 18.03 7.14 8.07 13.93 12.18 4.53 
Table A1 40 - Full Results from Paper 3, TXP 40µg disc residue EC- A formulation 
 
 
TXP Liquid EC- A 
       
Replicate Number 1 2 3 4 5 Mean StDev 
Applied (µg) 30 30 30 30 30 30  
Recovered in swabs (µg) 19.83 19.29 20.28 19.02 15.79 18.84 1.77 
Total recovery (%) 84.80 88.00 89.42 93.54 79.09 86.97 5.41 
Donor wash (µg) 0.25 0.48 0.19 0.92 0.46 0.46 0.29 
Disposition 
       
SC tape-strips 1-2 (µg) 0.93 1.08 1.00 1.67 0.82 1.10 0.33 
SC tape-strips 3-15 (µg) 0.39 0.66 0.35 1.15 0.19 0.55 0.38 
SC tape-strips 1-15 (µg) 1.33 1.74 1.35 2.82 1.01 1.65 0.70 
  
       
Remaining skin (µg) 1.25 1.46 1.16 0.81 0.80 1.09 0.29 
  
       
Receptor phase at 2 hr (µg) 0.96 0.62 1.10 1.07 1.59 1.07 0.35 
Receptor phase at 3 hr (µg) 1.40 1.10 1.70 1.91 2.48 1.72 0.52 
Receptor phase at 4 hr (µg) 1.68 1.41 2.01 2.44 3.14 2.14 0.68 
Receptor phase at 5 hr (µg) 1.82 1.66 2.28 3.06 3.76 2.52 0.88 
Receptor phase at 6 hr (µg) 1.99 1.97 2.55 3.37 4.03 2.78 0.90 
Receptor phase at 7 hr (µg) 2.09 2.19 2.67 3.45 4.28 2.93 0.92 
Receptor phase at 8 hr (µg) 2.24 2.29 2.71 3.58 4.64 3.09 1.02 
Receptor phase at 24 hr (µg) 2.79 3.43 3.85 4.49 5.66 4.04 1.09 
  





4.43 5.55 5.35 6.45 6.65 5.69 0.90 
  
       
% uptake/absorption of 
amount applied 
14.76 18.50 17.85 21.50 22.17 18.95 2.99 
Table A1 39 - Full Results from Paper 3, TXP 30µg liquid EC – A formulation 
Appendix – Full Results Tables 





























TXP Liquid EC- B 
      
Replicate Number 1 2 3 4 Mean StDev 
Applied (µg) 30 30 30 30 30 
 
Recovered in swabs (µg) 16.84 15.71 15.84 19.89 17.07 1.95 
Total recovery (%) 82.91 76.79 76.83 84.67 80.30 4.10 
Donor wash (µg) 1.11 0.92 0.90 0.35 0.82 0.33 
Disposition 
      
SC tape-strips 1-2 (µg) 0.75 0.97 0.70 0.87 0.82 0.12 
SC tape-strips 3-15 (µg) 0.83 0.69 0.39 0.34 0.56 0.24 
SC tape-strips 1-15 (µg) 1.58 1.66 1.09 1.21 1.39 0.28 
  
      
Remaining skin (µg) 1.53 1.06 1.49 0.65 1.18 0.41 
  
      
Receptor phase at 2 hr (µg) 0.84 1.05 0.74 < LOQ 0.66 0.46 
Receptor phase at 3 hr (µg) 1.46 1.45 1.31 1.30 1.38 0.09 
Receptor phase at 4 hr (µg) 1.92 1.75 1.79 1.48 1.73 0.18 
Receptor phase at 5 hr (µg) 2.16 1.89 1.95 1.65 1.91 0.21 
Receptor phase at 6 hr (µg) 2.46 2.20 2.26 1.90 2.20 0.23 
Receptor phase at 7 hr (µg) 1.97 2.36 2.52 2.13 2.24 0.25 
Receptor phase at 8 hr (µg) 2.72 2.47 2.68 2.16 2.51 0.26 
Receptor phase at 24 hr (µg) 3.81 3.68 3.73 3.29 3.63 0.23 
  
      
Total uptake/absorption (µg)
#
 6.17 5.43 5.61 4.29 5.38 0.79 
  
      
% uptake/absorption of 
amount applied 
20.58 18.10 18.71 14.30 17.92 2.63 
 Table A1 41 - A41 Full Results from Paper 3, TXP 30µg liquid EC – B formulation 
Appendix – Full Results Tables 

















TXP Residue EC- B 
         
Replicate Number 1 2 3 4 5 6 7 Mean StDev 
Applied (µg) 26.41 30.17 25.19 26.24 31.49 31.48 32.86 29.12 3.09 
Recovered in swabs (µg) 15.28 14.94 11.71 11.14 16.20 14.16 16.52 14.28 2.11 
Total recovery (%) 81.69 75.72 76.20 76.57 75.45 71.03 75.13 75.97 3.12 
Donor wash (µg) 0.49 0.21 0.33 0.27 0.78 0.71 0.44 0.46 0.22 
Disposition 
         
SC tape-strips 1-2 (µg) 0.63 0.75 0.80 0.98 0.70 1.51 0.54 0.85 0.32 
SC tape-strips 3-15 (µg) 0.33 0.56 0.45 0.37 0.49 0.54 0.15 0.41 0.14 
SC tape-strips 1-15 (µg) 0.95 1.31 1.25 1.35 1.19 2.05 0.70 1.26 0.42 
  
         
Remaining skin (µg) 0.48 0.39 0.30 0.89 0.55 0.62 2.04 0.75 0.60 
  
         
Receptor phase at 2 hr (µg) < LOQ 1.32 0.56 0.62 0.95 0.70 0.70 0.69 0.40 
Receptor phase at 3 hr (µg) 0.67 1.85 0.83 1.12 1.11 0.82 1.03 1.06 0.39 
Receptor phase at 4 hr (µg) 0.87 2.11 0.97 1.40 1.31 0.95 1.20 1.26 0.43 
Receptor phase at 5 hr (µg) 1.01 2.36 1.25 1.70 1.45 1.09 1.38 1.46 0.46 
Receptor phase at 6 hr (µg) 1.11 2.76 1.37 2.05 1.69 1.28 1.52 1.68 0.56 
Receptor phase at 7 hr (µg) 1.27 2.84 1.48 2.23 1.79 1.38 1.79 1.83 0.55 
Receptor phase at 8 hr (µg) 1.52 3.13 1.69 2.35 1.99 1.54 1.78 2.00 0.58 
Receptor phase at 24 hr (µg) 1.89 3.61 2.07 3.21 2.95 2.35 3.22 2.76 0.66 
  
         
Total uptake/absorption (µg)
#
 2.69 4.56 2.82 4.48 3.99 3.51 5.41 3.92 0.99 
  
         
% uptake/absorption of 
amount applied 
10.19 15.10 11.18 17.07 12.66 11.15 16.46 13.40 2.79 
  Table A1 42 - Full Results from Paper 3, TXP 40µg disc residue EC- B formulation 
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TXP Liquid WP 
       
Replicate Number 1 2 3 4 5 Mean StDev 
Applied (µg) 30 30 30 30 30 30 
 
Recovered in swabs (µg) 21.05 20.60 19.96 20.72 19.02 20.27 0.80 
Total recovery (%) 86.18 85.14 85.12 84.95 76.18 83.52 4.13 
Donor wash (µg) 0.28 0.69 0.60 0.39 1.11 0.61 0.32 
Disposition 
       
SC tape-strips 1-2 (µg) 1.10 0.82 1.01 1.08 0.84 0.97 0.13 
SC tape-strips 3-15 (µg) 0.67 0.44 0.53 0.35 0.15 0.43 0.20 
SC tape-strips 1-15 (µg) 1.77 1.26 1.55 1.43 0.99 1.40 0.29 
  
       
Remaining skin (µg) 0.86 1.03 0.96 1.06 0.46 0.87 0.25 
  
       
Receptor phase at 2 hr (µg) 0.47 0.47 0.67 0.58 0.33 0.50 0.13 
Receptor phase at 3 hr (µg) 0.81 0.70 0.92 0.86 0.53 0.76 0.15 
Receptor phase at 4 hr (µg) 1.01 0.90 1.08 1.22 0.69 0.98 0.20 
Receptor phase at 5 hr (µg) 1.20 1.03 1.48 1.27 0.81 1.16 0.25 
Receptor phase at 6 hr (µg) 1.27 1.12 1.59 1.43 0.95 1.27 0.25 
Receptor phase at 7 hr (µg) 1.29 1.15 1.45 1.47 1.00 1.27 0.20 
Receptor phase at 8 hr (µg) 1.30 1.27 1.64 1.54 1.00 1.35 0.25 
Receptor phase at 24 hr (µg) 1.90 1.95 2.46 1.89 1.28 1.90 0.42 
  
       
Total uptake/absorption (µg)
#
 3.43 3.42 3.96 3.29 1.88 3.20 0.78 
  
       
% uptake/absorption of amount 
applied 
11.42 11.41 13.20 10.97 6.27 10.65 2.59 
 Table A1 43 - Full Results from Paper 3, TXP 30 µg liquid WP formulation 
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TXP Residue WP 
           
Replicate Number 1 2 3 4 5 6 7 8 9 Mean StDev 
Applied (µg) 22.25 14.29 27.87 31.64 26.92 29.17 30.89 31.26 31.26 27.28 5.72 
Recovered in swabs (µg) 15.11 8.31 13.15 18.37 14.77 17.93 18.29 18.98 16.72 15.74 3.41 
Total recovery (%) 89.73 88.71 82.19 80.69 83.08 81.93 78.12 81.38 76.31 82.46 4.38 
Donor wash (µg) 0.34 0.30 0.43 0.40 0.63 0.76 0.56 0.43 0.88 0.52 0.20 
Disposition 
           
SC tape-strips 1-2 (µg) 0.61 0.35 3.21 1.40 1.11 0.63 0.85 0.94 1.36 1.16 0.84 
SC tape-strips 3-15 (µg) 0.24 0.12 0.42 0.83 0.24 0.28 0.44 0.44 0.35 0.37 0.20 
SC tape-strips 1-15 (µg) 0.85 0.47 3.62 2.22 1.36 0.91 1.29 1.37 1.72 1.54 0.93 
  
           
Remaining skin (µg) 0.61 0.35 0.12 0.75 1.13 0.80 0.55 0.46 0.72 0.61 0.29 
  
           
Receptor phase at 2 hr (µg) 0.41 < LOQ 1.64 0.46 0.71 0.66 0.62 1.05 0.84 0.71 0.46 
Receptor phase at 3 hr (µg) 0.56 < LOQ 2.02 0.79 1.03 0.91 0.83 1.34 1.07 0.95 0.55 
Receptor phase at 4 hr (µg) 0.71 < LOQ 2.25 0.97 1.21 0.99 0.90 1.53 1.09 1.07 0.61 
Receptor phase at 5 hr (µg) 0.82 0.20 2.43 1.15 1.40 1.02 0.94 1.69 1.15 1.20 0.62 
Receptor phase at 6 hr (µg) 0.86 0.20 2.69 1.37 1.62 1.09 1.02 1.69 1.23 1.31 0.68 
Receptor phase at 7 hr (µg) 1.14 0.26 2.80 1.41 1.63 1.15 1.03 1.65 1.21 1.36 0.68 
Receptor phase at 8 hr (µg) 0.96 0.27 2.84 1.53 1.79 1.19 1.02 1.85 1.35 1.42 0.72 
Receptor phase at 24 hr (µg) 1.24 0.35 3.43 2.16 2.27 1.54 1.45 2.56 1.75 1.86 0.88 
  
           
Total uptake/absorption (µg)
#
 2.08 0.82 3.96 3.74 3.64 2.62 2.44 3.46 2.82 2.84 1.00 
  
           
% uptake/absorption of 
amount applied 
9.36 5.71 14.21 11.83 13.53 8.97 7.90 11.07 10.12 10.30 2.70 
Table A1 44 - A44 Full Results from Paper 3, TXP 40µg disc residue WP formulation 
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TXP Liquid AI 
      
Replicate Number 1 2 3 4 Mean StDev 
Applied (µg) 30 30 30 30 30  
Recovered in swabs (µg) 12.81 12.89 14.26 12.58 13.13 0.76 
Total recovery (%) 64.07 71.24 65.61 58.72 64.91 5.15 
Donor wash (µg) 0.88 0.72 0.63 0.71 0.73 0.10 
Disposition 
      
SC tape-strips 1-2 (µg) 0.85 1.78 0.73 1.10 1.12 0.47 
SC tape-strips 3-15 (µg) 0.36 0.42 0.26 0.41 0.36 0.07 
SC tape-strips 1-15 (µg) 1.21 2.20 1.00 1.51 1.48 0.53 
  
      
Remaining skin (µg) 0.91 1.02 1.75 1.06 1.18 0.38 
  
      
Receptor phase at 2 hr (µg) 0.90 1.30 0.55 0.43 0.80 0.39 
Receptor phase at 3 hr (µg) 1.42 2.08 0.86 0.65 1.25 0.64 
Receptor phase at 4 hr (µg) 1.82 2.60 1.04 0.82 1.57 0.81 
Receptor phase at 5 hr (µg) 2.06 2.91 1.16 0.87 1.75 0.93 
Receptor phase at 6 hr (µg) 2.31 3.32 1.33 1.04 2.00 1.04 
Receptor phase at 7 hr (µg) 2.47 3.50 1.41 1.17 2.14 1.07 
Receptor phase at 8 hr (µg) 2.61 3.68 1.51 1.24 2.26 1.12 
Receptor phase at 24 hr (µg) 3.42 4.54 2.05 1.76 2.94 1.29 
  
      
Total uptake/absorption (µg)
#
 4.69 5.97 4.07 3.23 4.49 1.16 
  
      
% uptake/absorption of 
amount applied 
15.62 19.91 13.55 10.76 14.96 3.85 
Table A1 45 - Full Results from Paper 3, TXP 30µg liquid AI formulation 
TXP Residue AI 
     
Replicate Number 1 2 3 Mean StDev 
Applied (µg) 12.42 10.58 11.01 11.34 0.96 
Recovered in swabs (µg) 3.02 2.59 4.41 3.34 0.95 
Total recovery (%) 79.46 82.39 86.44 82.76 3.50 
Donor wash (µg) 0.52 0.79 0.35 0.55 0.22 
Disposition 
     
SC tape-strips 1-2 (µg) 0.19 0.10 0.30 0.19 0.10 
SC tape-strips 3-15 (µg) 0.03 0.05 0.03 0.04 0.01 
SC tape-strips 1-15 (µg) 0.22 0.15 0.33 0.23 0.09 
  
     
Remaining skin (µg) 0.19 < LOQ < LOQ 0.06 0.11 
  
     
Receptor phase at 2 hr (µg) < LOQ < LOQ < LOQ < LOQ < LOQ 
Receptor phase at 3 hr (µg) < LOQ < LOQ < LOQ < LOQ < LOQ 
Receptor phase at 4 hr (µg) < LOQ < LOQ < LOQ < LOQ < LOQ 
Receptor phase at 5 hr (µg) < LOQ < LOQ < LOQ < LOQ < LOQ 
Receptor phase at 6 hr (µg) < LOQ < LOQ < LOQ < LOQ < LOQ 
Receptor phase at 7 hr (µg) < LOQ < LOQ 0.18 0.06 0.11 
Receptor phase at 8 hr (µg) < LOQ < LOQ 0.27 0.09 0.15 
Receptor phase at 24 hr (µg) 0.25 < LOQ 0.49 0.25 0.25 
  
     
Total uptake/absorption (µg)
#
 0.47 0.05 0.53 0.35 0.26 
  
     
% uptake/absorption of 
amount applied 
3.82 0.48 4.80 3.04 2.26 
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CFL Liquid EC- A 
        
Replicate Number 1 2 3 4 5 6 Mean StDev 
Applied (µg) 30 30 30 30 30 30 30  
Recovered in swabs (µg) 21.67 21.49 17.12 21.78 22.08 26.06 21.70 2.84 
Total recovery (%) 87.77 84.53 63.24 85.33 88.04 95.67 84.10 10.95 
Donor wash (µg) 2.61 0.96 0.40 0.82 0.86 0.19 0.97 0.85 
  
        
Disposition 
        
SC tape-strips 1-2 (µg) 1.30 1.54 0.54 1.14 1.99 1.00 1.25 0.49 
SC tape-strips 3-15 (µg) 0.52 0.37 0.41 0.85 0.92 0.19 0.54 0.29 
SC tape-strips 1-15 (µg) 1.82 1.91 0.96 1.99 2.91 1.19 1.80 0.69 
  
        
Remaining skin (µg) 0.23 1.00 0.50 1.01 0.56 0.71 0.67 0.30 
  
        
Receptor phase at 24 hr (µg) < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ 
  





0.76 1.37 0.91 1.86 1.48 0.90 1.21 0.43 
  
        
% uptake/absorption of 
amount applied 
2.52 4.57 3.04 6.21 4.92 3.00 4.04 1.42 
Table A1 47 - Full Results from Paper 3, CFL 30µg liquid EC – A formulation 
 
 
CFL Residue EC- A 
        
Replicate Number 1 2 3 4 5 6 Mean StDev 
Applied (µg) 23.62 19.26 23.71 21.78 23.98 23.14 22.58 1.81 
Recovered in swabs (µg) 20.32 13.73 19.40 19.90 17.01 18.57 18.16 2.46 
Total recovery (%) 94.81 88.36 91.84 98.97 85.38 91.90 91.88 4.77 
Donor wash (µg) 0.22 < LOQ < LOQ 0.58 0.18 0.25 0.20 0.21 
  
        
Disposition 
        
SC tape-strips 1-2 (µg) 0.43 0.53 0.45 0.38 0.50 0.57 0.48 0.07 
SC tape-strips 3-15 (µg) 0.17 0.34 0.24 0.51 0.44 0.51 0.37 0.14 
SC tape-strips 1-15 (µg) 0.60 0.87 0.69 0.88 0.94 1.08 0.85 0.17 
  
        
Remaining skin (µg) 0.41 < LOQ 0.35 < LOQ < LOQ < LOQ 0.13 0.20 
  
        
Receptor phase at 24 hr 
(µg) 
< LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ 
  





0.57 0.34 0.59 0.51 0.44 0.51 0.49 0.09 
  
        
% uptake/absorption of 
amount applied 
2.43 1.74 2.48 2.33 1.84 2.21 2.17 0.31 
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CFL Liquid EC- B 
        
Replicate Number 1 2 3 4 5 6 Mean StDev 
Applied (µg) 30 30 30 30 30 30 30 
 
Recovered in swabs (µg) 21.26 19.43 20.10 22.58 23.13 24.38 21.82 1.89 
Total recovery (%) 84.71 75.06 83.37 88.12 89.11 89.93 85.05 5.52 
Donor wash (µg) 1.24 1.09 2.33 0.92 0.50 0.35 1.07 0.70 
  
        
Disposition 
        
SC tape-strips 1-2 (µg) 1.80 0.63 1.09 1.50 1.32 1.34 1.28 0.40 
SC tape-strips 3-15 (µg) 0.84 0.61 0.87 0.29 0.67 0.34 0.60 0.24 
SC tape-strips 1-15 (µg) 2.64 1.24 1.95 1.80 1.99 1.68 1.88 0.46 
  
        
Remaining skin (µg) 0.27 0.76 0.63 1.14 1.10 0.58 0.75 0.33 
  
        
Receptor phase at 24 hr 
(µg) 
< LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ 
  





1.11 1.37 1.50 1.44 1.78 0.91 1.35 0.30 
  
        
% uptake/absorption of 
amount applied 
3.71 4.57 4.99 4.79 5.92 3.05 4.50 1.01 
Table A1 49 - Full Results from Paper 3, CFL 30µg liquid EC – B formulation 
 
CFL Residue EC- B 
      
Replicate Number 1 2 3 4 Mean StDev 
Applied (µg) 24.43 25.84 26.93 27.43 26.16 1.33 
Recovered in swabs (µg) 18.51 21.48 20.12 18.62 19.68 1.41 
Total recovery (%) 89.49 92.23 86.93 81.75 87.60 4.46 
Donor wash (µg) 0.40 0.30 0.50 0.37 0.39 0.08 
  
      
Disposition 
      
SC tape-strips 1-2 (µg) 0.77 0.42 0.46 0.68 0.58 0.17 
SC tape-strips 3-15 (µg) 0.40 0.30 0.50 0.19 0.35 0.13 
SC tape-strips 1-15 (µg) 1.16 0.72 0.96 0.86 0.93 0.19 
  
      
Remaining skin (µg) 0.16 0.23 0.13 0.28 0.20 0.07 
  
      
Receptor phase at 24 hr (µg) < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ 
  
      
Total uptake/absorption (µg)
#
 0.56 0.53 0.63 0.46 0.55 0.07 
  
      
% uptake/absorption of 
amount applied 
2.27 2.06 2.33 1.69 2.09 0.29 
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CFL Liquid WP 
          
Replicate Number 1 2 3 4 5 6 7 8 Mean StDev 
Applied (µg) 30 30 30 30 30 30 30 30 30  
Recovered in swabs (µg) 23.72 23.73 24.70 23.70 26.18 23.30 29.77 22.28 24.67 2.35 
Total recovery (%) 91.66 87.97 91.49 89.55 99.90 91.54 110.61 89.14 93.98 7.64 
Donor wash (µg) 0.75 0.59 0.55 0.62 0.30 0.55 1.33 0.59 0.66 0.30 
  
          
Disposition 
          
SC tape-strips 1-2 (µg) 1.93 1.09 1.41 1.72 2.48 2.41 1.19 2.02 1.78 0.53 
SC tape-strips 3-15 (µg) 0.84 0.73 0.64 0.34 0.43 1.06 0.55 0.77 0.67 0.23 
SC tape-strips 1-15 (µg) 2.77 1.82 2.06 2.06 2.91 3.47 1.73 2.80 2.45 0.62 
  
          
Remaining skin (µg) 0.26 0.25 0.13 0.49 0.58 0.14 0.35 1.07 0.41 0.31 
  
          
Receptor phase at 24 hr (µg) < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ 
  
          
Total uptake/absorption (µg)
#
 1.10 0.98 0.78 0.83 1.00 1.20 0.89 1.85 1.08 0.34 
  
          
% uptake/absorption of 
amount applied 
3.68 3.27 2.59 2.77 3.35 4.01 2.98 6.16 3.60 1.13 
Table A1 51 - Full Results from Paper 3, CFL 30µg liquid WP formulation 
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CFL Residue WP 
          
Replicate Number 1 2 3 4 5 6 7 8 Mean StDev 
Applied (µg) 36.00 33.11 34.56 32.90 38.09 37.35 33.64 36.16 35.23 1.96 
Recovered in swabs (µg) 24.19 24.98 37.64 29.31 39.37 35.58 31.48 33.45 32.00 5.59 
Total recovery (%) 76.35 85.80 117.12 93.65 109.68 100.74 100.05 97.77 97.65 12.81 
Donor wash (µg) 0.33 0.56 0.92 0.39 0.95 0.66 0.95 0.53 0.66 0.25 
  
          
Disposition 
          
SC tape-strips 1-2 (µg) 1.27 1.36 2.12 0.27 1.34 0.88 0.66 0.75 1.08 0.57 
SC tape-strips 3-15 (µg) 0.63 0.54 0.73 0.23 0.16 0.31 0.38 0.36 0.42 0.20 
SC tape-strips 1-15 (µg) 1.90 1.89 2.85 0.50 1.50 1.19 1.04 1.11 1.50 0.72 
  
          
Remaining skin (µg) 0.12 < LOQ < LOQ 0.16 0.13 0.22 0.19 0.18 0.12 0.08 
  
          
Receptor phase at 24 hr (µg) < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ 
  
          
Total uptake/absorption (µg)
#
 0.74 0.54 0.73 0.39 0.29 0.53 0.56 0.54 0.54 0.15 
  
          
% uptake/absorption of 
amount applied 
2.07 1.62 2.10 1.19 0.76 1.43 1.68 1.50 1.54 0.44 
Table A1 52 - Full Results from Paper 3, CFL 40µg disc residue WP formulation 
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CFL Residue AI 
       
Replicate Number 1 2 3 4 5 Mean StDdev 
Applied (µg) 14.29 18.64 14.90 22.11 19.42 17.87 3.26 
Recovered in swabs (µg) 7.04 8.93 7.78 13.29 11.74 9.76 2.66 
Total recovery (%) 90.58 82.00 86.98 84.09 86.05 85.94 3.22 
Donor wash (µg) 2.59 1.75 0.90 1.54 1.11 1.58 0.66 
  
       
Disposition 
       
SC tape-strips 1-2 (µg) 0.53 0.24 0.51 0.48 0.58 0.47 0.13 
SC tape-strips 3-15 (µg) 0.23 0.29 0.24 0.25 0.20 0.24 0.03 
SC tape-strips 1-15 (µg) 0.77 0.53 0.76 0.73 0.79 0.71 0.11 
  
       
Remaining skin (µg) 0.12 0.24 0.25 0.19 0.21 0.20 0.05 
  
       
Receptor phase at 24 hr (µg) < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ 
  
       
Total uptake/absorption (µg)
#
 0.36 0.53 0.50 0.44 0.42 0.45 0.07 
  
       
% uptake/absorption of 
amount applied 
2.49 2.82 3.33 1.98 2.15 2.55 0.54 
Table A1 53 - Full Results from Paper 3, CFL 40µg disc residue AI formulation 
 
